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Preface  
 
It is with sadness that I dedicate the 13
th
 np-SAD annual report to the memory of Professor 
Ghodse, (1938-2012) who led in establishing this national programme to report on drug-related 
mortality. 
 
In 1978 he wrote, with others, a paper for the British Medical Journal on Mortality among drug 
addicts in London. His research interest in this area grew along with the belief that monitoring 
drug mortality data would contribute to the prevention and treatment of addiction, as well as 
informing policy, and as he stated in a press release in 1998:  
 
“Information on drug-related deaths is suspected to be greatly under-reported in the United 
Kingdom.  Factors which contribute to the under-reporting may include: the illicit nature of 
substance use, lack of training in recognising the problem, lack of resource and expertise in 
systematic data collection.  In recognition of this the Department of Addictive Behaviour, based 
at St George’s Hospital Medical School, established a programme on Substance Abuse Deaths 
(np-SAD), with the intention of gathering information from various sources to inform clinicians 
and policy makers on risks associated with premature death due to substance misuse” 
 
This report presents information on drug-related deaths, both of addicts and non–addicts, that 
occurred during 2011 and for which coronial inquests and similar formal investigations have 
been completed. Its main purpose is to provide an analytical summary of data received and 
provide high-quality and consistent surveillance, and to detect and identify emerging trends and 
issues in respect of this phenomenon. In this way, it contributes to the reduction and prevention 
of drug-related deaths in the UK due to the misuse of both licit and illicit drugs 
 
The Programme could not achieve its goals and objectives without the invaluable voluntary 
collaboration and co-operation of Coroners and their officers across England, Wales, Northern 
Ireland, Guernsey, Jersey, and the Isle of Man. Scottish drug–related deaths data are provided 
by the Scottish Crime and Drug Enforcement Agency. Additional data is provided by the 
Northern Ireland Statistics and Research Agency on drug-related poisonings from the General 
Mortality Register. The contributions from all these sources are important as it enables the 
Programme to maintain a UK-wide reporting and surveillance system. We thank them all for their 
active participation and support.  
 
The findings show a decrease in the number of deaths in 2011 reported directly to np-SAD by 
Coroners from England, Wales, Northern Ireland and the Islands when compared to the number 
reported in last year’s report. Death notifications recorded by the Scottish Police also decreased. 
Part of the fall in Coroners’ notifications may be attributed to a slightly lower notification rate, and 
partly to a fall in actual fatalities. The latter would be in line with official statistics which showed a 
fall in deaths registered in 2011.  
 
As in the previous fifteen years, the statistics in this report are intended to inform authorities at 
the local, regional and national levels, as well as health professionals and the general public, 
about the serious consequences of drug abuse, especially polydrug use. 
 
The report also provides a number of indications of changes in patterns of drug abuse, trends 
over time, and emerging issues from our surveillance activities so that appropriate and timely 
action can be taken. 
 
This programme owes its existence to the commitment and dedication that Professor Ghodse 
demonstrated, and we can only hope and trust that this excellent work continues as a memorial 
to him. 
 
 
Professor Fabrizio Schifano 
Acting Director 
International Centre for Drug Policy 
St George’s, University of London 
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Executive summary 
 
This thirteenth annual report from the national programme on Substance Abuse Deaths (np-SAD) 
presents information on drug-related deaths that occurred during 2011 and for which coronial inquests 
and similar formal investigations have been completed. The Programme’s principal function is to provide 
high-quality and consistent surveillance, and to detect and identify emerging trends and issues in respect 
of this phenomenon. In this way, it contributes to the reduction and prevention of drug-related deaths in 
the UK due to the misuse of both licit and illicit drugs. 
 
The data and analysis in this report is intended to inform government, and relevant bodies, such as the 
Advisory Council on the Misuse of Drugs, and authorities at the local, regional, and national country 
levels, as well as health professionals and the general public, about the serious consequences of drug 
abuse.  
 
Key findings for the UK and Islands 
 
There were 1,757 notifications of drug-related deaths occurring in 2011 in the UK and Islands. This 
represents a decrease of 126 (6.7%) over the same reporting period in 2010. Data were provided by 98 of 
the 114 Coroners’ jurisdictions in England & Wales; a response rate of about 86%. 
 
The highest rates of drug-related deaths per 100,000 population aged 16 and over in 2011 were in the 
following areas: City of Manchester (14.86); Blackburn, Hyndburn & Ribble Valley (13.35); Liverpool 
(11.37); and Blackpool & the Fylde (11.10). 
 
The principal demographic characteristics of the decedents have remained consistent with previous 
reports. The majority of cases were males (72%), under the age of 45 years (66%), and White (97%). 
Most deaths (78%) occurred at a private residential address. 
 
The main underlying cause(s) of death were: accidental poisoning (70%); intentional self-poisoning 
(13%); and poisoning of undetermined intent (9%). This pattern represents an increase in accidental 
overdoses compared to the previous year with consequent falls in other types of overdose deaths. 
Accidental poisoning still remains the most frequent underlying cause of death amongst all age-groups, 
and older females are more likely to die of intentional self-poisoning than males. 
 
The overall pattern in the types of psychoactive drugs implicated in death has remained similar to 
previous years. Heroin/morphine continues to be the principal substance implicated in death in the UK 
and Islands. However, the proportion of deaths involving this substance has fallen from 53% in 2009 to 
41% in 2010, and to 32% in 2011. The proportion of cases involving methadone rose by 4%, and that for 
other opiates/opioid analgesics rose by 6%. The proportion of cases in which hypnotics/sedatives (mainly 
the benzodiazepines diazepam and temazepam) remained stable, whilst cases involving alcohol-in-
combination with other substances fell by 3%.   
 
The involvement of multiple substances in death demonstrated in this report for England, a trend found 
across the UK as a whole, underlines the risks associated with the co-ingestion of substances, especially 
central nervous system depressants such as opiates/opioid analgesics, alcohol and benzodiazepines.   
 
The decline in deaths reported in 2010 from stimulants appears to have reversed slightly for cocaine, 
amphetamines and ecstasy-type substances. The number of deaths involving piperazines appears to 
have declined further, whilst GBL/GHB cases fell compared to 2010.  
 
As in 2010, there was a substantial number of deaths reported involving novel psychoactive substances 
such as mephedrone and other methcathinones, and the benzodiazepine phenazepam. 
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Regional key findings 
 
England – np-SAD definition 
 
A total of 1,263 deaths were reported for 2011 (1358 in 2010). The demographic and drug profiles 
remained stable. However, there was a significant fall in the proportion of deaths involving 
heroin/morphine and a modest increase in the proportion involving methadone. The most common 
prescribed medications implicated in death were anti-depressants followed by hypnotics/sedatives.  
 
England – Drug Strategy definition (“drug misuse”) 
 
A total of 904 deaths were reported for 2011 (968 in 2010). There was a substantial reduction in the 
proportion of deaths attributed to heroin/morphine in 2011 compared to 2010. Despite this, 
heroin/morphine remained the most frequently implicated substance in “drug misuse” cases. The number 
of deaths due to accidental poisoning rose from 75.1% in 2010 to 78.4% in 2011, whilst deaths attributed 
to intentional self-poisoning increased by 2.6%, from 10.1% to 12.6%. 
 
Wales (np-SAD) 
 
Notifications of 81 deaths were reported for 2011 (81 in 2010). There were increases in the proportions of 
males and those unemployed and those living with others. There were modest increases in the 
proportions of deaths involving methadone, other opiates/opioid analgesics, anti-depressants, and 
hypnotics/sedatives. 
 
Scotland (np-SAD) 
 
The number of deaths reported to police in Scotland fell in 2011 to 336 (365 in 2010). Opiates play a 
larger role in Scottish deaths than in other regions; this may be due in part to the different definition used 
by the police. Alcohol-in-combination with other substances and hypnotics/sedatives (mostly diazepam 
and temazepam) also featured prominently. There were falls in the proportions of deaths involving 
heroin/morphine and alcohol-in-combination, but increases for those involving methadone, other 
opiates/opioid analgesics and hypnotics/sedatives. 
 
Northern Ireland (np-SAD) 
 
The number of cases reported in 2011 was 70 (72 in 2010). The drug profile remained similar to recent 
years; heroin/morphine and methadone are less prominent than elsewhere. There was an increase in the 
proportion of female deaths. 
 
The Islands (np-SAD) 
 
Two deaths occurred on Jersey, two on the Isle of Man, and three on Guernsey during 2011. The general 
demographic profile of cases in the Islands is in line with the pattern in the UK as a whole. There were 
proportionately fewer deaths involving cocaine and methadone. 
 
Key messages 
 
The main changes noted in 2011 are a further overall fall in the proportion of deaths involving 
heroin/morphine but an increase in the contribution played by methadone. Whilst opiates and opioids 
continue to dominate, towards the end of 2009 there was a noticeable decline in the number and 
proportion of cases involving stimulants. To some extent these changes appear to have been reversed 
slightly for amphetamines, cocaine and ecstasy-type drugs. 
 
Substances such as piperazines, ketamine and GBL which at the time of the 2009 report were ‘legal 
highs’ but became controlled drugs, continue to be present in post-mortem toxicology reports - although 
declining in the case of piperazines and GHB/GBL. Towards the end of 2009 new substances, chiefly 
np-SAD 
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methcathinones such as mephedrone started to appear in reports to np-SAD. These increased during 
2010 and 2011. The speed with which these and other new substances are continuing to replace 
established recreational drugs means it is important that surveillance and monitoring of the situation 
continues.     
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Introduction 
 
This thirteenth annual report continues the series 
of reports published by the national programme on 
Substance Abuse Deaths (np-SAD). It covers 
deaths occurring between January and December 
2011 reported to the Programme, as well as 
presenting information on emerging trends, and 
seeking to identify future potential issues that need 
monitoring.  
 
There is a chapter for each constituent part of the 
UK (England, Wales, Scotland, Northern Ireland 
and Guernsey, Jersey and Isle of Man) with data 
tables. Chapter 1 provides a substantive 
description of the situation regarding drug-related 
deaths in England during 2011 meeting the np-
SAD case definition, including data tables for a 
detailed breakdown of areas within England. 
Chapter 2 looks at deaths in England meeting the 
definition used for the Drug Strategy. Chapters 3 to 
6 cover the other parts of the UK and Islands, with 
Chapter 7 presenting findings for the UK as a 
whole. A commentary on emerging issues is given 
in Chapter 8.  
 
The appendices provide information on the 
Programme (Appendix 1), drug-related death 
definitions (Appendix 2), the areas reporting, 
(Appendix 3), and the Programme’s data collection 
form (Appendix 4).  
  
Quality Assurance of Data 
 
The Programme has given consideration as to how 
it can ensure the quality, accuracy and 
comprehensiveness of the data collected in order 
to improve both the quality of information collected 
and to establish if all relevant cases are being 
identified and notified. Following a pilot phase in 
2008-9, a continuous rolling programme of visits to 
a sample of geographically representative 
Coroners’ areas in England and Wales was 
undertaken in 2009-10.  
 
Such surveys help to establish the extent to which 
cases are being correctly identified. This makes it 
possible to extrapolate from the deaths notified by 
participating areas to the expected number of 
cases if all Coroners were reporting all cases, 
thereby providing a much more precise estimate of 
drug-related deaths (DRDs) for policy and 
intervention planning. 
 
This activity also provides insights into the quality 
and accuracy of the information submitted to the 
Programme, and has provided a firm basis for a 
process of audit in the future, thereby ensuring the 
consistent validation of the Programme’s 
surveillance work. This work also facilitates the 
drawing up of detailed guidance for Coroners and 
their staff in identifying and reporting relevant 
cases to np-SAD.  
 
The methodology used for this study was to select 
and examine completed inquests for deaths, 
available in Coroners’ offices, occurring in 2008. A 
statistically representative sample of 150 DRDs 
reported to the Programme was drawn for the 
quality assurance aspect based on cases reported 
by Coroners in England and Wales.  
 
To ascertain the accuracy of case identification 
and reporting, a 10% sample of records was drawn 
randomly from files for all completed inquests (for 
whatever reason) for each selected Coroner’s 
area. A total of 375 such completed inquests on all 
types of death in 2008 were examined.  
 
Geographical representativeness was based on 
selecting one Coroner’s area in each of the ten 
Strategic Health Authority (SHA) areas in England 
and two in Wales. For England there was a two-
stage sampling process. In the first stage, three 
Coroners’ areas from each SHA area was selected 
on the basis of the highest number of inquests 
completed. The second stage consisted of 
randomly selecting one of these three areas for 
investigation.  
 
The key findings from this survey show that the 
information received by the Programme from 
Coroners is consistent with the coronial inquest file 
papers. This exercise did not identify any ‘false 
positives’ i.e. any over-reporting.  
 
In 2008 five cases, where one or more controlled 
drugs or psychoactive substances were 
mentioned, were not reported to np-SAD. An 
extrapolation of these five cases projects an 
increase of 50 in the number of reported cases 
from Coroners in England and Wales in 2008. The 
degree of under reporting in both the 2007 and 
2008 cases is comparable (3.9% and 3.3% 
respectively). This underlines the consistency in 
reporting. 
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Chapter 1: Drug-related deaths in England using the np-
SAD definition 
  
 
This chapter examines drug-related deaths 
which occurred in England in 2011 - reported 
voluntarily by Coroners - and also examines 
trends over the past decade for illicit 
substances and prescribed medications 
implicated in death. Responses were received 
from a total of 89 out of 101 Coroners' 
jurisdictions in England, giving a total 
coverage rate of 88.1%. The first section in 
this chapter examines the overall 
demographics of drug-related deaths reported 
to np-SAD; examines cases that capture a 
range of psychoactive drugs; and covers the 
history of drug use irrespective of the cause of 
death. Included within this section is a 
comparison of those with a history of drug use 
against those without. This section highlights 
any changes made between 2010 and 2011 
including figures for the Coroners’ jurisdictions 
and a breakdown for the English regions.  
 
 
Profile of np-SAD cases  
 
1. Demography 
 
In 2011, there were 1,263 np-SAD drug-
related deaths reported to the Programme. 
Male cases accounted for 70.5%, whilst 29.5% 
were female (Table 1.1 and Figure 1.2). Half 
(50.6%) were unemployed. Over sixty per cent 
(60.9%) of deaths occurred for those less than 
45 years old. 44.1% lived alone, 42.5% lived 
with others, and 2.1% were of no fixed abode.  
Where ethnicity was known (n = 894), the vast 
majority were White (95.4%); with the 
remainder Asian (1.9%); Black (1.6%); and 
Chinese and other ethnicities (1.1%). 
 
Table 1.1: Demographic variables for np-SAD drug-related deaths, England, 2011 
 
 
2. Age  
       
 
Most np-SAD drug-related deaths in England 
during 2011 occurred amongst those aged 35 
years and over (71.2%), with 21.9% aged 25-
34, and only 6.9% being 15-24 years old 
(Figure 1.1). The median age at death was 
41.9 years (interquartile range = 16.4). Older 
male, White drug users are at most risk of 
drug-related deaths (Bird et al., 2003; Ghodse 
Variable Category Number (%) 
Total 
 
1263 (100.0) 
Gender 
Male 890 (70.5) 
Female 373 (29.5) 
Employment status 
Unemployed 639 (50.6) 
Employed 350 (27.7) 
Childcare/house-person 30 (2.4) 
Student 21 (1.7) 
Retired/sickness/invalidity 116 (9.2) 
Other 11 (0.9) 
Not known 96 (7.6) 
Living arrangements 
Alone 557 (44.1) 
With others 537 (42.5) 
No fixed abode 26 (2.1) 
Other 58 (4.6) 
Not known 85 (6.7) 
Ethnicity 
Asian 17 (1.3) 
Black 14 (1.1) 
Chinese and other 10 (0.8) 
White 853 (67.5) 
Not known 369 (29.2) 
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et al., 2009). Of the 1,263 np-SAD drug-
related deaths in England in 2011, 87 were 24 
years old and under and 317 were 50 and 
over. 
 
 Figure 1.1: np-SAD drug-related deaths by age-group, England, 2011 
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Figure 1.2: np-SAD drug-related deaths by age and gender, England, 2011 
 
70
218
307
196
70
29
17
59
98
109
48 42
0
50
100
150
200
250
300
350
15 to 24 25 to 34 35 to 44 45 to 54 55 to 64 65 & over
Age-group at death
N
u
m
b
e
r
Male
Female
 
 
3.  Location of death 
 
In 2011, 71.0% of cases died at the 
deceased’s home address or another private 
residential address; 11.2% died in hospital; 
and 11.2% died elsewhere (e.g. park, public 
facilities, other public spaces), with 7.5% of 
cases for which the place of death was not 
specified. 
 
4.  Underlying cause(s) of death 
 
The categories of underlying cause(s) of death 
for coding within ICD-10 (Appendix 1) were as 
follows: 
 Accidental poisoning (X40-X47): 64.4% 
 Intentional self-poisoning (X60-X67): 
15.4%  
 Poisonings of undetermined intent (Y10-
Y15): 9.8% 
 Other (e.g. natural causes, drowning, 
hanging, unascertained): 10.4% 
 
Males were significantly more likely than 
females to die from accidental poisoning 
(68.8% vs. 53.9%). (Proportion Ratio [PR]: =                                     
1.3, 95% Confidence Interval [CI]: = 1.2 – 1.4). 
Females, by contrast, were more likely than 
males to die of intentional self-poisoning 
(22.3% vs. 12.6%) (PR = 1.8, 95% CI = 1.4 – 
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2.3), and poisoning of undetermined intent 
(15.5% vs. 7.5%) (PR = 2.1, 95% CI = 1.5 – 
2.9).  
 
In England, deaths amongst those aged 44 
years and younger were more likely than older 
cases to be attributed to accidental poisoning 
(71.3% vs. 53.6%) (PR = 1.3, 95% CI = 1.2 – 
1.5). By contrast, those aged 45 years or over 
were not only more likely to die of intentional 
self-poisoning than younger cases (25.5% vs. 
9.0%) (PR = 2.8, 95% CI = 2.2 – 3.7), but also 
from poisoning of undetermined intent (13.4% 
vs. 7.8%) (PR = 1.7, 95% CI = 1.2 – 2.4). 
 
5.  Manner of death  
 
The results for 2011 cases are as follows: 
 Accidental: 67.4% 
 Suicidal: 18.1% 
 Undetermined: 11.2% 
 Natural: 3.1% 
 Homicidal: 0.2% 
 
Males were more likely than females to die an 
accidental death (72.0% vs. 56.3%) (PR = 1.3, 
95% CI = 1.1 – 1.4). Conversely, there were 
more deaths attributed to suicide in females 
than in males (23.1% vs. 16.1%) (PR = 1.4, 
95% CI = 1.1 – 1.8), and also deaths where 
the manner was undetermined (16.9% vs. 
8.9%) (PR = 1.9, 95% CI = 1.4 – 2.6).  
 
Cases aged less than 45 years were more 
likely than older cases to die accidentally 
(75.7% vs. 54.5%) (PR = 1.4, 95% CI = 1.3 – 
1.5). Those aged 45 years or over were more 
likely than younger cases to have deaths 
attributed to suicide (27.7% vs. 12%) (PR = 
2.3, 95% CI = 1.8 – 2.9), or to a manner that 
was undetermined (14.2% vs. 9.4%) (PR = 
1.5, 95% CI = 1.1 – 2.1). 
 
Psychoactive substances implicated in death  
 
1.1 Psychoactive substances 
 
Of the 1,263 np-SAD-related deaths in 2011, 
psychoactive drugs, including alcohol, were 
directly implicated in 1,172 (92.8%). Of these, 
the principal substances implicated were  
 
heroin/morphine (30.3%); other opiates/opioid 
analgesics (28.0%); alcohol-in-combination 
with other substances (27.7%); methadone 
(27.9%); hypnotics/sedatives (24.4%); anti-
depressants (24.5%); and cocaine (10.4%) 
shown in Table 1.2. 
 
Table 1.2: Psychoactive substances implicated in np-SAD deaths, England, 2011 
 
Drug category 
Number (%) of cases 
where substance was 
implicated alone 
Number (%) of cases 
where substance was 
implicated both alone and 
in combination 
Total 1,172 (100.0) 
Alcohol-in-combination - 325 (27.7) 
Amphetamines 19 (1.6) 43 (3.7) 
Anti-depressants 65 (5.5) 287 (24.5) 
Anti-epileptics 6 (0.5) 34 (2.9) 
Anti-Parkinson’s 1 (0.1) 5 (0.4) 
Anti-psychotics 15 (1.3) 66 (5.6) 
Cannabis 6 (0.5) 23 (2.0) 
Cocaine 17 (1.5) 122 (10.4) 
Ecstasy-type drugs 6 (0.5) 20 (1.7) 
GHB/GBL 4 (0.3) 10 (0.9) 
Heroin/morphine 103 (8.8) 355 (30.3) 
Hypnotics/sedatives 28 (2.4) 286 (24.4) 
Methadone 82 (7.0) 327 (27.9) 
Other opiates/opioid analgesics 81 (6.9) 328 (28.0) 
Notes: Column totals may sum to more than 100% since more than one substance may be implicated in a death. Not 
all cases had drugs directly implicated in death; these are excluded from this table. 
 
1.2 Psychoactive substances most 
frequently implicated for each age-group  
 
As shown in Table 1.3 below, for 15-24 year 
olds, methadone was the most frequently 
implicated psychoactive drug (alone or in 
combination) in their deaths, whilst 
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heroin/morphine was identified as the 
psychoactive substance most frequently 
implicated in the deaths of those aged 
between 25-44 years, representing 65.6% of 
all deaths implicated to the drug reported in 
England, in 2011. Anti-depressants were once 
again the most frequently implicated 
psychoactive drugs in the deaths of those 
aged 45-54 years, with other opiates/opioid 
analgesics being the psychoactive substance 
implicated most often in the 55-64 years age-
group. Meanwhile, hypnotics/sedatives were 
the drugs most frequently implicated in the 
deaths of those aged 65 and over.  
 
1.3 Age-group with highest frequency for 
 each psychoactive substance implicated 
 
As Table 1.3 below shows, amphetamines; 
anti-psychotics; cocaine; heroin/morphine; 
hypnotics/sedatives; methadone; other 
opiates/opioid analgesics; and alcohol-in-
combination were most commonly implicated 
in the deaths of those aged between 35-44 
years. Anti-depressants were implicated most 
frequently in the deaths of those in the 45-54 
years age category, whilst cannabis was 
implicated most often in the deaths of 25-34 
year-olds. Ecstasy-type drugs were most 
commonly implicated in the deaths of the 15-
24 and 35-44 year age-groups. Anti-epileptics 
were implicated most often in the age-groups 
35-54, whilst anti-Parkinson’s featured more 
frequently in the age-groups of 25-34 and 45-
54 than in all other age-groups combined. 
GHB/GBL was most commonly implicated in 
the deaths of those aged between 25-44 
years. 
 
 
 
Table 1.3: Age-group and psychoactive substance implicated in death, np-SAD cases, 
England, 2011 
  
Age-group at death 
 
Total 
number of 
cases 
where 
substance 
implicated 
 
 
Percentage 
of total 
deaths 
overall with 
psychoactive 
substances 
implicated 
15-24 25-34 35-44 45-54 55-64 65+ 
 
N
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m
p
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c
a
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d
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Amphetamines 
5 
(11.6) 
13 
(30.2) 
17 
(39.5) 
5 
(11.6) 
3 
(7.0) 
0 
(0.0) 
43 3.7% 
Anti-
depressants 
7 
(2.4) 
46 
(16.0) 
84 
(29.3) 
95 
(33.1) 
28 
(9.8) 
27 
(9.4) 
287 24.5% 
Anti-epileptics 
1 
(2.9) 
5 
(14.7) 
10 
(29.4) 
10 
(29.4) 
6 
(17.6) 
2 
(5.9) 
34 2.9% 
Anti-
Parkinson’s 
0 
(0.0) 
1 
(20.0) 
1 
(20.0) 
2 
(40.0) 
0 
(0.0) 
1 
(20.0) 
5 0.4% 
Anti-
psychotics 
2 
(3.0) 
16 
(24.2) 
27 
(40.9) 
13 
(19.7) 
3 
(4.5) 
5 
(7.6) 
66 5.6% 
Cannabis 
6 
(26.1) 
8 
(34.8) 
5 
(21.7) 
3 
(13.0) 
1 
(4.3) 
0 
(0.0) 
23 2.0% 
Cocaine 
13 
(10.7) 
34 
(27.9) 
47 
(38.5) 
20 
(16.4) 
8 
(6.6) 
0 
(0.0) 
122 10.4% 
Ecstasy-type 
6 
(30.0) 
5 
(25.0) 
6 
(30.0) 
3 
(15.0) 
0 
(0.0) 
0 
(0.0) 
20 1.7% 
GHB/GBL 
2 
(20.0) 
3 
(30.0) 
3 
(30.0) 
2 
(20.0) 
0 
(0.0) 
0 
(0.0) 
10 0.9% 
Heroin/morphi
ne 
11 
(3.1) 
88 
(24.8) 
145 
(40.8) 
77 
(21.7) 
28 
(7.9) 
6 
(1.7) 
355 30.3% 
Hypnotic/sedat
ive 
14 
(4.9) 
63 
(22.0) 
99 
(34.6) 
54 
(18.9) 
30 
(10.5) 
26 
(9.1) 
286 24.4% 
Methadone 
19 
(5.8) 
 
81 
(24.8) 
 
119 
(36.4) 
88 
(26.9) 
 
17 
(5.2) 
3 
(0.9) 
327 
 
27.9% 
Other 
opiates/opioid 
analgesics 
13 
(4.0) 
51 
(15.5) 
102 
(31.1) 
 
 
92 
(28.0) 
 
47 
(14.3) 
23 
(7.0) 
328 
 
 
28.0% 
Alcohol-in-
combination 
14 
(4.3) 
81 
(24.9) 
 
121 
(37.2) 
64 
(19.7) 
 
34 
(10.5) 
 
11 
(3.4) 
 
325 27.8% 
Notes: Column totals may sum to more than 100% since more than one substance may be implicated in a death. Not all 
cases had drugs directly implicated in death; these are excluded from this table. 
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1.4 Gender and implicated psychoactive 
substance 
 
 
 
 
The type of psychoactive substances 
implicated in fatalities is somewhat different 
between male and female cases. 
 
Among males, the top five substances most 
frequently implicated alone or in combination, 
presented in numerical order were: 
1. Heroin/morphine (34.2%) 
2. Alcohol-in-combination (29.9%) 
3. Methadone (29.9%) 
4. Other opiates/opioid analgesics 
(25.3%) 
5. Hypnotics/sedatives (24.6%). 
 
Amongst female cases, the substances most 
frequently implicated alone or in combination 
were: 
1. Anti-depressants (42.7%) 
2. Other opiates/ opioid analgesics 
(34.5%) 
3. Hypnotics/sedatives (24.0%) 
4. Methadone (23.1%) 
5. Alcohol-in-combination (23.1%) 
 
Comparing the type of psychoactive 
substances implicated in the deaths of males 
and females reveals that there is a higher 
proportion of male deaths compared to female 
deaths involving heroin/morphine; alcohol-in-
combination; methadone; hypnotics/sedatives; 
cocaine; GHB/GBL; cannabis; and ecstasy-
type drugs. 
 
Females, compared to males, show a greater 
proportion of deaths implicating anti-
depressants; other opiates/opioid analgesics; 
anti-psychotics; anti-epileptics; anti-
Parkinson’s drugs; and amphetamines. 
 
2. Polysubstances 
 
In 2011, 10.2% of the 1,172 psychoactive 
substance-related deaths reported to np-SAD 
involved heroin/morphine in combination with 
alcohol. 7.0% of cases involved 
hypnotics/sedatives with anti-depressants; 
6.8% of cases involved other opiates/opioid 
analgesics combined with alcohol; whilst 6.2% 
of deaths involved heroin/morphine and other 
opiates/ opioid analgesics combined. The 
combination of heroin/morphine and other 
opiates/opioid analgesics fluctuated between 
4% and 9% over the past ten years, with a 
general downward trend. Over the last decade 
alcohol-in-combination with two other 
stimulants constantly featured. Combinations 
of drugs, with or without alcohol, pose greater 
risks for mortality (Ghodse et al., 2010). 
 
Hypnotics/sedatives in combination with other 
opiates/opioid analgesics accounted for 8.5% 
of cases in 2002 compared to 8.1% in 2011.  
 
In 2011, several different substance types, 
when implicated in combination, often featured 
with alcohol. Alcohol was implicated in 33.5% 
of deaths involving heroin/morphine, 35.2% 
involving cocaine, 34.8% of deaths involving 
cannabis, 30.0% of GHB/GBL deaths and 
27.8% of deaths in which methadone was 
implicated. 
 
3. Single substances 
 
In 2011, there were 433 (36.9%) psychoactive 
substance deaths in which only one of the 
following substances was implicated. Of these 
433 deaths from single substances, 
heroin/morphine accounted for 23.8% of 
deaths; methadone  for 18.9%; other 
opiates/opioid analgesics – 18.7%; anti-
depressants – 15.0%; cocaine – 3.9%; 
hypnotics/sedatives – 6.5%; amphetamines – 
4.4%; anti-psychotics – 3.5%; cannabis – 
1.4%; ecstasy-type drugs – 1.4%; anti-
epileptics – 1.4%; GHB/GBL – 0.9%; and anti-
Parkinson’s – 0.2%. 
 
4. Prescribed psychoactive drugs  
 
In total, 780/1263 cases (61.8%) were 
reported to be receiving prescribed 
psychoactive drugs at the time of their death in 
2011 (Table 1.4). Within this group, prescribed 
drugs reported were: anti-depressants 
(59.5%); hypnotic/sedatives (42.8%); other 
opiate/opioid analgesics (28.9%); anti-
psychotics (20.3%); methadone (19.3%); anti-
epileptics (14.3%); heroin/morphine (6.1%); 
anti-Parkinson’s (1.8%); and amphetamines 
(0.5%). ‘Polypharmacy’, i.e. multiple 
prescriptions of psychoactive drugs, occurred 
in 67.3% (525/780) of these cases. 
 
Age appeared to be related to whether the 
cases were on prescribed psychoactive 
medication or not when prescribing history 
was known at the time of death, with 21.8% of 
15-24 year olds prescribed psychoactive 
medication; 51.3% for 25-34; 35-44 (63.5%); 
45-54 (71.1%); 55-64 (75.4%); and 65 and 
over (78.9%). 
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Table 1.4: Prescribed psychoactive medication, np-SAD cases, England, 2011  
 
Drug category 
Number (%) of cases on 
prescribed 
psychoactive medication 
by drug 
Number (%) of these 
cases where same 
prescribed drug was 
implicated in death 
Total 780 (100.0)  
Amphetamines 4 (0.5) 1 (25.0) 
Anti-depressants 464 (59.5) 199 (42.9) 
Anti-epileptics 112 (14.4) 16 (14.3) 
Anti-Parkinson’s 14 (1.8) 3 (21.4) 
Anti-psychotics 158 (20.3) 47 (29.7) 
Heroin/morphine 47 (6.0) 35 (74.5) 
Hypnotic/sedatives 334 (42.8) 131 (39.2) 
Methadone 150 (19.2) 123 (82.0) 
Other opiates/opioid analgesics 225 (28.8) 143 (63.6) 
Note: Column totals may sum to more than 100% since more than one substance may be prescribed to an individual 
and more than one substance may be implicated in a death. 
  
The following paragraphs further examine np-
SAD deaths and the involvement of prescribed 
medication. 
 
Methadone, alone and in combination with 
other drugs, was implicated in 327 cases. Of 
these, 204 people (62.4%) may have obtained 
methadone from illicit sources, compared to 
123 (37.6%) who were known to be receiving 
prescribed methadone prior to their death (PR 
= 1.7, 95% CI = 1.4 – 2.0). Methadone alone 
was implicated in 82 cases. Of these, 47 
(57.3%) may have obtained the drug from illicit 
sources, compared to 35 (42.7%) who were 
known to be receiving prescribed methadone 
(PR = 1.3, 95% CI = 1.0 – 1.8).  
 
Hypnotic/sedatives, alone and in combination 
with other drugs, were implicated in 286 
cases. Of these, 131 (45.8%) were known to 
be prescribed this drug, thus 155 (54.2%) may 
have obtained them illicitly (PR = 1.2, 95% CI 
= 1.0 – 1.4). Of the 28 cases in which 
hypnotic/sedatives alone were implicated, 12 
(42.9%) had received the drug on prescription, 
compared to 16 (57.1%) who may have 
illegally obtained it (PR = 1.3, 95% CI = 0.8 – 
2.3).  
 
Anti-depressants, alone and in combination 
with other drugs, were implicated in 287 
cases. Of these, 199 (69.3%) were known to 
be receiving prescribed anti-depressants at 
the time of their death, compared to 88 
(30.7%) who may have taken drugs prescribed 
to others (PR = 2.3, 95% CI = 1.9 – 2.7). Anti-
depressants alone were implicated in 65 
cases. Of these, 48 (73.8%) were known to be 
prescribed anti-depressants, compared to 17 
(26.2%) who may have used drugs that were 
prescribed to others (PR = 2.8, 95% CI = 1.8 – 
4.4).  
 
Other opiates/opioid analgesics (e.g. 
dextropropoxyphene, or where the exact 
opiate-type drug was unknown) alone and in 
combination with other drugs, were implicated 
in 328 cases. Of these, 185 (56.4%) may have 
obtained the drug by illicit means, compared to 
the 143 (43.6%) who were known to be 
prescribed other opiates/opioid analgesics (PR 
= 1.3, 95% CI = 1.1 – 1.5). Other opiate/opioid 
analgesics alone were implicated in 81 cases. 
In 36 (44.4%) of these cases the drugs were 
listed as prescribed to the individual in whose 
death the drugs were implicated, however for 
the remaining 45 (55.6%) cases, the drugs 
appear to have been obtained by other means 
(PR = 1.3, 95% CI = 0.9 – 1.7). 
 
Heroin/morphine, alone and in combination 
with other drugs, was implicated in 355 
deaths. 320 (90.1%) of these cases were not 
prescribed heroin/morphine, and as such may 
have obtained the drug illegally. Only 35 
(9.9%) of the cases with heroin/morphine 
implicated were receiving the drug on 
prescription (PR = 9.1, 95% CI = 6.7 – 12.5). 
Where heroin/morphine was implicated alone, 
out of 103 cases, only 12 (11.7%) were known 
to be prescribed the drug, meaning 91 
individuals (88.3%) may have obtained 
heroin/morphine illegally (PR = 7.6, 95% CI = 
4.4 – 13.0). 
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Drug abuse/dependence 
 
Information was available for 946/1263 
individuals on their past or current history of 
drug abuse/dependence. Those with such a 
history (DAs) accounted for 64.2% (n = 
607/946). Those without such a history - non 
drug abusers (NDAs) - accounted for 35.8% 
(339/946). Out of the total number of np-SAD 
cases reported for 2011, 25.1% (317/1263) 
were reported as “not known” with respect to 
known history of drug abuse/dependence. 
These cases were excluded from further 
analysis.  
 
1. Demography  
 
Those with a history of drug abuse (DA) were 
more likely to be male than those without such 
a history (NDA) (78.7% vs. 56.6%) (PR = 1.4, 
95% CI = 1.3 – 1.5) and 44 years and younger 
(71.5% compared to 42.2%) (PR = 1.7, 95% 
CI = 1.5 – 1.9). The median age at death for 
DAs was 38.9 years (interquartile range = 
13.2), while that for NDAs was 47.2 years 
(interquartile range = 20.0) (Mann-Whitney U = 
66,385.0 p <0.001). 
 
2. Location of death 
 
When location of death was known, there was 
no difference between the two groups with 
respect to dying at home or at a private 
residential address, with DAs (76.5%) and 
NDAs (76.5%). Indeed, hospital deaths also 
accounted for a similar proportion of deaths in 
both DA (12.6%) and NDA (14.0%) groups. A 
similar proportion of DAs (6.7%) as NDAs 
(6.3%) died in public places (e.g. park, street, 
public toilets etc.).  
 
3. Underlying cause(s) of death  
 
DAs were more likely than NDAs to die of 
accidental poisoning (77.9% vs. 41.6%) (PR = 
1.9, 95% CI = 1.6 – 2.1) – see Figure 1.3. 
Conversely, a significantly greater proportion 
of NDAs died of intentional self-poisoning 
compared to DAs (35.1% vs. 4.4%) (PR = 7.9, 
95% CI = 5.3 - 11.7), and also poisoning of 
undetermined intent (15.0% vs. 5.6%) (PR = 
2.7, 95% CI = 1.8 – 4.1).  
 
4. Manner of death  
 
A similar pattern is exhibited with regard to 
manner of death. DAs were more likely than 
NDAs to die an accidental death (81.5% vs. 
44.2%) (PR = 1.8, 95% CI = 1.6 – 2.1). In 
contrast, deaths of NDAs were more likely 
than those of DAs to be attributed to suicide 
(38.3% vs. 6.4%) (PR = 6.0, 95% CI = 4.3 – 
8.3), or to a death where the manner was 
undetermined (15.6% vs. 7.6%) (PR = 2.1, 
95% CI = 1.4 – 3.0). Natural deaths were more 
common amongst DAs (4.4%) than NDAs 
(1.8%) (PR = 2.5, 95% CI = 1.0 – 6.0).
 
Figure 1.3: Principal underlying cause(s) of death by drug abuse/dependence history, np-
SAD cases, England, 2011  
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Changes between 2010 and 2011 
 
The following section compares deaths in 
2011 with those that occurred in 2010. Deaths 
in 2011 are reported as 1,263, whereas in 
2010, 1,358 cases were reported. This is a 
decrease in reported np-SAD deaths of 7.0% 
for 2011. These figures for 2011 (and 2010, to 
a lesser extent) can be expected to increase 
as further inquests on drug-related deaths of 
those who died in these calendar years are 
finally completed (some inquests do happen in 
the same calendar year) and reported to the 
Programme.  
 
1. Demography 
 
There were small changes between 2010 and 
2011 in the demographic profile of cases. 
There was a slight reduction in the number of 
male deaths, from 72.1% to 70.5%, with a 
0.5% drop in the number of deaths amongst 
White cases. Deaths amongst those aged 
between 15-34 years fell 6.3% (35.1% in 2010 
to 28.8%), whilst a rise was seen in deaths of 
those aged 35 years and over (64.6% to 
71.2%). Those listed as living with others rose 
3.9%, and those with no fixed abode fell 1.1%. 
Decreases were also observed in the 
proportion of deaths occurring at a defined 
residential address (from 75.2% to 70.1%), 
and those occurring in hospital (from 14.1% to 
11.2%). A 4.4% fall was seen in the number of 
people listed as drug addicts/abusers when 
history was known. 
                   
2. Underlying cause(s) of death 
 
The proportion of deaths attributed to 
accidental drug poisoning rose to 64.4% in 
2011 (59.9% in 2010), with intentional self-
poisoning deaths also increasing from 14.0% 
in 2010 to 15.4% in 2011. Deaths from other 
causes dropped from 16.0% to 10.4%, whilst 
poisonings of undetermined intent remained 
relatively stable at 9.8% in 2011 (10.1% in 
2010).  
 
3. Manner of death 
 
The patterns observed for manner of death in 
2011 remained relatively stable with those 
seen in 2010 – deaths attributed to accidents 
increased by 0.7%. This is consistent with the 
rise seen in accidental poisonings and the 
sharp drop in other accidental causes, such as 
drowning, RTA etc. A 0.1% reduction was 
witnessed in the number of deaths attributed to 
suicide.  
  
4. Psychoactive substances implicated in 
death 
 
In 2011 there were 1,172/1,263 deaths that 
involved psychoactive substances; 91 cases 
were therefore excluded from the following 
analyses as they did not involve psychoactive 
substances. In 2010, 1,222/1,358 cases 
involved psychoactive substances 
 
4.1 Psychoactive substances, both alone 
and in combination 
 
There were both absolute and proportional 
increases in deaths involving the following 
substances both alone and in combination: 
amphetamines; anti-depressants; anti-
epileptics; anti-psychotics; cannabis; cocaine; 
ecstasy-type drugs; hypnotics/sedatives; 
methadone; and other opiates/opioid 
analgesics (Table 1.5). Despite 
heroin/morphine once again being the most 
frequently implicated drug, both alone and in 
combination, a significant drop of 6.9% was 
seen between the years (37.2% in 2010 down 
to 30.3% in 2011). Drops were also seen in 
deaths involving alcohol-in combination; anti-
Parkinson’s; and GHB/GBL when implicated 
both alone and in combination. 
  
4.2 Single substance 
 
There were slight changes between 2010 and 
2011 in terms of the proportions accounted for 
by deaths involving a single psychoactive 
substance. For substances implicated alone, 
there were absolute and proportional 
increases in deaths attributed to 
amphetamines; anti-depressants; anti-
epileptics; cannabis; ecstasy-type drugs; 
hypnotics/sedatives; and other opiates/opioid 
analgesics (Table 1.6). Anti-psychotics 
meanwhile were implicated in just 0.1% more 
single substance deaths in 2011 than 2010. 
There were decreases in the proportions 
accounted for by the following substances 
when implicated alone: cocaine; GHB/GBL; 
heroin/morphine; and methadone.  
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Table 1.5: Changes in percentages of psychoactive substances, alone and in 
combination, implicated in psychoactive substance deaths, np-SAD cases, 
England, 2010 and 2011 
 
Substance 
2010 
(n = 
1,222) 
% 
2010 
(n = 
1,241) † 
% 
2011 
(n = 
1,172) 
% 
Ratio of 
Proportions 
(PR) 
95% CI 
Change  
(percentage 
points) 
Alcohol-in-
combination 
31.9 31.5 27.7 1.2 1.0 – 1.3 - 4.2 
Amphetamines 3.2 3.2 3.7 1.1 0.8 – 1.8 + 0.5 
Anti-depressants 21.5 21.5 24.5 1.1 1.0 – 1.3 + 3.0 
Anti-epileptics 2.3 2.3 2.9 1.3 0.8 – 2.1 + 0.6 
Anti-Parkinson’s 0.6 0.6 0.4 1.3 0.4 – 4.2 - 0.2 
Anti-psychotics 5.3 5.3 5.6 1.1 0.8 – 1.5 + 0.3 
Cannabis 1.6 1.6 2.0 1.3 0.7 – 2.3 + 0.4 
Cocaine 9.3 9.4 10.4 1.1 0.9 – 1.4 + 1.1 
Ecstasy-type drugs 0.7 0.6 1.7 2.6 1.2 – 5.9 + 1.0 
GHB/GBL 1.1 1.2 0.9 1.2 0.5 – 2.8 - 0.2 
Heroin/morphine 37.2 37.0 30.3 1.2 1.1 – 1.4 - 6.9 
Hypnotics/sedatives 21.7 21.4 24.4 1.1 1.0 – 1.3 + 2.7 
Methadone 25.2 25.0 27.9 1.1 1.0 – 1.3 + 2.7 
Other opiates/ opioid 
analgesics 
24.9 24.8 28.0 1.1 1.0 – 1.3 + 3.1 
Note: Column totals may sum to more than 100% since more than one substance may be implicated in a death. 
†On average approximately 300 cases of inquest from the year of death are not completed and are added to next year.  
Column highlighted in        includes deaths in 2010 reported since the last report and is not used in the PR, CI or change in 
percentage points calculations 
 
 
 
Table 1.6: Changes in percentages of single psychoactive substances implicated alone in 
psychoactive substance deaths, np-SAD cases, England, 2010 and 2011 
 
Substance 
2010 
(n = 
1,222) 
% 
2010 
(n = 
1,241) † 
% 
2011 
(n = 
1,172) 
% 
Ratio of 
Proportions 
(PR) 
95% CI 
Change 
(percentage 
points) 
Amphetamines 1.4 1.4 1.6 1.2 0.6 – 2.2 + 0.2 
Anti-depressants 4.7 4.7 5.5 1.2 0.8 – 1.6 + 0.8 
Anti-epileptics 0.4 0.4 0.5 1.3 0.4 – 4.1 + 0.1 
Anti-Parkinson’s 0.1 0.1 0.1 1.0 0.1 – 16.7 0.0 
Anti-psychotics 1.2 1.3 1.3 1.0 0.5 – 2.1 + 0.1 
Cannabis 0.2 0.2 0.5 3.1 0.6 – 15.5 + 0.3 
Cocaine 2.1 2.2 1.5 1.5 0.8 – 2.7 - 0.6 
Ecstasy-type drugs 0.3 0.3 0.5 1.3 0.4 – 4.1 + 0.2 
GHB/GBL 0.5 0.6 0.3 1.4 0.4 – 5.1 - 0.2 
Heroin/morphine 11.1 11.1 8.8 1.3 1.0 – 1.6 - 2.3 
Hypnotics/sedatives 1.6 1.7 2.4 1.5 0.8 – 2.6 + 0.8 
Methadone 7.1 7.1 7.0 1.0 0.8 – 1.4 - 0.1 
Other opiates/ opioid 
analgesics 
5.3 5.2 6.9 1.3 0.9 – 1.8 + 1.6 
†On average approximately 300 cases of inquest from the year of death are not completed and are added to next year. 
Column highlighted in        includes deaths in 2010 reported since the last report and is not used in the PR, CI or change in 
percentage points calculations 
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Deaths per 100,000 population by area  
 
 
This section provides a break-down of 
information by different geographical units for 
deaths of those aged 16 years and older. Table 
A provides information on rates per 100,000 
population by Coroners’ jurisdiction for 2011; 
Table B shows the rates per 100,000 for both 
2010 and 2011 by Coroners’ jurisdiction to 
allow for comparison between the two years; 
Tables C and E provide breakdowns by Drug 
and Alcohol Action Team (DAAT) and Primary 
Care Trust (PCT) areas respectively; and Table 
D gives detailed breakdowns by DAAT area for 
key aspects, such as key demographic details 
and primary drugs implicated. 
 
Coroners’ jurisdictions with highest and 
lowest rates in 2011 
 
The following Coroner’s jurisdictions in England 
reported annual drug-related death rates higher 
than 10/100,000 population in 2011: City of 
Manchester (14.86); Blackburn, Hyndburn & 
Ribble Valley (13.35); Liverpool (11.37); and 
Blackpool & the Fylde (11.10). 
 
The following Coroner’s jurisdictions reported 
drug-related death rates for 2011 below 
1/100,000 population: Stamford (0.91); 
Southern London (0.91); Black Country (0.88); 
Spilsby & Louth (0.78); Milton Keynes (0.51); 
West Lincolnshire (0.44); Newcastle-upon-Tyne 
(0.43); Knowsley, St Helens & Sefton (0.41); 
Plymouth & South West Devon (0.40); and 
Northern London (0.17). 
 
The following areas reported that there had 
been no relevant cases: The Queen’s 
household and the Isles of Scilly. Further 
information for each jurisdiction and its 
associated rate per 100,000 can be found in 
Table A. 
 
Changes in death rates from 2010 to 2011 by 
Coroners’ jurisdiction 
 
The following jurisdictions reported notable 
increases (>2.5/100,000) in annual drug-related 
death rates  by 100,000 population from 2010 
to 2011: North Tyneside (3.68 to 9.67); 
Blackburn, Hyndburn & Ribble Valley (9.23 to 
13.35); Hartlepool (4.09 to 8.09); Rutland & 
North Leicestershire (1.35 to 4.84); North & 
West Cumbria (1.80 to 4.82); Boston & 
Spalding (2.53 to 5.51); Wiltshire (2.25 to 4.92); 
Darlington & South Durham (1.34 to 3.92); and 
Western Dorset (0.54 to 3.08). 
 
The following jurisdictions reported notable 
decreases (>2.5/100,000) in annual drug-
related death rates by 100,000 population from 
2010 to 2011: Brighton & Hove (15.69 to 8.77); 
Inner North London (7.19 to 2.51); North 
Lincolnshire & Grimsby (5.80 to 1.88); 
Portsmouth & South East Hampshire (6.37 to 
2.54); Plymouth & South West Devon (4.04 to 
0.40); Cornwall (7.65 to 4.06); Teeside (10.24 
to 6.65); and Wirral (4.80 to 1.53). 
 
Further information for each jurisdiction and its 
associated rate per 100,000 for 2010 and 2011 
can be found in Table B. 
 
Brighton and Hove, as highlighted above, 
witnessed a drop in np-SAD deaths of 
6.92/100,000 population from 2010 to 2011. 
This continues the apparent steep downward 
trend in the number of such deaths for this 
jurisdiction, with a total drop in np-SAD-relevant 
deaths of 14.59/100,000 from 2009 to 2011 
(from 23.36 to 8.77). 
  
Commentary  
 
The demographic profile of drug-related 
deaths in England meeting the np-SAD case 
criteria for 2011 remains generally consistent 
with previous reports: a higher proportion of 
males to females; majority of White ethnicity; 
with the majority aged less than 45 years. 
Deaths amongst those aged 15-24 appear to 
have dropped over the past ten years by about 
60%. The number and proportion of deaths of 
known drug users aged more than 45 years at 
the time of death notified to the Programme 
also increased over the past decade: from 141 
(13.1%) to 183 (27.9%) cases. 
 
As found in previous years, accidental 
poisoning still remains the most frequent 
underlying cause of death across all age-
groups. However, when compared with 
females and males of younger age-groups, 
older females exhibit higher rates of deaths 
attributed to intentional self-poisoning. 
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Heroin/morphine was the drug most frequently 
implicated in the deaths of males, closely 
followed by methadone. In contrast, for 
females it was anti-depressants, closely 
followed by other opiates/opioid analgesics. 
 
The drug-related deaths in England reported 
to the Programme for 2011 show that there 
have been increases in involvement at death 
of amphetamines; anti-depressants; anti-
epileptics; anti-psychotics; cannabis; cocaine; 
ecstasy-type drugs; hypnotics/sedatives; 
methadone; and other opiates/opioid 
analgesics. Meanwhile, deaths involving 
heroin/morphine; alcohol-in-combination; anti-
Parkinson’s; and GHB/GBL have decreased.  
This trend is similar to that as found in “drug 
misuse” cases. 
 
The decline in monovalent deaths noted in last 
year’s report appears to be faltering, with a 
slight increase back to 2009 levels of around 
37%, as in 2010 they accounted for 36% of 
cases. With regards polysubstance deaths, 
heroin/morphine combined with alcohol 
remains the most frequent polysubstance 
combination over the past ten years, followed 
by anti-depressants combined with 
hypnotics/sedatives.  
 
The most commonly prescribed medications 
implicated in death were anti-depressants, 
followed by hypnotics/sedatives. From 
information available on individuals’ prescribed 
medication status, it would appear that 
upwards of 54% of hypnotics/sedatives, other 
opiates/opioid analgesics and methadone-
related deaths were sourced either illegally, or 
through other means. 
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Table A: England cases in 2011 by Coroner’s jurisdiction (16 years and over) and deaths 
   in 2010 reported in 2011/12  
 
Coroner’s Jurisdiction & county 
district 
np-SAD 
deaths 
Jan-Dec 2011 
Annual death 
rate per 
100,000 
population 
(1)
 
np-SAD  2010 
deaths 
reported in 
2011/12 
(2)
 
Queen's Household 0 0.00 0 
ENGLAND    
AVON - - - 
BEDFORDSHIRE & LUTON 27 5.54 0 
BERKSHIRE 15 2.52 0 
BUCKINGHAMSHIRE    
Buckinghamshire 5 1.23 0 
Milton Keynes 1 0.51 0 
CAMBRIDGESHIRE    
North & East Cambridgeshire 4 2.75 0 
Peterborough 8 5.84 0 
South & West Cambridgeshire 9 2.49 0 
CHESHIRE 26 3.11 0 
CORNWALL    
Cornwall 18 4.06 2 
Isles of Scilly 0 0.00 0 
CUMBRIA    
North & West Cumbria 11 4.82 1 
South & East Cumbria  6 3.17 0 
DERBYSHIRE    
Derby & South Derbyshire 12 2.41 0 
North Derbyshire 17 5.08 1 
DEVON    
Exeter & Greater Devon 19 3.79 3 
Plymouth & South West Devon 1 0.40 1 
Torbay & South Devon 4 2.03 0 
DORSET    
Bournemouth, Poole & Eastern 
Dorset 
24 5.61 0 
Western Dorset 6 3.08 0 
DURHAM    
Darlington & South Durham 9 3.92 0 
North Durham 10 3.56 0 
EAST SUSSEX    
Brighton & Hove 20 8.77 2 
East Sussex 16 3.67 0 
ESSEX    
Essex & Thurrock 0 0.00 0 
Southend & South East Essex 0 0.00 0 
GLOUCESTERSHIRE 10 2.04 0 
GREATER MANCHESTER    
Manchester (City) 60 14.86 7 
North Manchester - - 5 
South Manchester             41 6.97 2 
West Manchester 36 5.40 2 
HAMPSHIRE    
Central Hampshire 4 1.37 2 
North East Hampshire 8 2.43 0 
Portsmouth & South East Hampshire 12 2.54 0 
Southampton & New Forest 22 6.42 0 
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Coroner’s Jurisdiction & county 
district 
 
np-SAD 
deaths 
Jan-Dec 2011 
Annual death 
rate per 
100,000 
population 
(1)
 
np-SAD  2010 
deaths 
reported in 
2011/12 
(2)
 
HEREFORDSHIRE  - - - 
HERTFORDSHIRE 21 2.35 0 
HUMBERSIDE    
East Riding & Hull 17 3.49 0 
ISLE OF WIGHT 9 7.78 0 
KENT    
Central & South East Kent - - - 
Mid Kent & Medway - - - 
North East Kent 22 7.87 0 
North West Kent 12 3.07 3 
LANCASHIRE    
Blackburn, Hyndburn & Ribble Valley 30 13.35 0 
Blackpool & the Fylde 20 11.10 0 
East Lancashire 19 9.70 0 
Preston & West Lancashire 42 7.17 0 
LEICESTERSHIRE    
Leicester City & South Leicestershire 12 2.65 0 
Rutland & North Leicestershire 
 
 
18 4.84 5 
LINCOLNSHIRE    
Boston & Spalding 7 5.51 0 
North Lincolnshire & Grimsby 5 1.88 0 
Spilsby & Louth 1 0.78 0 
Stamford 1 0.91 0 
West Lincolnshire 1 0.44 0 
LONDON    
City of London 1 14.79 0 
Eastern London 11 1.11 0 
Inner North London            19 2.51 1 
Inner South London 29 3.36 0 
Inner West London 17 2.30 1 
Northern London 2 0.17 0 
Southern London 8 0.91 0 
Western London 78 6.96 7 
MERSEYSIDE    
Knowsley, St Helens & Sefton 2 0.41 0 
Liverpool            44 11.37 0 
Wirral 4 1.53 0 
NORFOLK 12 1.68 0 
NORTHAMPTONSHIRE 30 5.41 0 
NORTHUMBERLAND    
North Northumberland 2 2.03 0 
South Northumberland 4 2.43 0 
NORTH YORKSHIRE    
North Yorkshire Eastern - - - 
North Yorkshire Western 3 1.04 0 
York 4 2.41 2 
NOTTINGHAMSHIRE 21 2.35 0 
OXFORDSHIRE 0 0.00 0 
SHROPSHIRE    
Mid & North Shropshire 6 3.55 0 
South Shropshire - - - 
The Wrekin 6 4.53 0 
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Coroner’s Jurisdiction & county 
district 
np-SAD 
deaths 
Jan-Dec 2011 
Annual death 
rate per 
100,000 
population 
(1)
 
np-SAD  2010 
deaths 
reported in 
2011/12 
(2)
 
SOMERSET    
Eastern Somerset 6 2.70 0 
Western Somerset 6 2.80 0 
SOUTH YORKSHIRE    
South Yorkshire East 18 3.97 0 
South Yorkshire West - - - 
STAFFORDSHIRE    
South Staffordshire 15 2.91 0 
Stoke-on-Trent & North Staffordshire 12 3.13 0 
SUFFOLK 13 2.18 0 
SURREY 20 2.18 0 
TEESSIDE    
Hartlepool 6 8.09 0 
Teesside 25 6.65 1 
TYNE & WEAR    
Gateshead & South Tyneside - - - 
Newcastle-upon-Tyne 1 0.43 0 
North Tyneside 16 9.67 0 
Sunderland 15 6.65 0 
WARWICKSHIRE - - - 
WEST MIDLANDS    
Birmingham - - - 
Black Country 6 0.88 0 
Coventry 7 2.74 0 
Wolverhampton - - - 
WEST SUSSEX 12 1.81 0 
West YORKSHIRE    
West Yorkshire Eastern 33 3.75 0 
West Yorkshire Western  23 2.55 0 
WILTSHIRE 27 4.92 0 
WORCESTERSHIRE 5 1.07 0 
 
Note that (0) refers to either no drug-related deaths or death rates of less than 0.01, whilst (–) indicates that no reports 
were submitted for the specific period from that jurisdiction or area. In subsequent reports these rates may increase as 
more inquests on deaths in 2011 are held and/or notified to the np-SAD. These rates should therefore be regarded as 
minimum rates. Rows for administrative counties have been shaded where there are Coroners’ areas located within 
them; Coroners’ areas which correspond to a complete administrative county have not been shaded. 
 
(1) The rate per 100,000 population is based on published mid-year population estimates for local government 
administrative areas for the years in question. However, the areas covered by 23 of the Coroners' jurisdictions in 
England and Wales are not co-terminous with these boundaries and cover parts of such areas (see Appendix 3). 
Where administrative areas are split between jurisdictions, the estimated population has been divided into two or 
three as applicable. However, this means that the population of some Coroners' jurisdictions may be either over- or 
under-estimated. It is necessary to make such assumptions until more accurate figures can be obtained or 
calculated.   
(2) Notified after the publication of the np-SAD Annual Report, 2011. 
(3)   The amalgamations of the following Coroners’ jurisdictions during the period covered by this report mean that rates  
for the new areas have been calculated retrospectively based on published figures: High Peak and Scarsdale were 
merged to form North Derbyshire (1 February 2006); Gloucester and Cheltenham merged to form Gloucestershire (1 
April 2006). In Norfolk, King’s Lynn and Norwich & Central Norfolk to form Greater Norfolk (6 April 2007); in Cumbria, 
the three jurisdictions of North East Cumbria, Southern Cumbria & Furness, and Western Cumbria to form two new 
areas - North & West Cumbria and South & East Cumbria (1 May 2007). Great Yarmouth merged with Greater 
Norfolk to form Norfolk on 1 April 2010. 
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 Table B: Changes in annual death rate per 100,000 population for np-SAD cases (16 
    years old and over), and annual percentage of all inquests held, 2010 and 2011  
 
Coroner’s Jurisdiction & 
county district 
Number 
of np-
SAD 
deaths 
2010 
Annual 
death 
rate per 
100,000 
populati
on 
2010 (1) 
Annual 
% of all 
inquest
s held 
in 2010 
(2) 
Number 
of np-
SAD 
deaths 
2011 
Annual 
death 
rate per 
100,000 
populati
on 
2011 (1) 
Annual 
% of all 
inquest
s held 
in 2011 
(2) 
Queen's Household 0 0.00 0.00 0 0.00 0.00 
ENGLAND       
AVON - - - - - - 
BEDFORDSHIRE & LUTON 25 5.11 12.14 27 5.54 14.4 
BERKSHIRE 17 2.46 5.90 15 2.52 5.19 
BUCKINGHAMSHIRE       
Buckinghamshire 5 1.26 4.24 5 1.23 3.16 
Milton Keynes  0 0.00 0.00 1 0.51 0.88 
CAMBRIDGESHIRE       
North & East Cambridgeshire 4 2.78 6.78 4 2.75 9.3 
Peterborough 3 2.19 3.41 3 2.07 2.65 
South & West 
Cambridgeshire 
1 0.28 0.56 9 2.49 4.5 
CHESHIRE 27 3.29 4.07 26 3.11 3.59 
CORNWALL       
Cornwall 34 7.65 10.09 18 4.06 5.24 
Isles of Scilly - - - - - - 
CUMBRIA       
North & West Cumbria 4 1.80 2.22 11 4.82 5.69 
South & East Cumbria  6 3.19 3.45 6 3.17 3.22 
DERBYSHIRE       
Derby & South Derbyshire 16 3.23 5.56 12 2.41 4.30 
North Derbyshire 11 3.32 3.34 17 5.08 5.41 
DEVON       
Exeter & Greater Devon 26 5.05 7.37 19 3.79 5.33 
Plymouth & South West 
Devon  
 
10 4.04 2.54 1 0.40 0.29 
Torbay & South Devon 6 3.00 6.00 4 2.03 5.63 
DORSET       
Bournemouth, Poole & 
Eastern Dorset 
24 5.88 13.71 24 5.61 14.28 
Western Dorset 1 0.54 1.18 6 3.08 8.95 
DURHAM       
Darlington & South Durham 3 1.34 2.16 9 3.92 5.32 
North Durham 1 0.36 0.38 10 3.56 2.83 
EAST SUSSEX       
Brighton & Hove 34 15.69 15.31 20 8.77 9.38 
East Sussex 25 5.89 7.72 16 3.67 4.16 
ESSEX       
Essex & Thurrock 8 0.71 1.35 - - - 
Southend & South East 
Essex 
8 2.91 7.77 - - - 
GLOUCESTERSHIRE 4 0.82 0.96 10 2.04 2.38 
GREATER MANCHESTER       
Manchester (City) 62 15.15 7.70 60 14.86 8.13 
North Manchester 19 3.96 3.50 - - - 
South Manchester 41 7.06 8.55 41 6.97 7.03 
West Manchester 45 6.95 7.04 36 5.40 5.61 
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HAMPSHIRE       
Central Hampshire 10 3.53 4.30 4 1.37 2.29 
North East Hampshire 10 3.08 6.67 8 2.43 7.4 
Portsmouth & South East 
Hampshire 
30 6.37 7.73 12 2.54 2.7 
Southampton & New Forest 18 5.17 8.91 22 6.42 9.36 
HEREFORDSHIRE  4 2.70 3.70 - - - 
HERTFORDSHIRE 22 2.48 6.55 21 2.35 6.26 
HUMBERSIDE       
East Riding & Hull 15 3.01 5.47 17 3.49 5.96 
ISLE OF WIGHT 5 4.25 6.67 9 7.78 14.51 
KENT       
Central & South East Kent - - - - - - 
Mid Kent & Medway 1 0.23 0.48 - - - 
North East Kent 20 7.19 9.57 22 7.87 10.42 
North West Kent 14 3.68 6.43 12 3.07 7.79 
LANCASHIRE       
Blackburn, Hyndburn & 
Ribble Valley 
20 9.23 6.25 30 13.35 9.61 
Blackpool & the Fylde 21 11.77 16.03 20 11.10 15.87 
East Lancashire 19 9.85 14.96 19 9.70 12.41 
Preston & West Lancashire 29 4.96 7.16 42 7.17 8.89 
LEICESTERSHIRE       
Leicester City & South 
Leicestershire 
6 1.38 1.44 12 2.65 3.48 
Rutland & North 
Leicestershire 
5 1.35 3.7 18 4.84 8.69 
LINCOLNSHIRE       
Boston & Spalding 3 2.53 6.00 7 5.51 12.5 
North Lincolnshire & Grimsby 15 5.80 12.50 5 1.88 3.37 
Spilsby & Louth 1 0.76 2.04 1 0.78 2.43 
Stamford 0 0.00 0.00 1 0.91 9.09 
West Lincolnshire 0 0.00 0.00 1 0.44 0.70 
LONDON       
City of London 1 13.97 6.25 1 14.79 10 
Eastern London 9 1.01 2.33 11 1.11 3.34 
Inner North London 52 7.19 9.60 19 2.51 4.94 
Inner South London 38 4.41 9.95 38 4.21 8.17 
Inner West London 12 1.55 3.03 17 2.30 3.68 
Northern London 5 0.46 0.99 2 0.17 0.51 
Southern London 5 0.58 1.69 8 0.91 2.61 
Western London 91 8.35 15.11 78 6.96 15.05 
MERSEYSIDE       
Knowsley, St Helens & 
Sefton 
5 1.02 1.75 2 0.41 0.78 
Liverpool 35 9.49 6.77 44 11.37 8.38 
Wirral 12 4.80 4.74 4 1.53 1.54 
NORFOLK 24 3.34 5.03 12 1.68 2.45 
NORTHAMPTONSHIRE 
21 3.81 
8.61 
 
30 5.41 11.27 
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Coroner’s Jurisdiction & 
county district 
Number 
of np-
SAD 
deaths 
2010 
Annual 
death 
rate per 
100,000 
populati
on 
2010 (1) 
Annual 
% of all 
inquest
s held 
in 2010 
(2) 
Number 
of np-
SAD 
deaths 
2011 
Annual 
death 
rate per 
100,000 
populati
on 
2011 (1) 
Annual 
% of all 
inquest
s held 
in 2011 
(2) 
NORTHUMBERLAND       
North Northumberland 0 0.00 0.00 2 2.03 1.62 
South Northumberland 7 4.33 7.00 4 2.43 4.49 
NORTH YORKSHIRE       
North Yorkshire Eastern 2 0.96 1.55 - - - 
North Yorkshire Western 1 0.35 0.79 3 1.04 2.47 
York 2 1.17 1.5 4 2.41 3.53 
NOTTINGHAMSHIRE 2 0.22 0.50 21 2.35 5.18 
OXFORDSHIRE 9 1.71 3.18 - - - 
SHROPSHIRE       
Mid & North Shropshire 6 3.74 6.90 6 3.55 8.1 
South Shropshire - - - - - - 
The Wrekin 6 4.64 6.74 6 4.53 8.69 
SOMERSET       
Eastern Somerset 6 2.75 4.20 6 2.70 4.19 
Western Somerset 9 4.25 7.32 6 2.80 6.00 
SOUTH YORKSHIRE       
South Yorkshire East 13 2.95 4.50 18 3.97 5.32 
South Yorkshire West 12 1.86 3.16 12 1.86 2.51 
STAFFORDSHIRE       
South Staffordshire 18 3.62 5.81 15 2.91 4.13 
Stoke-on-Trent & North 
Staffordshire 
14 3.72 2.95 12 3.13 2.71 
SUFFOLK 15 2.55 5.45 13 2.18 4.74 
SURREY 30 3.30 7.61 20 2.18 6.38 
TEESSIDE       
Hartlepool 3 4.09 5.26 6 8.09 13.04 
Teesside 39 10.24 13.29 25 6.65 8.8 
TYNE & WEAR       
Gateshead & South Tyneside 7 2.45 3.11 - - - 
Newcastle-upon-Tyne 2 0.82 0.63 1 0.43 0.28 
North Tyneside 6 3.68 2.65 16 9.67 7.8 
Sunderland 18 7.68 3.95 15 6.65 4.02 
WARWICKSHIRE - - - - - - 
WEST MIDLANDS       
Birmingham 12 1.23 1.19 - - - 
Black Country - - - - - - 
Coventry 2 0.79 1.18 7 2.74 3.58 
Wolverhampton 0 0.00 0.00 - 0.00 0.00 
WEST SUSSEX 16 2.45 5.73 12 1.81 4.59 
West YORKSHIRE       
West Yorkshire Eastern 40 4.31 7.42 33 3.75 6.8 
West Yorkshire Western  42 4.75 9.15 23 2.55 5.06 
WILTSHIRE 12 2.25 2.88 27 4.92 8.08 
WORCESTERSHIRE 3 0.66 0.84 5 1.07 1.52 
 
 
 
Note that (0) refers to either no drug-related deaths or death rates of less than 0.01, whilst (–) indicates that no reports 
were submitted for the specific period from that jurisdiction or area. In subsequent reports these rates may increase as 
more inquests on deaths in 2011 are held and/or notified to the np-SAD. These rates should therefore be regarded as 
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minimum rates. Rows for administrative counties have been shaded where there are Coroners’ areas located within 
them; Coroners’ areas which correspond to a complete administrative county have not been shaded. 
 
(1) The rate per 100,000 population is based on published mid-year population estimates for local government 
administrative areas for the years in question. However, the areas covered by 23 of the Coroners' jurisdictions in 
England and Wales are not co-terminous with these boundaries and cover parts of such areas (see Appendix 3). 
Where administrative areas are split between jurisdictions, the estimated population has been divided into two or 
three as applicable.  However, this means that the population of some Coroners' jurisdictions may be either over- 
or under-estimated.  It is necessary to make such assumptions until more accurate figures can be obtained or 
calculated.   
(2) Inquests held on all ages. 
(3)    The amalgamations of the following Coroners’ jurisdictions during the period covered by this report mean that rates 
for the new areas have been calculated retrospectively based on published figures: High Peak and Scarsdale were 
merged to form North Derbyshire (1 February 2006); Gloucester and Cheltenham merged to form Gloucestershire 
(1 April 2006). In Norfolk, King’s Lynn and Norwich & Central Norfolk to form Greater Norfolk (6 April 2007); in 
Cumbria, the three jurisdictions of North East Cumbria, Southern Cumbria & Furness, and Western Cumbria to 
form two new areas - North & West Cumbria and South & East Cumbria (1 May 2007). Great Yarmouth merged 
with Greater Norfolk to form Norfolk on 1 April 2010. 
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Table C: np-SAD cases in 2011 by Drug and Alcohol Action Team area (16 years and over) 
 – number and rate per 100,000 population  
 
Drug and Alcohol Action Team Number and annual 
death rate per 100,000 
population – usual area 
of residence 
Number and annual 
death rate per 100,000 
population – place of 
death 
 No Rate No Rate 
ENGLAND     
NORTH EAST     
County Durham 16 3.77 6 1.42 
Darlington 4 4.65 3 3.49 
Gateshead 0 0.00 0 0.00 
Hartlepool 8 10.81 6 8.11 
Middlesbrough 11 10.00 6 5.45 
Newcastle upon Tyne 3 1.30 2 0.87 
North Tyneside* 12 7.23 13 7.83 
Northumberland 8 3.04 7 2.66 
Redcar and Cleveland 4 3.60 5 4.50 
South Tyneside 0 0.00 0 0.00 
Stockton on Tees 8 5.19 10 6.49 
Sunderland 14 6.17 14 6.17 
NORTH WEST     
Blackburn with Darwen 16 14.04 13 11.40 
Blackpool 17 14.53 15 12.82 
Bolton 12 5.45 12 5.45 
Bury 0 0.00 0 0.00 
Cheshire* 14 2.43 12 2.08 
Cumbria 15 3.60 13 3.12 
Halton 2 1.98 0 0.00 
Knowsley 2 1.71 1 0.85 
Lancashire 74 7.73 65 6.79 
Liverpool 35 9.04 33 8.53 
Manchester 49 12.16 45 11.17 
Oldham 2 1.14 1 0.57 
Rochdale 3 1.80 3 1.80 
Salford 22 11.64 20 10.58 
Sefton 7 3.08 2 0.88 
St Helens 0 0.00 0 0.00 
Stockport 13 5.65 10 4.35 
Tameside 17 9.60 14 7.91 
Trafford 6 3.31 7 3.87 
Warrington 11 6.71 9 5.49 
Wigan 10 3.88 10 3.88 
Wirral 4 1.53 0 0.00 
YORKSHIRE AND HUMBER     
Barnsley 0 0.00 0 0.00 
Bradford 14 3.49 10 2.49 
Calderdale 0 0.00 0 0.00 
Doncaster 4 1.63 3 1.22 
East Riding of Yorkshire 4 1.43 4 1.43 
Kingston upon Hull 13 6.28 13 6.28 
Kirklees 9 2.67 8 2.37 
Leeds 24 3.92 24 3.92 
North East Lincolnshire 3 2.33 1 0.78 
North Lincolnshire 2 1.47 1 0.74 
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Drug and Alcohol Action Team Number and annual 
death rate per 100,000 
population – usual area 
of residence 
Number and annual 
death rate per 100,000 
population – place of 
death 
 No Rate No Rate 
North Yorkshire 4 0.80 3 0.60 
Rotherham 1 0.48 1 0.48 
Sheffield 11 2.45 12 2.67 
Wakefield 11 4.14 11 4.14 
York* 4 2.42 3 1.82 
EAST MIDLANDS     
Derby 5 2.53 6 3.03 
Derbyshire 23 3.63 17 2.68 
Leicester 12 4.62 6 2.31 
Leicestershire* 17 3.19 8 1.50 
Lincolnshire 11 1.85 9 1.52 
Northamptonshire 27 4.86 24 4.32 
Nottingham 5 2.03 4 1.63 
Nottinghamshire* 17 2.64 12 1.86 
Rutland* 2 6.37 2 6.37 
WEST MIDLANDS     
Birmingham* 0 0.00 1 0.12 
Coventry 5 1.98 3 1.19 
Dudley* 3 1.18 3 1.18 
Herefordshire 1 0.66 0 0.00 
Sandwell 2 0.83 1 0.41 
Shropshire* 5 1.97 7 2.76 
Solihull* 0 0.00 0 0.00 
Staffordshire 16 2.29 14 2.00 
Stoke-on-Trent 10 5.00 9 4.50 
Telford and Wrekin 6 4.51 4 3.01 
Walsall* 1 0.47 1 0.47 
Warwickshire* 0 0.00 0 0.00 
Wolverhampton 2 1.00 1 0.50 
Worcestershire 5 1.07 5 1.07 
EAST     
Bedfordshire 19 5.72 18 5.42 
Cambridgeshire 9 1.77 6 1.18 
Essex 0 0.00 0 0.00 
Hertfordshire 17 1.90 21 2.34 
Luton 7 4.46 8 5.10 
Norfolk 11 1.54 8 1.12 
Peterborough 9 6.21 9 6.21 
Southend-on-Sea 0 0.00 0 0.00 
Suffolk 12 2.01 7 1.17 
Thurrock 0 0.00 0 0.00 
LONDON     
Inner London     
Camden 2 1.09 1 0.54 
City of London 0 0.00 0 0.00 
Hackney 8 4.08 5 2.55 
Hammersmith and Fulham 10 6.54 14 9.15 
Haringey 1 0.49 0 0.00 
Islington 7 4.05 2 1.16 
Kensington and Chelsea 1 0.75 2 1.49 
Lambeth 4 1.60 5 2.00 
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Drug and Alcohol Action Team Number and annual 
death rate per 100,000 
population – usual area 
of residence 
Number and annual 
death rate per 100,000 
population – place of 
death 
 No Rate No Rate 
Lewisham 5 2.27 1 0.45 
Newham 5 2.08 2 0.83 
Southwark 7 2.98 5 2.13 
Tower Hamlets 3 1.46 1 0.49 
Wandsworth 0 0.00 0 0.00 
Westminster 12 6.45 11 5.91 
Outer London         
Barking and Dagenham 1 0.72 1 0.72 
Barnet 2 0.71 1 0.35 
Bexley 2 1.08 1 0.54 
Brent 1 0.40 0 0.00 
Bromley 1 0.40 0 0.00 
Croydon 9 3.15 5 1.75 
Ealing 23 8.49 23 8.49 
Enfield 1 0.41 0 0.00 
Greenwich 2 1.00 1 0.50 
Harrow 1 0.52 1 0.52 
Havering 1 0.52 1 0.52 
Hillingdon 11 5.05 10 4.59 
Hounslow 12 5.91 12 5.91 
Kingston-upon-Thames 6 4.62 7 5.38 
Merton 3 1.86 1 0.62 
Redbridge 1 0.46 0 0.00 
Richmond-upon-Thames 9 6.00 8 5.33 
Sutton 3 1.96 2 1.31 
Waltham Forest 4 1.96 2 0.98 
SOUTH EAST     
Bracknell Forest 2 2.22 2 2.22 
Brighton and Hove 22 9.65 17 7.46 
Buckinghamshire 4 0.99 1 0.25 
East Sussex 16 3.67 13 2.98 
Hampshire 22 2.04 18 1.67 
Isle of Wight 9 7.76 8 6.90 
Kent* 35 2.96 32 2.70 
Medway towns 0 0.00 0 0.00 
Milton Keynes 2 1.03 2 1.03 
Oxfordshire 1 0.19 0 0.00 
Portsmouth 8 4.79 8 4.79 
Reading 2 1.60 6 4.80 
Slough 2 1.87 1 0.93 
Southampton 17 8.76 17 8.76 
Surrey 21 2.29 19 2.07 
West Berkshire 1 0.81 0 0.00 
West Sussex 9 1.36 9 1.36 
Windsor and Maidenhead 5 4.28 5 4.28 
Wokingham 0 0.00 0 0.00 
SOUTH WEST     
Bath and North East Somerset* 0 0.00 0 0.00 
Bournemouth 13 8.39 6 3.87 
Bristol* 0 0.00 0 0.00 
Cornwall & Isles of Scilly 14 3.14 9 2.02 
Devon 20 3.21 20 3.21 
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Drug and Alcohol Action Team National and annual 
death rate per 100,000 
population – usual area 
of residence 
National and annual 
death rate per 100,000 
population – place of 
death 
 No Rate No Rate 
Dorset 8 2.31 3 0.86 
Gloucestershire 10 2.04 9 1.83 
North Somerset* 1 0.60 0 0.00 
Plymouth 1 0.47 1 0.47 
Poole 10 8.20 7 5.74 
Somerset 10 8.00 11 2.52 
South Gloucestershire* 0 0.00 0 0.00 
Swindon 16 9.52 16 9.52 
Torbay 3 2.73 3 2.73 
Wiltshire 11 2.87 10 2.61 
 
Note: In addition there were a number of cases that could not be allocated to specific DAAT areas because they were of 
no fixed abode and/or the jurisdiction in which the inquest was held covers more than one DAAT. Some cases were 
usually resident outside the UK. Some DAATs are covered by Coroners’ jurisdictions that did not submit information or 
only partial information) to the np-SAD; they are marked thus - *.  
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Table D: np-SAD cases in 2011 by Drug and Alcohol Action Team area demographics and 
 drugs implicated. 
 
Drug and 
Alcohol Action 
Team 
No Gender Age-group Ethnicity Main Drug Strategy drug 
implicated 
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ENGLAND                     
NORTH EAST                     
County Durham 16 12 4 2 6 4 2 2 0 2 0 0 0 14 2 3 3 0 1 1 
Darlington 4 3 1 0 0 1 2 0 1 1 0 0 0 3 0 0 1 0 0 0 
Gateshead 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Hartlepool 8 6 2 0 1 1 4 2 0 8 0 0 0 0 1 1 2 0 0 0 
Middlesbrough 11 9 2 0 4 5 2 0 0 9 1 0 1 0 2 3 4 3 1 0 
Newcastle upon 
Tyne 
3 3 0 0 1 1 1 0 0 2 0 0 0 1 1 2 0 0 0 0 
North Tyneside* 12 6 6 2 5 0 2 3 0 11 0 0 0 1 0 2 2 1 1 0 
Northumberland 8 8 0 1 0 3 3 0 1 7 1 0 0 0 2 2 5 0 0 0 
Redcar and 
Cleveland 
4 2 2 0 1 0 1 0 2 4 0 0 0 0 0 1 3 0 0 0 
South Tyneside 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Stockton on 
Tees 
8 5 3 2 4 1 0 1 0 8 0 0 0 0 3 3 3 0 0 1 
Sunderland 14 12 2 2 4 5 1 1 1 13 0 0 0 1 2 0 2 0 0 0 
NORTH WEST                     
Blackburn with 
Darwen 
16 12 4 0 2 7 2 5 0 15 0 0 0 1 8 3 5 1 1 0 
Blackpool 17 12 5 2 5 6 3 1 0 15 0 0 0 2 10 3 3 0 2 1 
Bolton 12 11 1 1 1 4 5 1 0 5 0 0 0 7 5 3 3 0 0 0 
Bury 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Cheshire 14 10 4 0 4 4 2 1 3 14 0 0 0 0 4 2 4 0 0 0 
Cumbria 15 10 5 3 7 5 0 0 0 14 0 0 0 1 1 8 7 0 0 0 
Halton 2 1 1 0 0 1 1 0 0 2 0 0 0 0 0 0 0 1 1 1 
Knowsley 2 2 0 0 1 1 0 0 0 2 0 0 0 0 2 0 0 1 0 0 
Lancashire 74 54 20 3 15 30 15 4 7 22 0 0 0 52 24 20 23 2 6 0 
Liverpool 35 24 11 1 1 18 10 4 1 32 0 0 0 3 5 15 4 6 1 2 
Manchester 49 26 23 2 4 14 18 8 3 34 1 0 3 11 7 11 4 2 2 0 
Oldham 2 2 0 1 1 0 0 0 0 2 0 0 0 0 0 1 0 0 0 0 
Rochdale 3 3 0 1 0 1 1 0 0 2 0 1 0 0 1 1 0 1 1 0 
Salford 22 14 8 0 3 11 5 1 2 5 0 0 0 17 6 6 4 0 2 0 
Sefton 7 5 2 0 3 2 2 0 0 7 0 0 0 0 5 3 1 1 0 1 
St. Helens 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Stockport 13 12 1 0 4 5 2 0 2 11 0 0 1 1 3 4 5 3 0 0 
Tameside 17 10 7 0 6 6 5 0 0 14 0 0 0 3 3 6 0 1 0 2 
Trafford 6 4 2 0 0 4 1 1 0 6 0 0 0 0 2 3 1 0 0 0 
Warrington 11 7 4 1 4 2 1 2 1 10 0 0 0 1 1 3 3 1 1 1 
Wigan 10 8 2 1 4 3 1 1 0 0 0 0 0 10 2 5 2 0 0 0 
Wirral 4 4 0 0 1 1 0 2 0 3 0 0 0 1 0 0 1 0 0 0 
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Drug and 
Alcohol Action 
Team 
N
o 
Gender Age-group Ethnicity Main Drug Strategy drug 
implicated 
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YORKSHIRE 
AND HUMBER 
                    
Barnsley 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Bradford 14 9 5 2 3 7 2 0 0 13 0 1 0 0 1 4 0 2 1 0 
Calderdale 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Doncaster 4 4 0 0 1 3 0 0 0 3 0 0 0 1 2 2 2 0 0 0 
East Riding of 
Yorkshire 
4 4 0 0 2 2 0 0 0 4 0 0 0 0 2 3 2 0 0 0 
Kingston upon 
Hull 
13 11 2 2 5 6 0 0 0 9 0 0 0 4 7 6 6 1 0 0 
Kirklees 9 7 2 2 4 2 1 0 0 8 0 1 0 0 5 5 3 2 0 0 
Leeds 24 13 11 2 5 7 5 5 0 23 0 1 0 0 4 3 5 2 2 0 
North East 
Lincolnshire 
3 2 1 0 0 2 0 0 1 1 0 0 0 2 0 2 1 0 0 0 
North Lincolnshire 2 2 0 0 2 0 0 0 0 2 0 0 0 0 2 1 0 1 0 0 
North Yorkshire 4 4 0 0 2 2 0 0 0 3 0 0 0 1 3 2 2 1 1 0 
Rotherham 1 0 1 1 0 0 0 0 0 0 0 0 0 1 0 1 1 1 0 0 
Sheffield 11 8 3 3 1 5 1 0 1 11 0 0 0 0 1 3 2 1 1 0 
Wakefield 11 10 1 1 5 4 0 1 0 10 0 1 0 0 3 2 1 0 0 0 
York   4 4 0 1 0 3 0 0 0 4 0 0 0 0 1 1 0 0 1 0 
EAST 
MIDLANDS 
                    
Derby 5 4 1 0 2 1 2 0 0 3 1 0 1 0 1 1 2 0 2 0 
Derbyshire 23 17 6 2 4 9 6 1 1 19 0 0 0 4 7 6 2 3 2 0 
Leicester 12 10 2 0 1 7 0 1 3 10 0 0 0 2 5 4 6 0 0 0 
Leicestershire* 17 9 8 1 2 8 3 1 2 6 0 0 0 11 3 5 5 1 0 0 
Lincolnshire 11 9 2 1 5 3 1 0 1 10 0 1 0 0 6 4 2 0 2 0 
Northamptonshire 27 17 10 2 8 7 8 2 0 27 0 0 0 0 4 10 7 2 1 0 
Nottingham 5 3 2 1 0 1 2 0 1 5 0 0 0 0 2 2 2 1 0 0 
Nottinghamshire* 17 10 7 2 6 2 4 2 1 17 0 0 0 0 7 4 4 5 0 0 
Rutland* 2 1 1 0 0 0 1 0 1 0 0 0 0 2 1 0 0 0 0 0 
WEST 
MIDLANDS 
                    
Birmingham* 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Coventry 5 5 0 0 1 3 1 0 0 2 0 0 0 3 1 3 1 0 0 0 
Dudley* 3 3 0 0 1 1 0 0 1 3 0 0 0 0 0 2 2 0 0 0 
Herefordshire 1 1 0 0 1 0 0 0 0 0 0 0 0 1 1 0 1 0 0 0 
Sandwell 2 2 0 0 1 1 0 0 0 1 0 0 0 1 0 0 0 1 0 0 
Shropshire 5 3 2 0 0 4 0 0 1 0 0 0 0 5 3 0 1 0 0 0 
Solihull* 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Staffordshire 16 9 7 4 1 4 4 3 0 15 0 0 0 1 3 2 5 3 1 0 
Stoke-on-Trent 10 8 2 0 6 3 1 0 0 7 0 0 0 3 2 4 2 0 0 0 
Telford & Wrekin 6 4 2 2 0 1 2 1 0 5 0 0 0 1 1 1 0 0 0 0 
Walsall 1 1 0 0 0 0 1 0 0 1 0 0 0 0 0 0 0 0 0 0 
Warwickshire* 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Wolverhampton 2 2 0 0 0 2 0 0 0 1 0 0 0 1 1 0 0 1 0 0 
Worcestershire 5 4 1 0 4 0 1 0 0 3 0 0 0 2 0 2 1 0 0 0 
EAST                     
Bedfordshire 19 11 8 0 3 6 4 3 3 19 0 0 0 0 4 4 5 2 0 0 
Cambridgeshire 9 8 1 2 1 1 4 0 0 0 0 0 0 9 1 1 1 1 0 0 
Essex* 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Hertfordshire 17 8 9 0 5 4 4 4 0 0 0 0 0 17 8 4 4 0 0 0 
Luton 7 5 2 1 1 0 3 0 2 6 1 0 0 0 1 0 0 0 0 0 
Norfolk 11 9 2 1 3 4 1 1 1 2 0 0 0 9 7 4 4 0 0 0 
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Drug and 
Alcohol Action 
Team 
N
o 
Gender Age-group Ethnicity Main Drug Strategy drug 
implicated 
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Peterborough 9 7 2 1 4 2 1 0 1 8 0 0 0 1 4 1 0 1 0 0 
Southend-on-
Sea* 
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Suffolk 12 8 4 1 2 6 3 0 0 4 0 0 0 8 1 3 1 0 0 0 
Thurrock 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
LONDON                     
Inner London                     
Camden 2 2 0 0 1 0 0 1 0 1 0 0 0 1 1 0 1 0 0 0 
City of London 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Hackney 8 5 3 3 1 3 0 1 0 5 1 1 0 1 5 2 0 3 0 0 
Hammersmith 
and Fulham 
10 5 5 0 2 1 2 4 1 9 0 0 0 1 2 3 1 2 0 0 
Haringey 1 0 1 0 0 0 1 0 0 1 0 0 0 0 0 0 0 0 0 0 
Islington 7 5 2 0 1 1 5 0 0 5 0 0 0 2 3 1 1 1 0 0 
Kensington and 
Chelsea 
1 1 0 0 0 0 1 1 0 1 0 0 0 0 0 1 0 0 0 0 
Lambeth 4 3 1 0 2 0 1 1 0 2 1 0 0 1 2 2 0 0 0 0 
Lewisham 5 3 2 0 0 4 1 0 0 2 0 0 0 3 0 2 0 1 2 0 
Newham 5 5 0 1 0 3 1 0 0 1 0 1 1 2 1 0 1 1 1 1 
Southwark 7 5 2 0 2 4 1 0 0 5 1 0 0 1 2 3 1 3 0 1 
Tower Hamlets 3 3 0 1 1 0 1 0 0 2 0 0 0 1 1 1 1 0 0 0 
Wandsworth 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Westminster 12 7 5 1 1 5 3 1 1 4 0 0 0 8 2 3 5 5 0 1 
Outer London                     
Barking and 
Dagenham 
1 1 0 0 0 0 1 0 0 0 0 0 0 1 0 1 0 0 0 0 
Barnet  2 2 0 0 0 1 0 1 0 1 0 0 0 1 1 0 1 0 0 0 
Bexley 2 1 1 0 1 0 1 0 0 2 0 0 0 0 1 4 1 0 0 0 
Brent 1 1 0 0 1 0 0 0 0 1 0 0 0 0 1 0 1 0 0 0 
Bromley 1 1 0 0 0 0 1 0 0 1 0 0 0 0 0 1 0 0 0 0 
Croydon 9 8 1 0 4 3 2 0 0 3 0 0 0 6 2 2 0 5 0 0 
Ealing 23 17 6 1 4 5 6 4 3 14 2 5 0 1 7 9 2 6 0 0 
Enfield 1 1 0 0 0 1 0 0 0 1 0 0 0 0 0 0 1 0 0 0 
Greenwich 2 1 1 0 1 0 1 0 0 0 1 0 0 1 1 0 0 0 0 0 
Harrow 1 1 0 0 1 0 0 0 0 0 0 0 0 1 0 0 1 0 0 0 
Havering 1 1 0 0 0 1 0 0 0 0 0 1 0 0 1 0 0 0 0 0 
Hillingdon 11 6 5 1 1 2 5 0 2 6 0 2 0 3 2 5 3 4 1 0 
Hounslow 12 10 2 1 1 4 5 1 0 10 0 0 0 2 3 4 1 3 0 0 
Kingston-upon-
Thames 
6 5 1 0 3 1 1 1 0 6 0 0 0 0 2 1 4 3 0 0 
Merton 3 2 1 0 1 1 0 1 0 1 0 0 0 1 2 0 0 1 0 1 
Redbridge 1 1 0 0 0 1 0 0 0 0 1 0 0 0 1 0 0 0 0 0 
Richmond-upon-
Thames 
9 7 2 0 1 2 4 1 1 6 0 0 0 3 1 0 3 0 0 0 
Sutton 3 3 0 0 0 2 1 0 0 2 0 0 0 1 2 1 1 1 0 0 
Waltham Forest 4 2 2 0 0 2 0 2 0 3 1 0 0 0 0 0 0 0 0 0 
SOUTH EAST                     
Bracknell Forest 2 2 0 0 0 1 1 0 0 0 0 0 0 2 0 0 1 0 0 0 
Brighton & Hove 22 17 5 0 5 6 8 3 0 18 1 0 1 2 7 9 12 0 0 0 
Buckinghamshire 4 2 2 1 0 1 2 0 0 3 0 0 0 1 3 2 1 1 0 0 
East Sussex 16 11 5 3 4 2 6 1 0 16 0 0 0 0 8 3 6 1 0 0 
Hampshire 22 14 8 2 3 5 9 1 2 21 0 0 0 1 3 3 0 4 1 2 
Isle of Wight 9 6 3 1 1 3 3 1 0 9 0 0 0 0 2 0 2 0 0 0 
Kent 35 22 13 2 6 11 8 5 3 4 0 0 0 31 9 1 10 4 1 0 
Medway towns* 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Milton Keynes 2 2 0 0 0 0 2 0 0 2 0 0 0 0 0 0 0 0 0 0 
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Oxfordshire 1 0 1 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 
Portsmouth 8 6 2 0 1 3 3 1 0 7 0 0 0 1 5 1 2 1 0 0 
Reading 2 2 0 0 0 1 0 1 0 0 0 0 0 2 0 1 0 0 0 0 
Slough 2 1 1 1 0 1 0 0 0 1 0 0 0 1 1 0 0 0 0 0 
Southampton 17 13 4 3 1 4 5 3 1 15 0 0 0 2 2 3 0 2 0 1 
Surrey 21 16 5 1 4 9 5 0 2 5 0 0 0 16 6 3 6 3 1 1 
West Berkshire 1 0 1 0 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 
West Sussex 9 5 4 0 2 0 4 1 2 3 0 0 0 6 1 1 2 1 0 0 
Windsor and 
Maidenhead 
5 4 1 0 0 4 0 1 0 0 0 0 0 5 2 0 3 0 0 0 
Wokingham* 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
SOUTH WEST                     
Bath and North 
East Somerset* 
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Bournemouth 13 11 2 0 3 4 5 1 0 13 0 0 0 0 5 11 3 1 0 0 
Bristol* 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Cornwall & Isles 
of Scilly 
14 10 4 0 2 4 5 2 1 8 0 0 0 6 0 2 3 0 0 0 
Devon 20 13 7 0 5 4 4 4 3 2 0 0 0 18 3 2 4 0 0 0 
Dorset 8 7 1 1 3 1 2 1 0 7 0 0 0 1 6 2 2 0 0 0 
Gloucestershire 10 2 8 0 1 3 6 0 0 10 0 0 0 0 3 2 3 0 0 0 
North Somerset* 1 1 0 0 0 1 0 0 0 1 0 0 0 0 1 0 1 0 0 0 
Plymouth 1 1 0 1 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 
Poole 10 8 2 0 4 3 1 1 1 9 0 1 0 0 3 3 1 0 0 0 
Somerset 10 7 3 1 2 1 4 1 1 8 0 0 0 2 3 1 2 0 1 0 
South 
Gloucestershire* 
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Swindon 16 12 4 0 6 3 7 0 0 15 0 0 0 1 5 7 2 2 0 0 
Torbay 3 1 2 0 0 2 0 1 0 3 0 0 0 0 2 1 2 1 1 0 
Wiltshire 11 4 7 0 1 2 3 4 1 11 0 0 0 0 3 1 2 0 0 0 
 
Note: In addition there were a number of cases that could not be allocated to specific DAAT areas because they were of 
no fixed abode and/or the jurisdiction in which the inquest was held covers more than one DAAT. Some cases were 
usually resident outside the UK. Some DAATs are covered by coroner’s jurisdictions that did not submit information (or 
only partial information) to the np-SAD; they are marked thus - *. 
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Table E: np-SAD cases in 2011 by Primary Care Trust and Strategic Health Authority 
 areas in England (16 years and over)  
 
Area  Number and annual 
death rate per 100,000 
population – usual area 
of residence 
Number and annual 
death rate per 100,000 
population – place of 
death 
 No Rate No Rate 
ENGLAND (SHA and PCT)     
NORTH EAST SHA* 88 4.13 72 3.38 
County Durham 16 3.76 6 1.41 
Darlington 4 4.91 3 3.69 
Gateshead 0 0.00 0 0.00 
Hartlepool 8 10.96 6 8.22 
Middlesbrough 11 9.26 6 5.05 
Newcastle-upon-Tyne 3 1.28 2 0.85 
North Tyneside* 12 7.03 13 7.62 
Northumberland 8 3.09 7 2.71 
Redcar and Cleveland 4 3.73 5 4.66 
South Tyneside 0 0.00 0 0.00 
Stockton on Tees Teaching 80 5.21 10 6.52 
Sunderland Teaching 14 6.11 14 6.11 
NORTH WEST SHA* 334 5.83 293 5.11 
Ashton, Leigh and Wigan 10 4.06 10 4.06 
Blackburn with Darwen 16 13.81 13 11.22 
Blackpool 17 15.07 15 13.30 
Bolton 12 5.69 12 5.69 
Bury 0 0.00 0 0.00 
Central and Eastern Cheshire* 12 3.29 10 2.74 
Central Lancashire 19 5.21 16 4.38 
Cumbria Teaching 15 3.62 13 3.14 
Halton and St Helens 30 10.20 29 9.86 
Heywood, Middleton and Rochdale 2 0.81 0 0.00 
Knowsley 3 1.87 3 1.87 
Lancashire East 3 2.52 1 0.84 
Liverpool 35 9.32 33 8.78 
Manchester 49 11.39 45 10.46 
North Lancashire Teaching 25 9.24 21 7.76 
Oldham 2 1.15 1 0.58 
Salford 22 11.59 20 10.54 
Sefton 7 3.17 2 0.91 
Stockport 13 5.60 10 4.31 
Tameside and Glossop 20 10.96 17 9.31 
Trafford 6 3.49 7 4.07 
Warrington 11 6.95 9 5.69 
Western Cheshire* 2 0.99 2 0.99 
Wirral 4 1.60 4 1.60 
YORKSHIRE AND HUMBER SHA* 104 2.37 94 2.14 
Barnsley 0 0.00 0 0.00 
Bradford and Airedale Teaching 14 3.53 10 2.52 
Calderdale 0 0.00 0 0.00 
Doncaster 4 1.69 3 1.27 
East Riding of Yorkshire 4 1.55 4 1.55 
Hull Teaching 13 5.51 13 5.51 
Kirklees 9 2.83 8 2.51 
Leeds 24 3.60 24 3.60 
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Area Number and annual 
death rate per 100,000 
population – usual area 
of residence 
Number and annual 
death rate per 100,000 
population – place of 
death 
 No Rate No Rate 
North East Lincolnshire  
 
3 2.28 1 0.76 
North Lincolnshire 2 1.54 1 0.77 
North Yorkshire and York* 8 1.24 6 0.93 
Rotherham 1 0.51 1 0.51 
Sheffield 11 2.37 12 2.59 
Wakefield District 11 4.00 11 4.00 
EAST MIDLANDS SHA* 116 3.17 85 2.32 
Bassetlaw* 4 4.57 2 2.28 
Derby City 5 2.20 6 2.64 
Derbyshire 20 3.49 14 2.44 
Leicester City 12 4.70 5 1.96 
Leicestershire County and Rutland* 19 3.55 11 2.06 
NHS Lincolnshire 11 1.88 9 1.54 
NHS Northamptonshire 27 5.03 24 4.47 
Nottingham City 5 1.85 4 1.48 
Nottinghamshire County Teaching* 13 2.45 10 1.89 
WEST MIDLANDS SHA* 56 1.24 49 1.09 
Birmingham East and North* 0 0.00 0 0.00 
Coventry Teaching 5 1.86 3 1.11 
Dudley* 3 1.22 3 1.22 
Heart of Birmingham Teaching* 0 0.00 0 0.00 
Herefordshire 1 0.69 0 0.00 
North Staffordshire 2 1.18 2 1.18 
Sandwell 2 0.82 1 0.41 
Shropshire County* 5 2.13 7 2.98 
Solihull* 0 0.00 0 0.00 
South Birmingham* 0 0.00 1 0.35 
South Staffordshire 14 2.90 12 2.49 
Stoke-on-Trent 10 4.76 9 4.28 
Telford and Wrekin 6 4.65 4 3.10 
Walsall Teaching* 1 0.51 1 0.51 
Warwickshire* 0 0.00 0 0.00 
Wolverhampton City 2 1.04 1 0.52 
Worcestershire 5 1.12 5 1.12 
EAST OF ENGLAND SHA 84 1.77 77 1.62 
Bedfordshire 19 5.62 18 5.33 
Cambridgeshire 9 1.84 6 1.23 
Hertfordshire 17 1.88 21 2.33 
Great Yarmouth and Waveney 4 2.15 3 1.61 
Luton 7 4.62 8 5.28 
Mid Essex 0 0.00 0 0.00 
Norfolk 9 1.45 6 0.97 
North East Essex 0 0.00 0 0.00 
Peterborough 9 7.20 9 7.20 
South East Essex 0 0.00 0 0.00 
South West Essex 0 0.00 0 0.00 
Suffolk 10 2.05 6 1.23 
West Essex 
 
 
0 0.00 0 0.00 
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Area Number and annual 
death rate per 100,000 
population – usual area 
of residence 
Number and annual 
death rate per 100,000 
population – place of 
death 
 No Rate No Rate 
LONDON SHA 158 2.40 125 1.90 
Barking and Dagenham 1 0.75 1 0.75 
Barnet 2 0.72 1 0.36 
Bexley 2 1.16 1 0.58 
Brent Teaching 1 0.47 0 0.00 
Bromley 1 0.40 0 0.00 
Camden 2 0.96 1 0.48 
City and Hackney Teaching 8 4.37 5 2.73 
Croydon 9 3.34 5 1.86 
Ealing 23 8.51 23 8.51 
Enfield 1 0.46 0 0.00 
Greenwich Teaching 2 1.08 1 0.54 
Hammersmith and Fulham 10 7.34 14 10.28 
Haringey Teaching 1 0.52 0 0.00 
Harrow 1 0.59 1 0.59 
Havering 1 0.50 1 0.50 
Hillingdon 11 5.46 10 4.96 
Hounslow 12 6.35 12 6.35 
Islington 7 4.38 2 1.25 
Kensington and Chelsea 1 0.64 2 1.28 
Kingston 6 3.99 7 4.66 
Lambeth 4 1.60 5 2.00 
Lewisham 5 2.36 1 0.47 
Newham 5 2.73 2 1.09 
Redbridge 1 0.50 0 0.00 
Richmond and Twickenham 9 6.10 8 5.43 
Southwark 7 3.13 5 2.24 
Sutton and Merton 6 1.99 3 1.00 
Tower Hamlets 3 1.59 1 0.53 
Waltham Forest 4 2.20 2 1.10 
Wandsworth 0 0.00 0 0.00 
Westminster 12 5.51 11 5.05 
SOUTH EAST COAST SHA* 103 2.83 89 2.45 
Brighton and Hove City 22 9.96 17 7.69 
East Sussex Downs and Weald 7 2.56 6 2.20 
Eastern and Coastal Kent* 21 3.54 19 3.20 
Hastings and Rother 9 6.28 7 4.88 
Medway 0 0.00 0 0.00 
Surrey 21 2.37 19 2.14 
West Kent* 14 2.57 12 2.20 
West Sussex 9 1.38 9 1.38 
SOUTH CENTRAL SHA 74 2.20 67 1.99 
Berkshire East 9 2.81 8 2.50 
Berkshire West 3 0.79 5 1.31 
Buckinghamshire 4 1.00 1 0.25 
Hampshire 22 2.16 18 1.76 
Milton Keynes 9 7.74 8 6.88 
NHS Isle of Wight 2 1.05 2 1.05 
Oxfordshire 0 0.00 0 0.00 
Portsmouth City Teaching 8 4.62 8 4.62 
Southampton City 17 8.03 17 8.03 
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Area National and annual 
death rate per 100,000 
population – usual area 
of residence 
National and annual 
death rate per 100,000 
population – place of 
death 
 No Rate No Rate 
SOUTH WEST SHA 118 2.70 95 2.17 
Bath and North East Somerset* 0 0.00 0 0.00 
Bournemouth and Poole Teaching 23 8.35 13 4.72 
Cornwall & Isles of Scilly 0 0.00 0 0.00 
Devon 14 3.18 9 2.04 
Dorset 20 3.29 20 3.29 
Gloucestershire 8 2.55 3 0.96 
NHS Bristol* 10 2.08 9 1.87 
North Somerset* 1 0.58 0 0.00 
Plymouth Teaching 1 0.47 1 0.47 
Somerset 10 2.37 11 2.61 
South Gloucestershire* 0 0.00 0 0.00 
Swindon 17 10.35 16 9.74 
Torbay Care Trust 3 2.58 3 2.58 
Wiltshire 11 3.12 10 2.83 
 
Note: In addition there were a number of cases that could not be allocated to specific PCT areas because they were of 
no fixed abode and/or the jurisdiction in which the inquest was held covers more than one PCT. Some cases were 
usually resident outside the UK. Some PCTs are covered by Coroners’ jurisdictions that did not submit information (or 
only partial information) to the np-SAD; they are marked thus - *. 
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Chapter 2: “Drug misuse” deaths in England using the 
Drug Strategy definition 
 
 
This chapter considers cases meeting the 
definition used to monitor the Government’s 
drug strategy, i.e. “drug misuse”.  
 
The definition comprises two types of deaths. 
Firstly, deaths where the underlying cause of 
death is mental and/or behavioural disorders 
due to psychoactive substance use (excluding 
alcohol, tobacco and volatile solvents). 
Secondly, deaths coded to the following 
categories and where a drug controlled under 
the Misuse of Drugs Act 1971 was mentioned 
on the death record: (i) Accidental poisoning 
by drugs, medicaments and biological 
substances; (ii) Intentional self-poisoning by 
drugs, medicaments and biological 
substances; (iii) Poisoning by drugs, 
medicaments and biological substances, 
undetermined intent; (iv) Assault by drugs, 
medicaments and biological substances; and 
(v) Mental and behavioural disorders due to 
use of volatile solvents. For full details see 
Appendix 2. 
 
To derive these cases, the following two 
categories of cases are excluded from the np-
SAD cases: (a) deaths of non-drug abusers 
where no Controlled Drugs were found at post 
mortem or where specific compound 
analgesics were found at post mortem; and (b) 
deaths of drug abusers where no Controlled 
Drugs were found at post mortem or where 
specific compound analgesics were found at 
post mortem and the mechanism of death was 
traumatic, such as hanging, drowning, car 
accident, etc. Of the 1,263 cases reported to 
the Programme for 2011, 71.6% (n = 904) met 
the criteria for classification as a “drug misuse” 
death. 
 
Profile of Drug Strategy cases  
 
1. Demography 
 
Similar patterns were found to those seen in 
previous years. Of the 904 Drug Strategy (DS) 
cases reported to the Programme, 73.5% of 
cases were male and 26.5% female (Figure 
2.1 and Table 2.1). The majority (55.8%) were 
unemployed, whilst 235 cases (26.0%) were 
employed. Those aged less than 45 years  
 
 
 
accounted for 64.9% of deaths. Deaths 
amongst those who lived alone represented 
45.1% of cases, with 41.5% living with others, 
and 2.4% of no fixed abode. Where ethnicity 
was known (n = 638), the vast majority were 
White (96.2%); the rest were Black (1.3%), 
Asian (1.7%), and Chinese and other 
ethnicities (0.8%). 
 
 
Figure 2.1: “Drug misuse” deaths reported to np-SAD by age-group and gender, England, 
 2011
45
171
248
136
44
2014
34
75 72
22 23
0
50
100
150
200
250
300
15 to 24 25 to 34 35 to 44 45 to 54 55 to 64 65 & over
Age-group (years)
N
u
m
b
e
r
Male
Female
np-SAD 
 
International Centre for Drug Policy 36 
Table 2.1: Demographic characteristics of “drug misuse” deaths reported to np-SAD, 
England, 2011 
 
Variable Category Number (%) 
Total 
 
 
904 (100.0) 
Gender 
Male 664 (73.5) 
Female 240 (26.5) 
Employment status 
Unemployed 504 (55.8) 
Employed 235 (26.0) 
Childcare/house person 21 (2.3) 
Student 14 (1.5) 
Retired/sickness/invalidity 61 (6.7) 
Other 4 (0.4) 
Not known 65 (7.2) 
Living arrangements 
Alone 408 (45.1) 
With others 375 (41.5) 
No fixed abode 22 (2.4) 
Other 46 (5.1) 
Not known 53 (5.9) 
Ethnicity 
Asian 11 (1.2) 
Black 8 (0.9) 
Chinese and other 5 (0.6) 
White 614 (67.9) 
Not known 266 (29.4) 
 
2. Age         
 
Most DS deaths in England during 2011 
occurred amongst those aged 35 years and 
over (70.8%), 22.7% were aged 25-34, and 
15-24 years olds accounted for just 6.5% of 
DS cases (Figure 2.2). The median age at 
death was 40.9 years (interquartile range = 
15.0). Older male, White drug users are at 
most risk of drug-related deaths (Bird et al., 
2003; Ghodse et al., 2009). 
  
Figure 2.2: “Drug misuse” deaths reported to np-SAD by age-group, England, 2011 
 
59
205
323
208
66
43
0
50
100
150
200
250
300
350
15 to 24 25 to 34 35 to 44 45 to 54 55 to 64 65 & over
Age-group (years)
N
u
m
b
e
r
 
 
 
 
 
np-SAD 
 
                International Centre for Drug Policy 
 
37 
3.  Location of death 
 
In 2011, 74.7% of DS cases died either at the 
deceased’s home address or at another 
private residential address, whilst 9.4% died in 
hospital, 8.1% died elsewhere (e.g. public 
open space, public facilities, railway station 
etc.) and the remaining 7.9% were listed with 
an unknown location of death. 
 
4.  Underlying cause(s) of death 
 
The categories of underlying cause of death 
(based on ICD-10 codes) were as follows: 
 Accidental poisoning (X40-X47): 78.4% 
 Intentional self-poisoning (X60-X67): 
12.6%  
 Poisonings of undetermined intent (Y10-
Y14): 8.5% 
 Other (e.g. natural causes, drowning, 
hanging, unascertained): 0.4% 
 
Males were significantly more likely than 
females to die from accidental poisoning 
(83.0% vs. 65.8%) (Proportion Ratio [PR]: = 
1.3, 95% Confidence Interval [CI]: = 1.1 – 1.4). 
Females, by contrast, were significantly more 
likely than males to die of intentional self-
poisoning (19.6% vs. 10.1%) (PR = 1.9, 95% 
CI = 1.4 – 2.7), and also from poisoning of 
undetermined intent (14.2% vs. 6.5%) (PR = 
2.2, 95% CI = 1.4 – 3.3.  
 
Deaths of those aged less than 45 years were 
more likely than older cases to be as a result 
of accidental poisoning (85.9% vs. 64.7%) (PR 
= 1.3, 95% CI = 1.2 – 1.4). Those aged 45 
years or over were more likely than younger 
cases to die of intentional self-poisoning 
(22.5% vs. 7.3%) (PR = 3.1, 95% CI = 2.1 – 
4.4), and poisoning of undetermined intent 
(12.6% vs. 6.3%) (PR = 2.0, 95% CI = 1.3 – 
3.1). 
 
5.  Manner of death  
 
The manner of death in DS cases was as 
follows:  
 Natural: 1.1% 
 Accidental: 77.5% 
 Suicidal: 12.7% 
 Undetermined: 8.6% 
 
Males were more likely than females to die an 
accidental death (82.2% vs. 64.6%) (PR = 1.3, 
95% CI = 1.2 – 1.4). Conversely, females were 
more likely than males to have deaths 
attributed to suicide (19.6% vs. 10.2%) (PR = 
1.9, 95% CI = 1.4 – 2.7), or a death where the 
manner was undetermined (14.2% vs. 6.6%) 
(PR = 2.1, 95% CI = 1.4 – 3.3).  
 
Cases aged less than 45 years were more 
likely than older cases to die accidentally 
(85.5% vs. 62.8%) (PR = 1.4, 95% CI = 1.2 – 
1.5). Those aged 45 years or over were more 
likely than younger cases to die intentionally 
(22.7% vs. 7.3%) (PR = 3.1, 95% CI = 2.2 – 
4.4), or in a manner that was undetermined 
(12.6% vs. 6.5%) (PR = 1.9, 95% CI = 1.3 – 
3.0). 
  
Substances implicated in death  
 
1. Psychoactive substances 
 
Of the 904 Drug Strategy (DS) cases reported, 
888 (98.2%) were directly attributed to 
psychoactive drugs. Sixteen DS cases (1.8%) 
were excluded from further analysis, as no 
psychoactive drugs were implicated in the 
cause of death. The principal substances 
implicated in psychoactive drug-related deaths 
were: heroin/morphine (38.2%) and 
methadone (35.2%). 
 
 
 
Other psychoactive substances implicated 
alone and in combination that made a sizeable 
contribution (10% or over) to deaths were: 
alcohol-in-combination with other drugs 
(28.0%); other opiates/opioid analgesics 
(27.9%); hypnotics/sedatives (26.8%); anti-
depressants (19.1%) and cocaine (12.0%). 
Deaths attributed to heroin/morphine alone 
accounted for 11.3% of cases (Table 2.2). 
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Table 2.2: Psychoactive substances implicated in “drug misuse” deaths reported to np-
SAD, England, 2011  
 
Drug category 
Number (%) of cases where 
substance was implicated 
alone 
Number (%) of cases 
where drug was 
implicated both alone and 
in combination 
Total 888 (100.0) 
Alcohol-in-combination - 249 (28.0) 
Amphetamines 15 (1.7) 39 (4.4) 
Anti-depressants 12 (1.4) 170 (19.1) 
Anti-epileptics 3 (0.3) 23 (2.6) 
Anti-Parkinson’s 0 (0.0) 1 (0.1) 
Anti-psychotics 4 (0.5) 34 (3.8) 
Cannabis 1 (0.1) 14 (1.6) 
Cocaine 16 (1.8) 107 (12.0) 
Ecstasy-type drugs 6 (0.7) 19 (2.1) 
GHB 4 (0.5) 10 (1.1) 
Heroin/morphine 100 (11.3) 339 (38.2) 
Hypnotic/sedatives 17 (1.9) 238 (26.8) 
Methadone 83 (9.3) 313 (35.2) 
Other opiates/opioid 
analgesics 
55 (6.2) 248 (27.9) 
Notes: Column totals may sum to more than 100% since more than one substance may be implicated in a death. Not 
all cases had drugs directly implicated in death; these are excluded from this table. 
 
 
1.1 Psychoactive substances most 
frequently implicated by age-group 
 
As Table 1.3 below shows, for the 15-24 year 
age-group, methadone was the psychoactive 
substance most frequently implicated (alone or 
in combination) in their deaths (19/52 = 
36.5%), whilst heroin/morphine was found to 
be most commonly implicated in the deaths of 
those aged between 25-44 years (222/524 = 
42.4%), accounting for 65.5% of all DS deaths 
implicated to the drug in England in 2011 
reported to np-SAD. Methadone was the 
psychoactive drug most frequently implicated 
for those aged between 45-54 years (86/205 = 
42.0%), whilst other opiates/opioid analgesics 
were implicated in the greatest proportion of 
deaths amongst those aged from 55-64 years 
(29/65 = 44.6%). For those older than 65, 
hypnotics/sedatives featured most frequently 
in their deaths compared to other psychoactive 
drugs (19/42 = 45.2%).  
 
1.2 Highest frequency of each psychoactive 
substance implicated 
 
As shown in Table 1.3 below, amphetamines; 
anti-depressants; anti-epileptics; anti-
psychotics; cocaine; ecstasy-type; 
heroin/morphine; hypnotics/sedatives; 
methadone; other opiates/opioid analgesics; 
and alcohol-in-combination were most 
commonly implicated in the deaths of those 
aged between 35-44 years. GHB/GBL was 
most frequently implicated in the 25-44 year 
age-group, whilst cannabis and anti-
Parkinson’s drugs were implicated most often 
in the 25-34 year age-group. 
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Table 2.3: Age-group and psychoactive substance implicated Drug Strategy death in 2011 
 in England reported to np-SAD  
 
  
Age-group at death 
 
 
Total 
number of 
cases 
where 
substance 
implicated 
 
 
 
Percentage of 
total deaths 
overall with 
psychoactive 
drugs 
implicated 
15-24 25-34 35-44 45-54 55-64 65+ 
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Amphetamines 
5 
(12.8) 
11 
(28.2) 
15 
(38.5) 
5 
(12.8) 
3 
(7.7) 
0 
(0.0) 39 4.4% 
Anti-depressants 
3 
(1.8) 
31 
(18.2) 
58 
(34.1) 
55 
(32.4) 
12 
(7.1) 
11 
(6.5) 170 19.1% 
Anti-epileptics 
0 
(0.0) 
4 
(17.4) 
9 
(39.1) 
5 
(21.7) 
3 
(13.0) 
2 
(8.7) 23 2.6% 
Anti-Parkinson’s 
0 
(0.0) 
1 
(100) 
0 
(0.0) 
0 
(0.0) 
0 
(0.0) 
0 
(0.0) 1 0.1% 
Anti-psychotics 
1 
(2.9) 
10 
(29.4) 
14 
(41.2) 
6 
(17.6) 
1 
(2.9) 
2 
(5.9) 34 3.8% 
Cannabis 
3 
(21.4) 
5 
(35.7) 
3 
(21.4) 
3 
(21.4) 
0 
(0.0) 
0 
(0.0) 14 1.6% 
Cocaine 
10 
(9.3) 
31 
(29.0) 
42 
(39.3) 
19 
(17.8) 
5 
(4.7) 
0 
(0.0) 107 12.0% 
Ecstasy-type 
5 
(26.3) 
5 
(26.3) 
6 
(31.6) 
3 
(15.8) 
0 
(0.0) 
0 
(0.0) 19 2.1% 
GHB/GBL 
2 
(20.0) 
3 
(30.0) 
3 
(30.0) 
2 
(20.0) 
0 
(0.0) 
0 
(0.0) 10 1.1% 
Heroin/morphine 
10 
(2.9) 
86 
(25.4) 
136 
(40.1) 
76 
(22.4) 
25 
(7.4) 
6 
(1.8) 339 38.2% 
Hypnotics/sedatives 
13 
(5.5) 
59 
(24.8) 
85 
(35.7) 
42 
(17.6) 
20 
(8.4) 
19 
(8.0) 238 26.8% 
Methadone 
19 
(6.1) 
 
79 
(25.2) 
 
113 
(36.1) 
86 
(27.5) 
 
13 
(4.2) 
3 
(1.0) 313 35.2% 
Other opiates/opioid 
analgesics 
11 
(4.4) 
40 
(16.1) 
86 
(34.7) 
 
65 
(26.2) 
 
29 
(11.7) 
17 
(6.9) 248 27.9% 
Alcohol-in-
combination 
9 
(3.6) 
71 
(28.5) 
100 
(40.2) 
46 
(18.5) 
 
17 
(6.8) 
 
6 
(2.4) 
 
249 28.0% 
Notes: Column totals may sum to more than 100% since more than one substance may be implicated in a death. Not all 
cases had drugs directly implicated in death; these are excluded from this table. 
 
 
1.3 Gender and implicated psychoactive 
substance 
 
 
 
The pattern of psychoactive substances with 
regards their implication in the deaths of the 
different genders reveals some interesting 
differences. 
 
Amongst males, the five most frequently 
implicated psychoactive substances (alone or 
in combination), presented in numerical order, 
were: 
1. Heroin/morphine (41.4%) 
2. Methadone (36.0%) 
3. Alcohol-in-combination (29.8%) 
4. Hypnotics/sedatives (26.3%) 
5. Other opiates/opioid analgesics 
(25.2%) 
Among female cases, the most frequently 
implicated psychoactive substances, alone or 
in combination were: 
1. Anti-depressants (36.1%) 
2. Other opiates/opioid analgesics 
(35.6%) 
3. Methadone (33.0%) 
4. Heroin/morphine (29.2%) 
5. Hypnotics/sedatives (28.3%) 
 
Comparing the type of psychoactive 
substances implicated in the deaths of males 
and females reveals that there is a higher 
proportion of male compared to female deaths 
in which the following drugs were implicated: 
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heroin/morphine; alcohol-in-combination; 
cocaine; cannabis; and GHB/GBL. 
Meanwhile, females showed a greater 
proportion of deaths attributed to anti-
depressants; other opiates/opioid analgesics; 
hypnotics/sedatives;  anti-epileptics; 
amphetamines; anti-psychotics; and anti-
Parkinson’s. Equal proportions of males and 
females had deaths attributed to ecstasy-type 
substances. 
 
2. Polysubstances 
 
In 2011, heroin/morphine in combination with 
alcohol was implicated in 13.0% of the 888 
psychoactive drug-related Drug Strategy 
deaths reported to np-SAD. Where other 
opiates/opioid analgesics combined with 
heroin/morphine was implicated, these cases 
made up 7.8% of reported deaths, whilst when 
heroin/morphine was implicated in combination 
with hypnotics/sedatives, such deaths 
accounted for 9.0%. 6.3% of deaths involved 
other opiates/opioid analgesics combined with 
alcohol, whilst 7.0% of deaths had 
hypnotics/sedatives implicated with alcohol. 
 
When implicated in combination, several 
different substance types often featured with 
alcohol. Alcohol was implicated in 33.9% of all 
deaths involving heroin/morphine; 31.8% 
involving cocaine; 28.6% involving cannabis; 
and 26.8% of deaths in which methadone was 
implicated.  
 
Over the past decade, one-fifth (18%) of drug-
related deaths has involved heroin/morphine in 
combination with alcohol. 7.8% of deaths 
involved other opiates/opioid analgesics 
combined with alcohol, and in 8.2% of deaths 
heroin/morphine and other opiates/opioid 
analgesics were combined. Opiates and 
opioids including heroin/morphine accounted 
for 82% of deaths where a psychoactive 
substance was involved. This pattern has 
remained stable over the past decade. The 
combination of heroin/morphine and other 
opiates/opioid analgesics fluctuated between 
5% and 12% over the past ten years.  
 
The most prevalent substance combinations 
implicated during 2002-11 were: heroin/ 
morphine with alcohol (18%); heroin/morphine 
with hypnotics/sedatives (9.6%); and 
hypnotics/sedatives with alcohol (8.5%). Over 
the last decade alcohol-in-combination with 
two other stimulants did not feature (1.3%) 
compared to alcohol with one stimulant 
(6.4%). Combinations of drugs, with or without 
alcohol, pose greater risks for mortality 
(Ghodse et al., 2010).   
 
3. Single substances 
 
In 2011, there were 316 (35.6%) Drug 
Strategy deaths reported to np-SAD in which 
only one of the following substances was 
implicated. Of these single substance deaths, 
heroin/morphine accounted for 31.6%; 
methadone for 26.3%; other opiates/opioid 
analgesics – 17.4%; hypnotics/sedatives – 
5.4%; cocaine – 5.1%; amphetamines – 4.7%; 
anti-depressants – 3.8%; ecstasy-type drugs – 
1.9%; GHB/GBL – 1.3%; anti-psychotics – 
1.3%; anti-epileptics – 0.9%; and cannabis – 
0.3%. 
 
4. Prescribed psychoactive drugs  
 
Of the 904 Drug Strategy cases reported to 
np-SAD for 2011, 61.5% (n = 556) were 
reported as being prescribed psychoactive 
drugs at the time of their death (Table 2.4). Of 
those being prescribed such drugs, the most 
common prescribed medications were anti-
depressants (57.6%); hypnotics/sedatives 
(47.3%); other opiates/opioid analgesics 
(30.4%); methadone (23.9%); anti-psychotics 
(19.2%); anti-epileptics (15.1%); 
heroin/morphine (7.6%); anti-Parkinsons 
(1.4%) and amphetamines (0.7%). 
 
‘Polypharmacy’, i.e. multiple prescriptions of 
psychoactive drugs, occurred in 69.1% 
(384/556) of cases. 
 
As with np-SAD cases, age appeared to be 
related in some way to whether cases were 
being prescribed psychoactive medication 
when prescribing history was known. For 15-
24 year olds, 29.3% were prescribed 
psychoactive medication; 25-34 – 66.5%; 35-
44 – 75.7%; 45-54 – 85.8%; 55-64 – 87.7%; 
and 65 & over – 86.5%. 
 
The following paragraphs further examine the 
Drug Strategy deaths and the involvement of 
prescribed medication.  
 
The most frequent combinations of prescribed 
psychoactive drugs in 2002 were also the 
most common in 2011. However, no single 
drug combination exceeded more than 26%. 
Prescribed hypnotics/sedatives in combination 
with anti-depressants accounted for 17.9% of 
cases in 2002 and 25.8% in 2011. 
Hypnotics/sedatives in combination with other 
opiates/opioid analgesics accounted for 14.3% 
of cases in 2002 compared to 13.5% in 2011. 
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Hypnotics/sedatives together with anti-
psychotics accounted for 8.5% in 2002 and 
11.5% of cases in 2011. Methadone and 
hypnotics/sedatives accounted for 4.6% of 
cases in 2002 and 8.5% in 2011. There was 
also a slight increase in the proportion of 
cases involving both methadone and anti-
depressants from 1.9% in 2002 to 7.7% in 
2011. 
 
In 2011, methadone alone and in combination 
with other drugs, was implicated in 313 cases. 
Of these, 62.9% may have obtained 
methadone from illicit sources, compared to 
37.1% who were known to be receiving 
prescribed methadone prior to their death (PR 
= 1.7, 95% CI = 1.4 – 2.0). Methadone alone 
was implicated in 83 cases. Of these, 59.0% 
may have obtained the drug from illicit 
sources, compared to 41.0% who were known 
to be receiving prescribed methadone (PR = 
1.4, 95% CI = 1.1 – 2.0).  
Table 2.4: Prescribed psychoactive medication, “drug misuse” deaths reported to np-
SAD, England, 2011 
 
 
Drug category 
Number (%) of cases on 
prescribed 
psychoactive medication 
by drug 
Number (%) of these 
cases where same 
prescribed drug was 
implicated in death 
Total 556 (100.0) 
 
Amphetamines 4 (0.7) 1 (25.0) 
Anti-depressants 320 (57.6) 114 (35.6) 
Anti-epileptics 84 (15.1) 9 (10.7) 
Anti-Parkinson’s 8 (1.4) 0 (0.0) 
Anti-psychotics 107 (19.2) 22 (20.6) 
Heroin/morphine 42 (7.6) 33 (78.6) 
Hypnotics/sedatives 263 (47.3) 108 (41.1) 
Methadone 133 (23.9) 116 (87.2) 
Other opiates/opioid analgesics 169 (30.4) 111 (65.7) 
Note: Column totals may sum to more than 100% since more than one substance may be prescribed to an individual 
and more than one substance may be implicated in a death. 
 
 
 
Hypnotics/sedatives, alone and in combination 
with other drugs, were implicated in 238 
cases. Of these, 54.6% may have obtained 
them illicitly, compared to the 45.4% who were 
known to be receiving a prescription for this 
drug (PR = 1.2, 95% CI = 1.0 – 1.4). 
Seventeen cases had hypnotics/sedatives 
alone implicated in their death, of whom 9 
(52.9%) had received the drug on prescription, 
compared to 8 (47.1%) who may have 
obtained it illicitly (PR = 1.1, 95% CI = 0.6 – 
2.2).  
 
Anti-depressants, alone and in combination 
with other drugs, were implicated in 170 
cases. Of these, 67.1% were known to be 
receiving prescribed anti-depressants at the 
time of their death, compared to 32.9% who 
may have used drugs prescribed for others 
(PR = 2.0, 95% CI = 1.6 – 2.9). Anti-
depressants alone were implicated in 12 
cases. Of these, 10 (83.3%) were known to be 
receiving prescribed anti-depressants, 
compared to 2 (16.7%) who may have used 
drugs prescribed for others (PR = 5.0, 95% CI 
= 1.4 – 18.2).  
 
Other opiates/opioid analgesics (e.g. 
dihydrocodeine, dextropropoxyphene) alone 
and in combination with other drugs, were 
implicated in 248 cases. Of these, 55.2% may 
have obtained the drug by other means, 
compared to the 44.8% who were known to be 
receiving prescribed opiate/opioid analgesics 
prior to their death (PR = 1.2, 95% CI = 1.0 – 
1.5). Other opiate/opioid analgesics alone 
were implicated in 55 cases. Of these, the 
drugs were prescribed in 47.3% of cases, 
compared to 52.7% apparently being obtained 
by other means (PR = 1.1, 95% CI = 0.8 – 
1.6). 
 
Heroin/morphine, alone and in combination 
with other drugs, was implicated in 339 
deaths. The majority (90.3%) of these cases 
were not prescribed heroin/morphine, and as 
such may have obtained the drug illegally. 
Only 9.7% of the cases with heroin/morphine 
implicated were receiving the drug on 
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prescription (PR = 9.3, 95% CI = 6.7 – 12.8). 
Where heroin/morphine was implicated alone, 
out of 100 cases, only 11.0% of these were 
they known to be prescribed the drug, 
meaning 89.0% may have obtained 
heroin/morphine illegally (PR = 8.1, 95% CI = 
4.6 – 14.2). 
Drug abuse/dependence 
 
No information was available for 211/904 
cases with regards past or current history of 
drug abuse/dependence, but those with such a 
history (DAs) accounted for 71.3% of cases 
where history was known (n = 494/693). 
Individuals listed as non-drug abusers (NDAs) 
accounted for 28.7% (n = 199/693). The 211 
cases where such history was not known were 
excluded from the following analyses.  
 
1. Demography  
 
Those with a history of drug 
abuse/dependence (DA) were more likely than 
those without such a history (NDA) to be male 
(79.1% vs. 62.3%)  (PR = 1.3, 95% CI = 1.1 – 
1.4) and less than 45 years of age (72.9% 
compared to 48.2%) (PR = 1.5, 95% CI = 1.3 – 
1.8). The median age at death for DAs was 
39.1 years (interquartile range = 12.8), while 
that for NDAs was 45.6 years (interquartile 
range = 20.0) (Mann-Whitney U = 34,722.5 p < 
0.001). 
 
Where ethnicity was known, there was a 
similar proportion of cases recorded as 
belonging to a White ethnic group for NDA and 
DA cases (96.4% vs. 96.3% White) (PR = 1.0, 
95% CI = 1.0 – 1.0). 
 
DA cases were more likely to live alone 
(47.6% vs. 45.2%) (PR = 1.1, 95% CI = 0.9 – 
1.3) or be of no fixed abode than NDAs (3.0% 
vs. 0.0%). The latter group however, were 
more likely to live with others, 50.8% vs. 
36.8%, (PR = 1.4, 95% CI = 1.2 – 1.6). 
 
DA cases were more likely to be unemployed, 
64.2% vs. 36.2%, (PR = 1.8, 95% CI = 1.5 – 
2.2). NDA cases were more likely to be 
employed, 33.7% compared to 23.9%, (PR = 
1.4, 95% CI = 1.1 – 1.8) or to be 
retired/receiving invalidity benefits: 18.6% 
compared to 1.8%, (PR = 10.2, 95% CI = 5.0 – 
20.8), or carrying-out childcare, 4.5% vs. 1.8% 
(PR = 2.5, 95% CI = 1.0 – 6.2).   
 
2. Location of death 
 
With respect to the location of death for DAs 
and NDAs, in both groups the majority died at 
home or in a defined residential address 
(74.1% of DAs and 72.9% of NDAs) (PR = 1.0, 
95% CI = 0.9 – 1.1). Hospital deaths 
accounted for a slightly greater proportion of 
NDA (12.1%) than DA (9.1%) deaths (PR = 
1.3 95% CI = 0.8 – 2.1). 
 
3. Underlying cause(s) of death  
 
DAs were more likely than NDAs to die from 
accidental poisoning, (89.5% vs. 51.8%) (PR = 
1.7, 95% CI = 1.5 – 2.0) – see Figure 2.3. 
NDAs, by contrast, were more likely than DAs 
to die of intentional self-poisoning (36.2% vs. 
3.4%: PR = 10.5, 95% CI = 6.4 – 17.4), and 
poisoning of undetermined intent (12.1% vs. 
6.3%: PR = 1.9, 95% CI = 1.2 – 3.2).  
 
4. Manner of death  
 
A similar pattern is exhibited with regard to 
manner of death. DAs were more likely than 
NDAs to die as the result of an accident 
(88.3% vs. 51.8%: PR = 1.7, 95% CI = 1.5 – 
2.0). Conversely, NDAs were more likely than 
DAs to suffer deaths attributed to suicide 
(36.2% vs. 3.4%: PR = 10.5, 95% CI = 6.4 – 
17.4), or a death where the manner was 
undetermined (11.6% vs. 6.9%: PR = 1.7, 95% 
CI = 1.0 – 2.8). 
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Figure 2.3: Principal underlying cause(s) of death by drug abuse/dependence history, 
“drug misuse” (DS) deaths, England, 2011  
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Other issues 
 
Information on other aspects of the “drug 
misuse” individuals reported to np-SAD was 
also reported on the data collection form, such 
as whether the individual had at some point 
been in prison; had certain diseases such as 
hepatitis or HIV/AIDS; or was recorded as 
having certain mental health issues. These 
cases are investigated further below. 
 
6.1 Prison 
 
Ten “drug misuse” cases in 2011 were 
reported to np-SAD with information on their 
prison history (9 in 2010 and 52 in 2009). The 
majority of these had been imprisoned for 
drug-related offences and assault. As found in 
previous years, the principal substances 
implicated were opiates or synthetic opioids 
alone or in combination, such as methadone 
or heroin/morphine, with methadone 
implicated in 6/10 cases; heroin/morphine in 
4/10; hypnotics/sedatives also in 4/10; other 
opiates/opioid analgesics in 3/10; and alcohol-
in-combination implicated in 2/10 of the 
individuals with prison history. 
 
6.2 Hepatitis and HIV/AIDS 
 
A total of 23 individuals were noted as being 
infected with hepatitis C at death. The primary 
underlying cause of death for this group was 
accidental poisoning by narcotics and 
psychodysleptics (20/23 – 87.0%), whilst in 
only four cases was hepatitis C recorded as a 
contributory factor in death. This condition is 
frequently associated with intravenous drug 
use, and of the nine individuals in which 
injecting status was known, seven (77.8%) 
were known to be injecting.  
 
Three cases were reported to np-SAD as 
suffering from HIV/AIDS, and in one of these 
cases the disease was a contributory factor in 
death. 
 
6.3 Mental Health Issues 
 
Of the cases reported to the Programme, 131 
were noted as having some form of mental 
health problem. These included depression; 
schizophrenia; bipolar disorder; and 
psychosis, amongst others (see Table 2.5 for 
detailed breakdown) 
 
Of the 131 cases noted as diagnosed with 
mental health issues, 51.9% (68/131) were 
listed as suffering from depression, with 25.0% 
of these (17/68) having deaths attributed to 
suicide. The principal substances implicated in 
the deaths of those listed with depression 
were other opiates and opioid analgesics 
(27/68 – 39.7%); anti-depressants (20/68 – 
29.4%); hypnotics/sedatives (20/68 – 29.4%); 
methadone (17/68 – 25.0%); heroin/morphine 
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(16/68 – 23.5%); and alcohol-in-combination 
(14/68 – 20.6%). 
 
Thirteen individuals were reported as being 
schizophrenic (13/131 – 9.9%), with the 
principal implicated substance being 
heroin/morphine (5/13 – 38.5%), with anti-
psychotics, anti-depressants, methadone and 
hypnotics/sedatives each being implicated 
equally in 30.8% (4/13) of cases. Amongst 
those listed as diagnosed with schizophrenia, 
76.9% (10/13) died as the result of an 
accident, whilst 23.1% (3/13) committed 
suicide. 
 
 
 
 
 
 
Table 2.5: Psychoactive substances implicated alone and in combination in percentage of cases 
    diagnosed with specific mental health problems 
 Mental health problem 
Psychoactive 
substance 
implicated alone 
and in combination 
 
Depression 
n = 68 (%) 
 
Schizophrenia  
n = 13 (%) 
 
Bipolar 
disorder  
n = 7 (%) 
 
Anxiety  
n = 8 
(%) 
 
Psychosis  
n = 6 (%) 
Behavioural 
and 
personality 
disorders   
n = 8 (%) 
 
Mental 
issues  
n = 26 
(%) 
Alcohol-in-
combination 
20.6 15.4 14.3 25.0 16.7 25.0 26.9 
Amphetamines 1.5 0.0 0.0 0.0 16.7 0.0 0.0 
Anti-depressants 29.4 30.8 14.3 25.0 33.4 25.0 34.6 
Anti-epileptics 1.5 0.0 14.3 0.0 16.7 0.0 7.6 
Anti-Parkinson’s 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Anti-psychotics 4.4 15.4 14.3 0.0 16.7 12.5 19.2 
Cannabis 0.0 0.0 0.0 0.0 0.0 0.0 3.8 
Cocaine 11.7 15.4 0.0 0.0 33.3 0.0 7.7 
Ecstasy-type drug 1.5 0.0 0.0 0.0 0.0 0.0 0.0 
GHB/GBL 0.0 0.0 0.0 0.0 16.7 0.0 0.0 
Heroin/morphine 23.6 38.5 28.6 12.5 16.7 0.0 26.9 
Hypnotics/sedatives 29.4 30.8 28.6 12.5 33.3 12.5 38.4 
Methadone 25.0 30.8 28.6 12.5 16.7 37.5 26.9 
Other opiates/ 
opioid analgesics 
39.7 23.1 42.9 50.0 16.7 37.5 34.6 
Note: Column totals may sum to more than 100% since more than one substance may be implicated in a death. The case total sums to greater 
than the total number of cases of 131 since an individual may have more than one disorder. 
Cells highlighted in        indicate the drug most frequently implicated for each mental health problem 
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Changes between 2010 and 2011  
 
The following section compares deaths in 
2011 with those that occurred in 2010. Drug 
Strategy (DS) deaths in 2011 are reported as 
904, whereas in 2010, 968 cases were 
reported. This is a decrease in reported DS 
deaths of 6.6% in 2011. Figures for 2011 (and 
2010, to a lesser extent) can be expected to 
increase as further inquests on drug-related 
deaths are completed and reported to the 
Programme.  
 
1. Demography 
 
There were changes between 2010 and 2011 
in terms of the demographic profile of cases. 
Whilst ethnicity, gender, living arrangements 
and employment status remained relatively 
stable, there were marked changes in other 
aspects. The median age at death rose from 
38.5 to 40.9 years, with the number of deaths 
amongst those aged 35 years and over rising 
from 62.0% to 70.8%. The number of 
individuals listed as having a history of drug 
abuse/addiction when such information was 
given fell by 5.0%, from 76.3% to 71.3%, whilst 
a drop of 4.3% was also observed in the 
number of deaths occurring at the deceased’s 
home or other private residential address (from 
79.0% to 74.7%), and also in hospital deaths 
(from 14.0% to 9.4%). 
                   
2. Underlying cause(s) of death 
 
The number of deaths due to accidental 
poisoning rose from 75.1% in 2010 to 78.4% in 
2011 whilst deaths attributed to intentional 
self-poisoning increased by 2.5%, from 10.1% 
to 12.6%. Meanwhile, there was a reduction in 
poisonings of undetermined intent, from 10.3% 
to 8.5%, and deaths from other causes 
dropped from 4.5% to 0.4%.  
 
3. Manner of death 
 
There was a slight decrease in accidental 
deaths between 2010 and 2011 from 78.2% to 
77.5% and an increase in suicides from 10.5% 
to 12.7%. Cases in which the manner of death 
was undetermined showed a small decrease, 
from 10.0% in 2010 to 8.6% in 2011. 
 
 
4. Psychoactive substances implicated in 
death 
 
In 2011 there were 888/904 Drug Strategy 
deaths that involved psychoactive substances; 
16 cases were therefore excluded from the 
following analyses due to their not involving 
psychoactive substances. In 2010, 955 of the 
968 DS cases reported involved psychoactive 
drugs. 
 
4.1 Psychoactive substances, both alone 
and in combination 
 
There was a substantial reduction in the 
proportion of deaths attributed to 
heroin/morphine in 2011 compared to 2010 
(46.2% down to 38.2% of deaths). Despite 
this, heroin/morphine remained the most 
frequently implicated substance in deaths of 
DS cases. A reduction was also seen in the 
proportion of cases in which alcohol was 
implicated in combination with other 
psychoactive substances (from 32.5% to 
28.0%), and also in deaths involving GHB/GBL 
(1.4% to 1.1%). 
 
Significant increases were seen in the 
proportion of cases in which anti-depressants, 
ecstasy-type drugs, hypnotics/sedatives and 
methadone were implicated. Non-significant 
increases were found in the number of cases 
in which the following drugs were implicated: 
amphetamines; anti-epileptics; anti-psychotics; 
cannabis; cocaine; and other opiates/opioid 
analgesics (Table 2.6). 
  
4.2 Single substance 
 
 A significant increase in deaths in which other 
opiates/opioid analgesics were implicated 
alone was seen, shown by a 1.8% rise from 
2010 to 2011 (4.4% to 6.2%), whilst deaths 
involving heroin/morphine as the sole drug 
dropped significantly by 2.5% (from 13.8% to 
11.3%). Other non-significant rises were seen 
in the number of deaths involving the following 
drugs when implicated alone: amphetamines; 
anti-depressants; anti-epileptics; ecstasy-type 
drugs; hypnotics/sedatives; and methadone. 
Non-significant decreases were seen in the 
number of deaths in which GHB/GBL and 
Cocaine were implicated alone (Table 2.7).  
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Table 2.6: Changes in percentages of psychoactive substances, alone and in 
combination, implicated in psychoactive substance “drug misuse” deaths, 
England, 2010 and 2011 
 
Substance 
2010 
(n = 955) 
% 
2011 
(n = 888) 
% 
Ratio of 
Proportions 
(PR) 
95% CI 
Change  
(percentage 
points) 
      
Alcohol-in-
combination 
32.5 28.0 1.2 1.0 – 1.3 - 4.5 
Amphetamines 3.5 4.4 1.3 0.8 – 2.0 + 0.9 
Anti-depressants 14.9 19.1 1.3 1.1 – 1.6 + 4.2 
Anti-epileptics 1.6 2.6 1.6 0.9 – 3.1 + 1.0 
Anti-Parkinson’s 0.1 0.1 1.1 0.1 – 17.2 0.0 
Anti-psychotics 2.8 3.8 1.4 0.8 – 2.2 + 1.0 
Cannabis 1.3 1.6 1.3 0.6 – 2.7 + 0.3 
Cocaine 10.4 12.0 1.2 0.9 – 1.5 + 1.6 
Ecstasy-type drugs 0.8 2.1 2.6 1.1 – 5.8 + 1.3 
GHB/GBL 1.4 1.1 1.2 0.5 – 2.7 - 0.3 
Heroin/morphine 46.2 38.2 1.2 1.1 – 1.3 - 8.0 
Hypnotics/sedatives 24.1 26.8 1.1 1.0 – 1.3 + 2.7 
Methadone 31.3 35.2 1.1 1.0 – 1.3 + 3.9 
Other opiates/ 
opioid analgesics 
25.8 27.9 1.1 0.9 – 1.3 + 2.1 
Note: Column totals may sum to more than 100% since more than one substance may be implicated in a death. 
 
 
 
Table 2.7: Changes in percentages of psychoactive substances implicated alone in 
psychoactive substance “drug misuse” deaths, England, 2010 and 2011 
 
Substance 
2010 
(n = 955) 
% 
2011 
(n = 888) 
% 
Ratio of 
Proportions 
(PR) 
95% CI 
Change 
(percentage 
points) 
      
Amphetamines 1.5 1.7 1.2 0.6 – 2.4 + 0.2 
Anti-depressants 1.0 1.4 1.3 0.6 – 3.0 + 0.4 
Anti-epileptics 0.1 0.3 3.2 0.3 – 31.0 + 0.2 
Anti-Parkinson’s 0.0 0.0 n/a n/a 0.0 
Anti-psychotics 0.4 0.5 1.1 0.3 – 4.3 + 0.1 
Cannabis 0.1 0.1 1.1 0.7 – 17.2 0.0 
Cocaine 2.6 1.8 1.5 0.8 – 2.7 - 0.8 
Ecstasy-type drugs 0.4 0.7 1.6 0.5 – 5.7 + 0.3 
GHB/GBL 0.6 0.5 1.4 0.4 – 4.9 - 0.1 
Heroin/morphine 13.8 11.3 1.2 1.0 – 1.6 - 2.5 
Hypnotics/sedatives 1.2 1.9 1.7 0.8 – 3.5 + 0.7 
Methadone 9.0 9.3 1.0 0.8 – 1.4 + 0.3 
Other opiates/ 
opioid analgesics 
4.4 6.2 1.4 1.0 – 2.1 + 1.8 
†On average approximately 300 cases of inquest from the year of death are not completed and are added to next year. 
n/a Not applicable 
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Ten-year trends in death 2002-2011  
 
This section examines deaths that occurred 
between 2002 and 2011 using the “drug 
misuse” definition used to monitor the 
Government’s drug strategy. The analysis is 
based on a ‘panel’ approach, that is, only 
areas which reported in every single year of 
the 2002-11 ten-year period were examined.  
 
This selection has resulted in a different panel 
to that reported on in the previous annual 
report. Therefore, the results for this year 
cannot be compared with those for previous 
reports. 
 
Sixty-eight coronial areas in England (total = 
101) are represented, accounting for 73.1% of 
all cases reported. In all, a total of 9,101 cases 
meet the criteria for inclusion in the sample 
analysed here, for the ten-year period.  
 
This method had been adopted as it enhances 
the statistical robustness of the findings and 
the conclusions that can be derived from them.  
 
Table 2.8: Demographic characteristics of “drug misuse” deaths reported to np-SAD, 
panel of Coroners’ areas, 2002-2011 
 
Variable Category Number (%) 
Total 
 
9,101 (100.0) 
Gender 
Male 6,973 (76.6) 
Female 2,128 (23.4) 
Age (years) 
Under 15 10 (0.1) 
15-24 1,006 (11.1) 
25-34 2,889 (31.7) 
35-44 2,935 (32.2) 
45-54 1,372 (15.1) 
55-64 508 (5.6) 
Over 64 381 (4.2) 
Ethnicity 
White 6,788 (74.6) 
Black 139 (1.5) 
Asian 96 (1.1) 
Other 147 (1.6) 
Not known 1,931 (21.2) 
Employment status 
Unemployed 4,866 (53.5) 
Employed 2,559 (28.1) 
Childcare/house person 145 (1.6) 
Student/pupil 167 (1.8) 
Retired/sickness/invalidity 763 (8.4) 
Other 62 (0.7) 
Not known 539 (5.9) 
Living arrangements 
Alone 3,657 (40.2) 
With others 3,844 (42.2) 
No fixed abode 479 (5.3) 
Other 485 (5.3) 
Not known 636 (7.0) 
History of drug use 
History 5,848 (64.3) 
No history 1,839 (20.2) 
Not known 1,414 (15.5) 
Place of death 
Defined residential address 6,323 (69.5) 
Hospital 1,880 (20.7) 
Other locations 798 (8.8) 
Not specified 100 (1.1) 
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1. Demography 
 
Summary information for some of the key 
demographics is given in Table 2.8 for the 
period as a whole. The information has not 
been broken down by year since there was 
very little variation either across the decade or 
in terms of changes from year-to-year. 
Previous annual reports have noted the 
consistency in many of these attributes over 
time especially in terms of the proportion of 
ethnic groups represented, those aged less 
than 45 years, gender, living arrangements, 
employment status, place of death, and 
manner of death.  
 
 
 
 
Figure 2.6 shows the trend (using a 2-year 
moving average) in the number of deaths 
meeting the ‘drug misuse’ criteria for the Drug 
Strategy definition that occurred in a panel of 
English coronial areas from 2002 to 2011. The 
number of deaths fell steadily from a peak in 
2002/3 to 2005/6 before rising again by 2006-
7, followed by a decline. Although this 
decrease appears to continue in the last year 
or so, this fall may not be as pronounced as 
the graph indicates, as more inquests relating 
to deaths in 2010 and 2011 are completed and 
notified to the Programme. Upward revisions 
to figures for these two years reported on 
should be expected.    
 
 
Figure 2.6: Trend in number of “drug misuse” deaths reported to np-SAD, selected panel 
of coronial areas, 2002-2011 
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The number of cases broken down by gender 
is presented in Figure 2.7. There have been 
some fluctuations in the male : female ratio 
(range 2.9:1 to 4.2) over the decade; there 
was a gradual increase up to 2006 followed by 
a general decline. Overall, there were 10 
deaths of individuals aged less than 15 years, 
with 3 in 2010. The number of deaths amongst 
those aged 15 to 24 years tended to fall over 
time, as did those in the 25-34 age-group 
(Figure 2.8). An increasing proportion of 
deaths was accounted for by those in the 35-
44 and 45-54 age-groups, and to a lesser 
extent in the 55-64 age-group. In the oldest 
age-group (65 years and over) there was a 
fairly stable pattern of death. The median age 
at death increased progressively year on year 
from 34.0 to 40.7 years between 2002 and 
2011. Where known, the proportion of cases 
with a known history of drug abuse or 
dependence fell from 78% to 71% over the 
decade, although there were year-to-year 
variations.  
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Figure 2.7: Trend in number of “drug misuse” deaths reported to np-SAD, selected panel of 
coronial areas, by gender, 2002-2011 
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Figure 2.8: Trend in proportion accounted for by age-group of “drug misuse” deaths 
reported to np-SAD, selected panel of coronial areas, 2002-2011 
 
0%
20%
40%
60%
80%
100%
2002 2003 2004 2005 2006 2007 2008 2009 2010 2011
Year
A
g
e
-g
ro
u
p
< 15 15-24 25-34 35-44 45-54 55-64 65+
np-SAD 
 
International Centre for Drug Policy 50 
2. Substances implicated in death 
 
Figure 2.9 shows the substances most 
commonly implicated, whether alone or in 
combination, in death. The figure indicates the 
proportion of selected substances implicated 
in death rather than the proportion of cases in 
which the substances is involved. Overall, 
heroin/morphine (27.9%) accounted for the 
largest proportion of these selected 
substances, followed by alcohol-in-
combination (18.0%); other opiates/opioid 
analgesics (13.2%); and hypnotics/sedatives 
(12.1%). The other most frequently implicated 
drugs were methadone (11.3%); cocaine 
(7.7%); anti-depressants (7.5%); and 
amphetamines (2.3%). These proportions did 
not change dramatically over time, although 
there appears to have been a recent decline in 
the contribution made by amphetamine-type 
substances, and an increasing presence of 
methadone.  
 
Figure 2.9: Trend in substances implicated in “drug misuse” deaths reported to np-SAD, 
selected panel of coronial areas in England, 2002-2011 
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Breakdowns for English regions 
  
This section provides information by different 
geographical units for “drug misuse” deaths 
reported to np-SAD. Tables F and H provide 
rates by Drug and Alcohol Action Team 
(DAAT) and Primary Care Trust (PCT) areas 
respectively per 100,000 population; and G 
gives detailed breakdowns by key aspects 
(gender, age, ethnicity, drug implicated) by 
DAAT area.  
 
Tables I to L provide a profile of cases in the 
English regions which are the same as the 
Clusters used since autumn 2011 for 
Strategic Health Authorities. The annual rate 
of “drug misuse” deaths per 100,000 
population ranged from 0.91 in the West 
Midlands to 4.31 in the North West. [The 
rates in most English regions are affected by 
partial geographical coverage, and thus 
these rates should be regarded as the 
minimum]. The proportion of males ranged 
from 68.0% in the South East Coast to 
85.4% in the West Midlands. The North East, 
South Central and Yorkshire and Humber 
showed proportionately more deaths in the 
15-24 year age-group than other regions. 
Where ethnicity is known, most deaths 
amongst minority communities appear to 
occur in the following regions: London; 
Yorkshire and Humber; and the South East 
Coast. However, numbers are low. The 
proportion of cases with a known history of 
drug use or addiction ranges from 44.9% in 
South Central England to 64.6% in the East 
Midlands. 
 
In each region, the overall profile of drugs 
commonly implicated in death is consistent 
with the national picture. However, there 
appear to be some drugs with a higher 
presence in some regions compared to 
others.  For example, in the East of England 
heroin/morphine was implicated in 43.6% of 
cases, whilst in the North East the same 
drugs accounted for just 26.0% of cases. 
London exhibited the highest proportion of 
cocaine-related deaths (30.5%), which is in 
stark contrast to the South West in which 
cocaine was implicated in 3.7% of relevant 
deaths. Meanwhile, hypnotics/sedatives 
were implicated in 48.0% of deaths in the 
North East compared to just 20.3% in 
London. Deaths attributed to suicide 
accounted for 20.4% of deaths in South 
Central England, compared to 6.8% in 
London. Further information on such aspects 
for each English region can be found in 
Tables I to L. 
 
Commentary  
 
The demographic profile of “drug misuse” 
deaths in England remains generally 
consistent with previous reports: a higher 
proportion (73.5%) of males to females, White, 
with the majority under 45 years of age. “Drug 
misuse” deaths reported to the Programme 
amongst those aged 15-24 appear to have 
dropped over the past ten years by nearly 
70%; the median age increased over the 
period by nearly seven years. 
 
Accidental poisoning, as noted in previous 
years, still remains the most frequent 
underlying cause of death across all age-
groups. However, in comparison with females 
and males of younger age-groups, older 
females show a greater proportion of deaths 
attributed to intentional self-poisoning. 
 
As was found in np-SAD cases, 
heroin/morphine followed by methadone were 
the most frequently implicated drug in deaths 
of males, whilst in females it was anti-
depressants, closely followed by other opiates/ 
opioid analgesics. 
 
“Drug misuse” deaths reported to the 
Programme for 2011 suggest that the 
involvement in death of amphetamines, anti-
depressants, anti-epileptics, cocaine, ecstasy-
type drugs, hypnotics/sedatives, methadone 
and other opiates/opioid analgesics have 
increased, whilst deaths in which 
heroin/morphine and alcohol-in-combination 
with other drugs have decreased. The patterns 
seen here are similar to those found in np-
SAD cases in respect of controlled drugs. The 
decline in monovalent deaths noted in last 
year’s report appears to have plateaued 
somewhat: in 2011 they accounted for 36% of 
cases – the same rate as in 2010, whilst in 
2009 they represented 37%. Heroin/morphine 
combined with alcohol remains the most 
frequently implicated polysubstance 
combination over the past ten years, followed 
by heroin/morphine combined with 
hypnotics/sedatives, and then 
hypnotics/sedatives with alcohol.  
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The most commonly prescribed medications 
implicated in death were methadone; anti-
depressants; other opiates/opioid analgesics; 
followed by hypnotics/sedatives. From 
information on the prescribed drugs of cases, 
it appears that upwards of 54% of 
hypnotics/sedatives, other opiates/opioid 
analgesics, methadone and heroin/morphine-
related deaths are more likely to involve drugs 
obtained by illicit rather than legal means. 
 
It has to be acknowledged that there are some 
distinct differences between the definition of 
drug-related death used by np-SAD and that of 
“drug misuse” employed by Government 
departments to monitor trends in the 
effectiveness of drug strategies. 
 
Whilst the main source of information for the 
Office for National Statistics is the medical 
certificate of death, supplemented by part V of 
the Coroner’s Inquisition form, the np-SAD 
receives detailed information from inquests 
with reports from various sources (including 
toxicology) to the Coroner to determine the 
cause of death and thus the verdict. Both sets 
of data are of value and complementary. The 
detailed data from Coroners allows for the 
Programme to contribute to early warning 
monitoring systems, providing information on 
the epidemiology of Novel Psychoactive 
Substances (including “legal highs”), as well as 
on prescribing history, risk factors, etc. Both 
sources of data are needed to obtain a fuller 
understanding of the nature of drug-related 
mortality in England, and the UK as a whole.   
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Table F: “Drug misuse” cases in 2011 by Drug and Alcohol Action Team area (16 years 
and over) – number and rate per 100,000 population  
 
Drug and Alcohol Action Team Number and annual 
death rate per 100,000 
population – usual area 
of residence 
Number and annual 
death rate per 100,000 
population – place of 
death 
 No Rate No Rate 
ENGLAND     
NORTH EAST     
County Durham 10 2.36 3 0.71 
Darlington 0 0.00 1 1.16 
Gateshead 0 0.00 0 0.00 
Hartlepool 4 5.41 4 5.41 
Middlesbrough 5 4.55 4 3.64 
Newcastle upon Tyne 2 0.87 1 0.43 
North Tyneside* 7 4.22 8 4.82 
Northumberland 7 2.66 6 2.28 
Redcar and Cleveland 3 2.70 4 3.60 
South Tyneside 0 0.00 0 0.00 
Stockton on Tees 4 2.60 4 2.60 
Sunderland 8 3.52 8 3.52 
NORTH WEST     
Blackburn with Darwen 12 10.53 8 7.02 
Blackpool 15 12.82 14 11.97 
Bolton 9 4.09 10 4.55 
Bury 0 0.00 0 0.00 
Cheshire* 8 1.39 7 1.22 
Cumbria 11 2.64 9 2.16 
Halton 1 0.99 0 0.00 
Knowsley 2 1.71 1 0.85 
Lancashire 55 5.75 48 5.02 
Liverpool 24 6.20 27 6.98 
Manchester 30 7.44 29 7.20 
Oldham 1 0.57 0 0.00 
Rochdale 3 1.80 3 1.80 
Salford 22 11.64 20 10.58 
Sefton 7 3.08 2 0.88 
St Helens 0 0.00 0 0.00 
Stockport 10 4.35 7 3.04 
Tameside 10 5.65 8 4.52 
Trafford 5 2.76 6 3.31 
Warrington 10 6.10 8 4.88 
Wigan 8 3.10 8 3.10 
Wirral 2 0.77 0 0.00 
YORKSHIRE AND HUMBER     
Barnsley 0 0.00 0 0.00 
Bradford 7 1.75 5 1.25 
Calderdale 0 0.00 0 0.00 
Doncaster 4 1.63 3 1.22 
East Riding of Yorkshire 4 1.43 4 1.43 
Kingston upon Hull 12 5.80 12 5.80 
Kirklees 9 2.67 8 2.37 
Leeds 12 1.96 13 2.12 
North East Lincolnshire 2 1.55 1 0.78 
North Lincolnshire 2 1.47 1 0.74 
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Drug and Alcohol Action Team Number and annual 
death rate per 100,000 
population – usual area 
of residence 
Number and annual 
death rate per 100,000 
population – place of 
death 
 No Rate No Rate 
North Yorkshire 4 0.80 3 0.60 
Rotherham 1 0.48 1 0.48 
Sheffield 6 1.34 6 1.34 
Wakefield 6 2.26 6 2.26 
York 2 1.21 1 0.61 
EAST MIDLANDS     
Derby 3 1.52 4 2.02 
Derbyshire 20 3.15 16 2.52 
Leicester 12 4.62 6 2.31 
Leicestershire* 14 2.63 5 0.94 
Lincolnshire 10 1.69 8 1.35 
Northamptonshire 19 3.42 18 3.24 
Nottingham 5 2.03 4 1.63 
Nottinghamshire* 9 1.40 8 1.24 
Rutland* 1 3.18 1 3.18 
WEST MIDLANDS     
Birmingham* 0 0.00 1 0.12 
Coventry 4 1.58 2 0.79 
Dudley 3 1.18 3 1.18 
Herefordshire 1 0.66 0 0.00 
Sandwell 1 0.41 1 0.41 
Shropshire 5 1.97 7 2.76 
Solihull* 0 0.00 0 0.00 
Staffordshire 11 1.57 9 1.29 
Stoke-on-Trent 6 3.00 7 3.50 
Telford and Wrekin 3 2.26 1 0.75 
Walsall* 1 0.47 1 0.47 
Warwickshire* 0 0.00 0 0.00 
Wolverhampton 2 1.00 1 0.50 
Worcestershire 4 0.86 4 0.86 
EAST     
Bedfordshire 9 2.71 8 2.41 
Cambridgeshire 4 0.79 1 0.20 
Essex 0 0.00 0 0.00 
Hertfordshire 15 1.67 18 2.01 
Luton 3 1.91 4 2.55 
Norfolk 9 1.26 7 0.98 
Peterborough 7 4.83 7 4.83 
Southend-on-Sea 0 0.00 0 0.00 
Suffolk 8 1.34 5 0.84 
Thurrock 0 0.00 0 0.00 
LONDON     
Inner London     
Camden 1 0.54 0 0.00 
City of London 0 0.00 0 0.00 
Hackney 7 3.57 4 2.04 
Hammersmith and Fulham 7 4.58 12 7.84 
Haringey 1 0.49 0 0.00 
Islington 6 3.47 1 0.58 
Kensington and Chelsea 1 0.75 2 1.49 
Lambeth 3 1.20 3 1.20 
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Drug and Alcohol Action Team Number and annual 
death rate per 100,000 
population – usual area 
of residence 
Number and annual 
death rate per 100,000 
population – place of 
death 
 No Rate No Rate 
Lewisham 5 2.27 1 0.45 
Newham 4 1.67 1 0.42 
Southwark 6 2.55 5 2.13 
Tower Hamlets 2 0.98 0 0.00 
Wandsworth 0 0.00 0 0.00 
Westminster 10 5.38 8 4.30 
Outer London         
Barking and Dagenham 1 0.72 1 0.72 
Barnet 2 0.71 1 0.35 
Bexley 2 1.08 1 0.54 
Brent 1 0.40 0 0.00 
Bromley 1 0.40 0 0.00 
Croydon 9 3.15 5 1.75 
Ealing 14 5.17 13 4.80 
Enfield 1 0.41 0 0.00 
Greenwich 1 0.50 1 0.50 
Harrow 1 0.52 1 0.52 
Havering 1 0.52 1 0.52 
Hillingdon 9 4.13 9 4.13 
Hounslow 7 3.45 7 3.45 
Kingston-upon-Thames 6 4.62 6 4.62 
Merton 1 0.62 0 0.00 
Redbridge 1 0.46 0 0.00 
Richmond-upon-Thames 3 2.00 2 1.33 
Sutton 3 1.96 1 0.65 
Waltham Forest 2 0.98 1 0.49 
SOUTH EAST     
Bracknell Forest 1 1.11 1 1.11 
Brighton and Hove 18 7.89 14 6.14 
Buckinghamshire 4 0.99 1 0.25 
East Sussex 12 2.75 10 2.29 
Hampshire 16 1.49 12 1.12 
Isle of Wight 6 5.17 5 4.31 
Kent* 21 1.78 21 1.78 
Medway towns 0 0.00 0 0.00 
Milton Keynes 1 0.52 1 0.52 
Oxfordshire 0 0.00 0 0.00 
Portsmouth 7 4.19 7 4.19 
Reading 1 0.80 4 3.20 
Slough 2 1.87 1 0.93 
Southampton 7 3.61 8 4.12 
Surrey 17 1.85 17 1.85 
West Berkshire 0 0.00 0 0.00 
West Sussex 7 1.05 7 1.05 
Windsor and Maidenhead 4 3.42 4 3.42 
Wokingham 0 0.00 0 0.00 
SOUTH WEST     
Bath and North East Somerset* 0 0.00 0 0.00 
Bournemouth 13 8.39 6 3.87 
Bristol* 0 0.00 0 0.00 
Cornwall & Isles of Scilly 8 1.79 5 1.12 
Devon 10 1.60 10 1.60 
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Drug and Alcohol Action Team National and annual 
death rate per 100,000 
population – usual area 
of residence 
National and annual 
death rate per 100,000 
population – place of 
death 
 No Rate No Rate 
Dorset 7 2.02 3 0.86 
Gloucestershire 7 1.43 7 1.43 
North Somerset* 1 0.60 0 0.00 
Plymouth 1 0.47 1 0.47 
Poole 7 5.74 6 4.92 
Somerset 6 8.00 7 1.60 
South Gloucestershire* 0 0.00 0 0.00 
Swindon 13 7.74 12 7.14 
Torbay 2 1.82 2 1.82 
Wiltshire 6 1.57 6 1.57 
 
Note: In addition there were a number of cases that could not be allocated to specific DAAT areas because they were of 
no fixed abode and/or the jurisdiction in which the inquest was held covers more than one DAAT. Some cases were 
usually resident outside the UK. Some DAATs are covered by Coroners’ jurisdictions that did not submit information or 
only partial information) to the np-SAD; they are marked thus - *.  
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Table G: “Drug misuse” cases reported in 2011 by Drug and Alcohol Action Team area 
(demographics and drugs implicated)     
 
Drug and 
Alcohol Action 
Team 
No Gender Age-group Ethnicity Main Drug Strategy drug 
implicated 
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ENGLAND                     
NORTH EAST                     
County Durham 10 7 3 1 3 4 1 1 0 1 0 0 0 9 2 3 3 0 1 1 
Darlington 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Gateshead 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Hartlepool 4 4 0 0 0 1 1 2 0 4 0 0 0 0 1 1 2 0 0 0 
Middlesbrough 5 4 1 0 2 2 1 0 0 5 0 0 0 0 2 2 4 2 1 0 
Newcastle upon 
Tyne 
2 2 0 0 0 1 1 0 0 2 0 0 0 0 1 1 0 0 0 0 
North Tyneside 7 4 3 2 3 0 1 1 0 6 0 0 0 1 0 2 2 0 1 0 
Northumberland 7 7 0 1 0 2 3 0 0 6 1 0 0 0 2 2 5 0 0 0 
Redcar and 
Cleveland 
3 1 2 0 1 0 0 0 2 3 0 0 0 0 0 1 3 0 0 0 
South Tyneside 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Stockton on 
Tees 
4 2 0 3 1 0 0 0 0 4 0 0 0 0 3 3 3 0 0 1 
Sunderland 8 7 0 3 3 0 0 1 1 7 0 0 0 1 2 1 2 0 0 0 
NORTH WEST                     
Blackburn with 
Darwen 
12 10 2 0 2 6 2 2 0 11 0 0 0 1 8 3 4 1 1 0 
Blackpool 15 11 4 2 5 5 2 1 0 13 0 0 0 2 9 3 3 0 2 1 
Bolton 9 8 1 0 1 4 3 1 0 4 0 0 0 5 5 4 2 0 0 0 
Bury 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Cheshire 8 8 0 0 3 3 0 0 2 8 0 0 0 0 4 2 4 0 0 0 
Cumbria 11 7 4 3 5 3 0 0 0 10 0 0 0 1 1 8 6 0 0 0 
Halton 1 1 0 0 0 1 0 0 0 1 0 0 0 0 0 0 0 1 1 1 
Knowsley 2 2 0 0 1 1 0 0 0 2 0 0 0 0 2 0 0 1 0 0 
Lancashire 55 43 12 2 7 27 13 3 3 19 0 0 0 36 22 19 19 2 5 0 
Liverpool 24 15 9 1 1 11 8 2 1 22 0 0 0 2 5 13 1 4 1 2 
Manchester 30 15 15 2 3 11 9 3 2 22 0 0 1 7 7 10 2 2 2 0 
Oldham 1 1 0 1 0 0 0 0 0 1 0 0 0 0 0 1 0 0 0 0 
Rochdale 3 3 0 1 0 1 1 0 0 2 0 1 0 0 1 1 0 1 1 0 
Salford 22 14 8 0 3 11 5 1 2 5 0 0 0 17 6 6 4 0 2 0 
Sefton 7 5 2 0 3 2 2 0 0 7 0 0 0 0 5 3 1 1 0 1 
St. Helens 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Stockport 10 9 1 0 2 5 2 0 1 9 0 0 0 1 3 4 4 3 0 0 
Tameside 10 7 3 0 3 4 3 0 0 8 0 0 0 2 2 5 0 1 0 2 
Trafford 5 4 1 0 0 3 0 1 0 5 0 0 0 0 2 3 0 0 0 0 
Warrington 10 7 3 1 3 2 1 2 1 9 0 0 0 1 1 3 3 1 1 1 
Wigan 8 6 2 1 3 3 0 1 0 0 0 0 0 8 2 5 2 0 0 0 
Wirral 2 2 0 0 1 1 0 0 0 0 1 0 0 1 0 0 1 0 0 0 
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Drug and 
Alcohol Action 
Team 
No Gender Age-group Ethnicity Main Drug Strategy drug 
implicated 
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YORKSHIRE 
AND HUMBER 
                    
Barnsley 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Bradford 7 3 4 0 2 4 1 0 0 6 0 1 0 0 0 4 0 1 1 0 
Calderdale 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Doncaster 4 4 0 0 1 3 0 0 0 3 0 0 0 1 2 2 2 0 0 0 
East Riding of 
Yorkshire 
4 4 0 0 2 2 0 0 0 4 0 0 0 0 2 3 2 0 0 0 
Kingston upon 
Hull 
12 10 2 2 5 5 0 0 0 9 0 0 0 3 7 6 6 1 0 0 
Kirklees 9 7 2 2 4 2 1 0 0 8 0 0 0 0 5 5 3 2 0 0 
Leeds 12 8 4 0 3 5 1 3 0 12 0 0 0 0 4 19 4 2 1 0 
North East 
Lincolnshire 
2 2 0 0 0 2 0 0 0 0 0 0 0 2 0 2 1 0 0 0 
North 
Lincolnshire 
2 2 0 0 2 0 0 0 0 2 0 0 0 0 2 1 0 1 0 0 
North Yorkshire 4 4 0 0 2 2 0 0 0 3 0 0 0 1 3 2 2 1 1 0 
Rotherham 1 0 1 1 0 0 0 0 0 0 0 0 0 1 0 1 1 1 0 0 
Sheffield 6 3 3 2 1 2 1 0 0 6 0 0 0 0 1 3 2 1 0 0 
Wakefield 6 5 1 0 2 3 0 1 0 5 0 1 0 0 3 2 1 0 0 0 
York 2 2 0 1 0 1 0 0 0 2 0 0 0 0 1 0 0 0 1 0 
EAST 
MIDLANDS 
                    
Derby 3 3 0 0 2 0 1 0 0 2 1 0 0 0 1 1 2 0 2 0 
Derbyshire 20 15 5 1 4 9 5 1 0 18 0 0 0 2 7 6 2 2 2 0 
Leicester 12 10 2 0 1 7 0 1 3 10 0 0 0 2 5 4 6 0 0 0 
Leicestershire 14 8 6 1 2 7 2 0 4 0 0 0 1 10 3 5 3 1 0 0 
Lincolnshire 10 9 1 1 4 3 1 0 1 9 0 1 0 0 6 4 2 0 2 0 
Northamptonshire 19 11 8 1 5 6 5 2 0 19 0 0 0 0 4 10 5 2 1 0 
Nottingham 5 3 2 1 0 1 2 0 1 5 0 0 0 0 2 2 2 1 0 0 
Nottinghamshire 9 7 2 1 2 1 4 1 0 9 0 0 0 0 6 4 2 2 0 0 
Rutland 1 0 1 0 0 0 0 0 1 0 0 0 0 1 1 0 0 0 0 0 
WEST 
MIDLANDS 
                    
Birmingham* 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Coventry 4 4 0 0 1 2 1 0 0 2 0 0 0 2 1 3 1 0 0 0 
Dudley 3 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Herefordshire 1 1 0 0 0 2 1 0 0 0 0 0 0 1 1 0 1 0 0 0 
Sandwell 1 1 0 0 0 1 0 0 0 0 0 0 0 1 1 0 0 1 0 0 
Shropshire 5 3 2 0 0 4 0 0 1 0 0 0 0 5 3 0 1 0 0 0 
Solihull* 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Staffordshire 11 7 4 2 0 4 4 1 0 10 0 0 0 1 3 2 5 3 1 0 
Stoke-on-Trent 6 6 0 0 4 1 1 0 0 6 0 0 0 0 2 4 2 0 0 0 
Telford and 
Wrekin 
3 3 0 1 0 1 0 1 0 2 0 0 0 1 1 1 0 0 0 0 
Walsall* 1 1 0 0 0 0 1 0 0 1 0 0 0 0 0 1 0 0 0 0 
Warwickshire* 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Wolverhampton 2 2 0 0 0 2 0 0 0 1 0 0 0 1 1 0 0 1 0 0 
Worcestershire 
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EAST                     
Bedfordshire 9 5 4 0 2 3 2 1 1 9 0 0 0 0 3 4 3 1 0 0 
Cambridgeshire 4 4 0 1 1 1 1 0 0 0 0 0 0 4 1 1 1 1 0 0 
Essex* 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Hertfordshire 15 8 7 0 5 4 3 3 0 0 0 0 0 15 8 4 4 0 0 0 
Luton 3 2 1 0 0 0 2 0 1 3 0 0 0 0 1 0 0 0 0 0 
Norfolk 9 7 2 1 2 3 1 1 1 2 0 0 0 7 6 3 3 0 0 0 
Peterborough 7 6 1 1 4 0 1 0 1 6 0 0 0 1 4 1 0 1 0 0 
Southend-on-Sea 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Suffolk 8 6 2 0 2 4 2 0 0 3 0 0 0 5 1 3 1 0 0 0 
Thurrock* 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
LONDON                     
Inner London                     
Camden 1 1 0 0 0 0 0 1 0 0 0 0 0 1 1 0 1 0 0 0 
City of London 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Hackney 7 5 2 2 1 3 0 1 0 4 1 1 0 1 5 2 0 3 0 0 
Hammersmith 
and Fulham 
7 3 4 0 1 1 1 3 1 6 0 0 0 1 2 3 1 2 0 0 
Haringey 1 0 1 0 0 0 1 0 0 1 0 0 0 0 0 0 0 0 0 0 
Islington 6 4 2 0 1 1 4 0 0 4 0 0 0 2 3 1 1 0 0 0 
Kensington and 
Chelsea 
1 1 0 0 0 1 0 0 0 1 0 0 0 0 0 1 0 0 0 0 
Lambeth 3 2 1 0 2 0 0 1 0 1 1 0 0 1 2 2 0 0 0 0 
Lewisham 5 3 2 0 0 4 1 0 0 2 0 0 0 3 0 2 0 1 2 0 
Newham 4 4 0 1 0 2 1 0 0 1 0 0 1 2 1 0 0 1 1 1 
Southwark 6 4 2 0 1 4 1 0 0 5 1 0 0 0 2 3 1 3 0 1 
Tower Hamlets 2 2 0 1 0 0 1 0 0 2 0 0 0 0 1 1 1 0 0 0 
Wandsworth 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Westminster 10 6 4 1 1 4 3 1 0 4 0 0 0 6 2 3 4 5 0 1 
Outer London                     
Barking and 
Dagenham 
1 1 0 0 0 0 1 0 0 0 0 0 0 1 0 1 0 0 0 0 
Barnet 2 2 0 0 0 1 0 1 0 1 0 0 0 1 1 0 1 0 0 0 
Bexley 2 1 1 0 1 0 1 0 0 0 2 0 0 0 1 0 1 0 0 0 
Brent 1 1 0 0 1 0 0 0 0 1 0 0 0 0 1 0 0 0 0 0 
Bromley 1 1 0 0 0 0 1 0 0 1 0 0 0 0 0 1 0 0 0 0 
Croydon 9 8 1 0 4 3 2 0 0 3 0 0 0 6 2 2 0 5 0 0 
Ealing 14 11 3 1 3 3 5 1 1 7 1 5 1 0 5 7 1 4 0 0 
Enfield 1 1 0 0 0 1 0 0 0 1 0 0 0 0 0 0 1 0 0 0 
Greenwich 1 1 0 0 0 0 1 0 0 0 0 0 0 1 1 0 3 0 0 0 
Harrow 1 1 0 0 1 0 0 0 0 0 0 0 0 1 0 0 1 0 0 0 
Havering 1 1 0 0 0 1 0 0 0 0 0 1 0 0 0 0 0 0 0 0 
Hillingdon 9 5 4 1 1 2 4 0 0 6 0 0 0 3 2 5 3 4 1 0 
Hounslow 7 5 2 1 0 2 3 1 0 6 0 0 0 1 2 3 1 2 0 0 
Kingston-upon-
Thames 
6 5 1 0 3 1 1 1 0 6 0 0 0 0 2 1 4 3 0 0 
Merton 1 1 0 0 1 0 0 0 0 0 0 0 0 1 1 0 0 1 0 1 
Redbridge 1 1 0 0 0 1 0 0 0 0 1 0 0 0 1 0 0 0 0 0 
Richmond-upon-
Thames 
3 2 1 0 1 0 2 0 0 3 0 0 0 0 1 0 0 0 0 0 
Sutton 3 3 0 0 0 2 1 0 0 2 0 0 0 1 2 1 1 1 0 0 
Waltham Forest 
 
 
 
2 1 1 0 0 1 0 1 0 2 0 0 0 0 1 0 0 0 0 0 
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Drug and 
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SOUTH EAST                     
Bracknell Forest 1 1 0 0 0 0 1 0 0 0 0 0 0 1 0 0 1 0 0 0 
Brighton and 
Hove 
18 14 4 0 5 5 6 2 0 14 1 0 1 2 6 9 10 0 0 0 
Buckinghamshire 4 2 2 1 0 1 2 0 0 3 0 0 0 1 3 2 1 1 0 0 
East Sussex 12 7 5 1 4 1 5 1 0 12 0 0 0 0 7 3 5 1 0 0 
Hampshire 16 11 5 2 2 3 6 1 2 15 0 0 0 1 3 3 3 4 1 2 
Isle of Wight 6 4 2 1 1 2 2 0 0 6 0 0 0 0 2 0 1 0 0 0 
Kent 21 13 8 1 4 7 4 4 1 2 0 0 0 19 8 1 7 4 1 0 
Medway towns 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Milton Keynes 1 1 0 0 0 0 1 0 0 1 0 0 0 0 0 0 0 0 0 0 
Oxfordshire 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Portsmouth 7 5 2 0 1 3 3 0 0 6 0 0 0 1 5 0 2 1 0 0 
Reading 1 1 0 0 0 1 0 0 0 0 0 0 0 1 0 1 0 0 0 0 
Slough 2 1 1 1 0 1 0 0 0 1 0 0 0 1 3 0 0 0 0 0 
Southampton 7 7 0 1 1 3 2 0 0 7 0 0 0 0 2 3 0 1 0 0 
Surrey 17 13 4 1 3 7 4 0 2 3 0 0 0 14 6 3 6 3 0 1 
West Berkshire 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
West Sussex 7 4 3 0 1 0 3 1 2 2 0 0 0 5 1 1 1 1 0 0 
Windsor and 
Maidenhead 
4 3 1 0 0 4 0 0 0 0 0 0 4 2 2 0 2 0 0 0 
Wokingham 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
SOUTH WEST                     
Bath and North 
East Somerset* 
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Bournemouth 13 11 2 0 3 4 5 1 0 13 0 0 0 0 5 11 3 1 0 0 
Bristol* 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Cornwall & Isles 
of Scilly 
8 7 1 0 1 2 2 2 1 5 0 0 0 3 0 2 3 0 0 0 
Devon 10 9 1 0 3 4 2 1 0 2 0 0 0 8 3 2 3 0 0 0 
Dorset 7 6 1 1 3 1 1 1 0 6 0 0 0 1 6 2 2 0 0 0 
Gloucestershire 7 2 5 0 1 2 4 0 0 7 0 0 0 0 3 2 3 0 0 0 
North Somerset 1 1 0 0 0 1 0 0 0 1 0 0 0 0 0 0 1 0 0 0 
Plymouth 1 1 0 1 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 
Poole 7 5 2 0 3 3 0 0 1 7 0 0 0 0 3 3 1 0 0 0 
Somerset 6 5 1 1 2 1 1 0 0 5 0 0 0 1 3 1 1 0 1 0 
South 
Gloucestershire* 
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Swindon 13 12 1 0 6 3 4 0 0 13 0 0 0 0 5 7 2 2 0 0 
Torbay 2 0 2 0 0 1 0 1 0 2 0 0 0 0 2 1 1 0 1 0 
Wiltshire 6 2 4 0 0 3 2 1 0 6 0 0 0 0 3 1 0 0 0 0 
 
Note: In addition there were a number of cases that could not be allocated to specific DAAT areas as they were of no 
fixed abode and/or the jurisdiction in which the inquest was held covers more than one DAAT. Some cases were usually 
resident outside the UK. Some DAATs are covered by Coroners’ jurisdictions that did not submit information (or only 
partial information) to the np-SAD; they are marked thus - *. 
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Table H: “Drug misuse” cases in 2011 by Primary Care Trust and Strategic Health 
Authority areas in England (16 years and over)  
Area  Number and annual 
death rate per 100,000 
population – usual area 
of residence 
Number and annual 
death rate per 100,000 
population – place of 
death 
 No Rate No Rate 
ENGLAND (SHA and PCT)     
NORTH EAST SHA* 50 2.35 44 2.06 
County Durham 10 2.35 3 0.71 
Darlington 0 0.00 1 1.23 
Gateshead 0 0.00 0 0.00 
Hartlepool 4 5.48 4 5.48 
Middlesbrough 5 4.21 4 3.37 
Newcastle 2 0.85 1 0.43 
North Tyneside 7 4.10 6 3.52 
Northumberland 7 2.71 4 1.55 
Redcar and Cleveland 3 2.80 5 4.66 
South Tyneside 0 0.00 0 0.00 
Stockton-on-Tees Teaching 4 2.61 8 5.21 
Sunderland Teaching 8 3.49 8 3.49 
NORTH WEST SHA* 247 4.31 218 3.81 
Ashton, Leigh and Wigan 8 3.25 8 3.25 
Blackburn with Darwen 12 10.36 8 6.90 
Blackpool 15 13.30 14 12.41 
Bolton 9 4.27 10 4.74 
Bury 0 0.00 0 0.00 
Central and Eastern Cheshire 7 1.92 6 1.65 
Central Lancashire 14 3.84 11 3.01 
Cumbria Teaching 11 2.66 9 2.17 
East Lancashire Teaching 22 7.48 22 7.48 
Halton and St Helens 1 0.41 0 0.00 
Heywood, Middleton and Rochdale 3 1.87 3 1.87 
Knowsley 2 1.68 1 0.84 
Liverpool 24 6.39 27 7.19 
Manchester 30 6.97 29 6.74 
North Lancashire Teaching 19 7.02 16 5.91 
Oldham 1 0.58 0 0.00 
Salford 22 11.59 20 10.54 
Sefton 7 3.17 2 0.91 
Stockport 10 4.31 7 3.01 
Tameside and Glossop 
1
 12 6.57 10 5.48 
Trafford 5 2.91 6 3.49 
Warrington 10 6.32 8 5.05 
Western Cheshire 1 0.49 1 0.49 
Wirral 2 0.80 0 0.00 
YORKSHIRE AND HUMBER SHA* 71 1.62 64 1.46 
Barnsley 0 0.00 0 0.00 
Bradford and Airedale Teaching 7 1.76 5 1.26 
Calderdale 0 0.00 0 0.00 
Doncaster 4 1.69 3 1.27 
East Riding of Yorkshire 4 1.55 4 1.55 
Hull Teaching 12 5.09 12 5.09 
Kirklees 9 2.83 8 2.51 
Leeds 12 1.80 13 1.95 
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Area Number and annual 
death rate per 100,000 
population – usual area 
of residence 
Number and annual 
death rate per 100,000 
population – place of 
death 
 No Rate No Rate 
North East Lincolnshire 2 1.52 1 0.76 
North Lincolnshire 2 1.54 1 0.77 
North Yorkshire and York 6 0.93 4 0.62 
Rotherham 1 0.51 1 0.51 
Sheffield 6 1.30 6 1.30 
Wakefield District 6 2.18 6 2.18 
EAST MIDLANDS SHA* 91 2.49 68 1.86 
Bassetlaw 3 3.43 2 2.28 
Derby City 3 1.32 4 1.76 
Derbyshire County 18 3.14 14 2.44 
Leicester City 12 4.70 5 1.96 
Leicestershire County and Rutland 15 2.80 7 1.31 
Lincolnshire Teaching
2
 10 1.71 8 1.37 
Northamptonshire Teaching 19 3.54 18 3.35 
Nottingham City 5 1.85 4 1.48 
Nottinghamshire County Teaching 6 1.13 6 1.13 
WEST MIDLANDS SHA* 41 0.91 36 0.80 
Birmingham East and North 0 0.00 0 0.00 
Coventry Teaching 4 1.49 2 0.74 
Dudley 3 1.22 3 1.22 
Heart of Birmingham Teaching 0 0.00 0 0.00 
Herefordshire 1 0.69 0 0.00 
North Staffordshire 0 0.00 0 0.00 
Sandwell 1 0.41 1 0.41 
Shropshire County 5 2.13 7 2.98 
Solihull
 
 0 0.00 0 0.00 
South Birmingham 0 0.00 0 0.00 
South Staffordshire 11 2.28 9 1.87 
Stoke on Trent 6 2.86 7 3.33 
Telford and Wrekin 3 2.33 1 0.78 
Walsall Teaching 1 0.51 1 0.51 
Warwickshire 0 0.00 0 0.00 
Wolverhampton City 2 1.04 1 0.52 
Worcestershire 4 0.89 4 0.89 
EAST OF ENGLAND SHA 55 1.16 50 1.05 
Bedfordshire 9 2.66 8 2.37 
Cambridgeshire 4 0.82 1 0.20 
Hertfordshire 15 1.66 18 1.99 
Great Yarmouth and Waveney 2 1.08 2 1.08 
Luton 3 1.98 4 2.64 
Mid Essex 0 0.00 0 0.00 
Norfolk 8 1.29 6 0.97 
North East Essex 0 0.00 0 0.00 
Peterborough 7 5.60 7 5.60 
South East Essex 0 0.00 0 0.00 
South West Essex 0 0.00 0 0.00 
Suffolk 7 1.43 4 0.82 
West Essex 
 
 
 
0 0.00 0 0.00 
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Area Number and annual 
death rate per 100,000 
population – usual area 
of residence 
Number and annual 
death rate per 100,000 
population – place of 
death 
 No Rate No Rate 
LONDON SHA 119 1.81 87 1.32 
Barking and Dagenham 1 0.75 1 0.75 
Barnet 2 0.72 1 0.36 
Bexley 2 1.16 1 0.58 
Brent Teaching 1 0.47 0 0.00 
Bromley 1 0.40 0 0.00 
Camden 1 0.48 0 0.00 
City and Hackney Teaching 7 3.82 4 2.18 
Croydon 9 3.34 5 1.86 
Ealing 14 5.18 13 4.81 
Enfield 1 0.46 0 0.00 
Greenwich Teaching 1 0.54 1 0.54 
Hammersmith and Fulham 7 5.14 12 8.81 
Haringey Teaching 1 0.52 0 0.00 
Harrow 1 0.59 1 0.59 
Havering 1 0.50 1 0.50 
Hillingdon 9 4.47 9 4.47 
Hounslow 7 3.71 7 3.71 
Islington 6 3.75 1 0.63 
Kensington and Chelsea 1 0.64 2 1.28 
Kingston 6 3.99 6 3.99 
Lambeth 3 1.20 3 1.20 
Lewisham 5 2.36 1 0.47 
Newham 4 2.18 1 0.55 
Redbridge 1 0.50 0 0.00 
Richmond and Twickenham 3 2.03 2 1.36 
Southwark 6 2.69 5 2.24 
Sutton and Merton 4 1.33 1 0.33 
Tower Hamlets 2 1.06 0 0.00 
Waltham Forest 2 1.10 1 0.55 
Wandsworth 0 0.00 0 0.00 
Westminster 10 4.59 8 3.67 
SOUTH EAST COAST SHA* 75 2.06 68 1.87 
Brighton and Hove City 18 8.15 14 6.34 
East Sussex Downs and Weald 4 1.47 4 1.47 
Eastern and Coastal Kent* 11 1.85 11 1.85 
Hastings and Rother 8 5.58 6 4.18 
Medway 0 0.00 0 0.00 
Surrey 17 1.92 17 1.92 
West Kent* 10 1.84 9 1.65 
West Sussex 7 1.07 7 1.07 
SOUTH CENTRAL SHA 49 1.45 43 1.28 
Berkshire East 7 2.19 6 1.88 
Berkshire West 1 0.26 3 0.79 
Buckinghamshire 4 1.00 1 0.25 
Hampshire 16 1.57 12 1.18 
Milton Keynes 1 0.86 1 0.86 
NHS Isle of Wight 6 3.14 5 2.62 
Oxfordshire 0 0.00 0 0.00 
Portsmouth City Teaching 7 4.05 7 4.05 
Southampton City 7 3.31 8 3.78 
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Area National and annual 
death rate per 100,000 
population – usual area 
of residence 
National and annual 
death rate per 100,000 
population – place of 
death 
 No Rate No Rate 
SOUTH WEST SHA* 81 1.85 65 1.49 
Bath and North East Somerset* 0 0.00 0 0.00 
Bournemouth and Poole Teaching 20 7.26 12 4.36 
Bristol 0 0.00 0 0.00 
Cornwall & Isles of Scilly 8 1.82 5 1.13 
Devon 10 1.64 10 1.64 
Dorset 7 2.23 3 0.96 
Gloucestershire 7 1.45 7 1.45 
North Somerset* 1 0.58 0 0.00 
Plymouth Teaching 1 0.47 1 0.47 
Somerset 6 1.42 7 1.66 
South Gloucestershire* 0 0.00 0 0.00 
Swindon 13 7.91 12 7.30 
Torbay  2 1.72 2 1.72 
Wiltshire 6 1.70 6 1.70 
 
Note: In addition there were a number of cases that could not be allocated to specific PCT areas because they were of 
no fixed abode and/or the jurisdiction in which the inquest was held covers more than one PCT. Some cases were 
usually resident outside the UK. Some PCTs are covered by Coroners’ jurisdictions that did not submit information (or 
only partial information) to the np-SAD; they are marked thus - *. 
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Table I : Profile of “drug misuse” deaths in English regions – Northern cluster 
 
 
Government Office Region North East* North West* Yorkshire & 
Humber* 
Demographics No % No % No % 
Population mid-2011 aged 16 
years and over 
2,131, 600 
 
 5,728,380  4,387,720  
‘Drug misuse’ deaths reported 50  247  70  
Number of deaths/100,000 
population aged 16 and over 
2.16  4.31  1.60  
Gender                         
Male 38 76.0 179 72.5 53 75.7 
Female 12 24.0 68 27.5 17 24.3 
Age-group (years)        
15-24  4 8.0 14 5.7 7 10.0 
25-34 15 30.0 46 18.6 24 34.3 
35-44  14 28.0 106 42.9 31 44.3 
45-54 8 16.0 52 21.1 4 5.7 
55-64 5 10.0 17 6.9 4 5.7 
65 and over  4 8.0 12 4.9 0 0.0 
Ethnicity       
White 38 76.0 161 65.2 59 84.3 
Black 1 2.0 0 0.0 0 0.0 
Asian 0 0.0 1 0.4 2 2.9 
Other  0 0.0 1 0.4 1 1.4 
Unknown 11 22.0 84 34.0 8 11.4 
Drug use/addiction history       
Yes 30 60.0 122 49.4 44 62.9 
No  13 26.0 54 21.9 8 11.4 
Unknown 7 14.0 71 28.7 18 25.7 
Selected main drugs 
implicated**              
      
Heroin/morphine 13 26.0 86 34.8 30 42.9 
Methadone 16 32.0 94 38.1 34 48.6 
Hypnotics/sedatives 24 48.0 57 23.1 23 32.9 
Cocaine 3 6.0 19 7.7 10 14.3 
Amphetamines 3 6.0 17 6.9 4 5.7 
Ecstasy-type drugs 2 4.0 8 3.2 0 0.0 
Other opiates/opioid 
analgesics 
15 30.0 74 30.0 11 15.7 
Anti-depressants 10 20.0 48 19.4 11 15.7 
Anti-psychotics 0 0.0 5 2.0 4 5.7 
Manner of death       
Natural 1 2.0 4 1.6 0 0.0 
Accidental 36 72.0 194 78.5 62 88.6 
Suicidal 9 18.0 29 11.7 4 5.7 
Homicidal 0 0.0 0 0.0 0 0.0 
Undetermined 4 8.0 20 8.1 4 5.7 
Unascertained/unknown 0 0 0 0.0 0 0.0 
* Not all Coroners’ jurisdictions submitted data or only partial information 
** Percentages may add to more than 100% because of more than one substance being implicated 
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Table J: Profile of “drug misuse” deaths in English regions – Midlands cluster 
 
 
Government Office Region East of England* East Midlands West Midlands* 
 
Demographics No % No % No % 
Population mid-2011 aged 16 
years and over 
4,753,320  3,659,880  4,511,860  
‘Drug misuse’ deaths reported 55  82  41  
Number of deaths/100,000 
population aged 16 and over 
1.16  2.24  0.91  
Gender                         
Male 38 69.1 57 69.5 35 85.4 
Female 17 30.9 25 30.5 6 14.6 
Age-group (years)        
15-24  3 5.5 5 6.1 3 7.3 
25-34 16 29.1 17 20.7 10 24.4 
35-44  15 27.3 29 35.4 16 39.0 
45-54 12 21.8 19 23.2 8 19.5 
55-64 5 9.1 5 6.1 2 4.9 
65 and over  4 7.3 7 8.5 2 4.9 
Ethnicity       
White 23 41.8 66 80.5 27 65.9 
Black 0 0.0 1 1.2 0 0.0 
Asian 0 0.0 0 0.0 0 0.0 
Other  0 0.0 0 0.0 0 0.0 
Unknown 32 58.2 15 18.3 14 34.1 
Drug use/addiction history       
Yes 35 63.6 53 64.6 19 46.3 
No  12 21.8 18 22.0 7 17.1 
Unknown 8 14.5 11 13.4 15 36.6 
Selected main drugs 
implicated**              
      
Heroin/morphine 24 43.6 29 35.4 13 31.7 
Methadone 16 29.1 31 37.8 15 36.6 
Hypnotics/sedatives 12 21.8 21 25.6 12 29.3 
Cocaine 3 5.5 7 8.5 5 12.2 
Amphetamines 0 0.0 5 6.1 1 2.4 
Ecstasy-type drugs 0 0.0 0 0.0 0 0.0 
Other opiates/opioid analgesics 19 34.5 22 26.8 4 9.8 
Anti-depressants 9 16.4 18 22.0 2 4.9 
Anti-psychotics 0 0.0 5 6.1 5 12.2 
Manner of death       
Natural 0 0.0 0 0.0 0 0.0 
Accidental 44 80.0 62 75.6 36 87.8 
Suicidal 10 18.2 13 15.9 5 12.2 
Homicidal 0 0.0 0 0.0 0 0.0 
Undetermined 1 1.8 7 8.5 0 0.0 
Unascertained/unknown 0 0.0 0 0.0 0 0.0 
* Not all Coroners’ jurisdictions submitted data or only partial information 
** Percentages may add to more than 100% because of more than one substance being implicated 
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Table K: Profile of “drug misuse” deaths in English regions – London cluster 
 
 
Government Office Region London 
Demographics No % 
Population mid-2011 aged 16 
years and over 
6,573,140  
‘Drug misuse’ deaths reported 118  
Number of deaths/100,000 
population aged 16 and over 
1.80  
Gender                     
Male 86 72.9 
Female 32 27.1 
Age-group (years)    
15-24  8 6.8 
25-34 23 19.5 
35-44  37 31.4 
45-54 35 29.7 
55-64 12 10.2 
65 and over  3 2.5 
Ethnicity   
White 71 60.2 
Black 5 4.2 
Asian 7 5.9 
Other  2 1.7 
Unknown 33 28.0 
Drug use/addiction history   
Yes 70 59.3 
No  26 22.0 
Unknown 22 18.6 
Selected main drugs 
implicated**              
  
Heroin/morphine 43 36.4 
Methadone 39 33.1 
Hypnotics/sedatives 24 20.3 
Cocaine 36 30.5 
Amphetamines 4 3.4 
Ecstasy-type drugs 4 3.4 
Other opiates/opioid analgesics 39 33.1 
Anti-depressants 20 16.9 
Anti-psychotics 5 4.2 
Manner of death   
Natural 3 2.5 
Accidental 94 79.7 
Suicidal 8 6.8 
Homicidal 0 0.0 
Undetermined 13 11.0 
Unascertained/unknown 0 0.0 
* Not all Coroners’ jurisdictions submitted data or only partial 
information 
** Percentages may add to more than 100% because of more 
than one substance being implicated 
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Table L: Profile of “drug misuse” deaths in English regions – Southern cluster  
 
 
Government Office Region South East 
Coast* 
South Central* South West* 
 
Demographics No % No % No % 
Population mid-2011 aged 16 
years and over 
3,637, 920  3,368,860  4,368,660  
‘Drug misuse’ deaths reported 75  49  81  
Number of deaths/100,000 
population aged 16 and over 
2.06  1.45  1.85  
Gender                         
Male 51 68.0 36 73.5 61 75.3 
Female 24 32.0 13 26.5 20 24.7 
Age-group (years)        
15-24  3 4.0 6 12.2 3 3.7 
25-34 17 22.7 5 10.2 22 27.2 
35-44  20 26.7 18 36.7 25 30.9 
45-54 22 29.3 17 34.7 21 25.9 
55-64 8 10.7 1 2.0 7 8.6 
65 and over  5 6.7 2 4.1 3 3.7 
Ethnicity       
White 33 44.0 39 79.6 68 84.0 
Black 1 1.3 0 0.0 0 0.0 
Asian 0 0.0 0 0.0 0 0.0 
Other  1 1.3 0 0.0 0 0.0 
Unknown 40 53.3 10 20.4 13 16.0 
Drug use/addiction history       
Yes 35 46.7 22 44.9 44 54.3 
No  16 21.3 19 38.8 19 23.5 
Unknown 24 32.0 8 16.3 18 22.2 
Selected main drugs 
implicated**              
      
Heroin/morphine 28 37.3 18 36.7 34 42.0 
Methadone 17 22.7 9 18.4 32 39.5 
Hypnotics/sedatives 29 38.7 10 20.4 20 24.7 
Cocaine 9 12.0 7 14.3 3 3.7 
Amphetamines 1 1.3 1 2.0 2 2.5 
Ecstasy-type drugs 1 1.3 2 4.1 0 0.0 
Other opiates/opioid analgesics 20 26.7 15 30.6 18 22.2 
Anti-depressants 17 22.7 10 20.4 21 25.9 
Anti-psychotics 5 6.7 1 2.0 3 3.7 
Manner of death       
Natural 0 0.0 0 0.0 1 1.2 
Accidental 47 62.7 32 65.3 61 75.3 
Suicidal 14 18.7 10 20.4 12 14.8 
Homicidal 0 0.0 0 0.0 0 0.0 
Undetermined 14 18.7 7 14.3 7 8.6 
Unascertained/unknown 0 0.0 0 0.0 0 0.0 
* Not all Coroners’ jurisdictions submitted data or only partial information 
** Percentages may add to more than 100% because of more than one substance being implicated 
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Chapter 3: Drug-related deaths in Wales  
 
This chapter describes the pattern of drug-
related deaths in Wales reported by Coroners 
to the np-SAD that meet the Programme’s 
case criteria.  
 
1. Demography 
 
There were 81 notifications of drug-related 
deaths occurring in 2011 from Coroners in 
Wales. Furthermore there were some 
additional notifications for deaths occurring in 
2010 (4); 2009 (4); 2008 (2) and one from 
2004.  
 
In 2011 there was a rate of 2.83 drug-related 
deaths per 100,000 population aged 16 years 
and over, compared with 3.30 in 2010 and 
5.23 in 2009.  
 
The majority (80.2%) of the cases in 2011 
were male (Table 3.1). The median age at 
death was 36 years (interquartile range = 
12.6) (Figure 3.1) and 79% of cases were 
aged under 45 years. Those who were 
unemployed accounted for 66.7% of cases, 
and the living arrangements showed 43.2% 
living with others. Addict status was known in 
60 cases, 80% of which had a history of 
dependence or drug use. Ethnicity was known 
in 48 cases, 97.9% were White; 2.1% other; 
and in 33 cases ethnic background was not 
provided.
 
Table 3.1: Demographic variables for drug-related deaths reported by Coroners meeting 
np-SAD criteria, Wales, 2011  
 
 
 
2.  Location of death 
 
Most fatalities (93.8%) occurred at a defined 
residential address (i.e. the deceased’s home 
address or other private residential address). 
Deaths in hospital accounted for 1.2% and 5% 
occurred elsewhere. 
 
 
3. Cause(s) of death 
 
Accidental poisoning accounted for 76.5% of 
the deaths, with 14.8% from intentional self-
poisoning, and in 6.1% of cases the intent was 
undetermined. The remaining two deaths were 
related to accidental poisoning by gases and 
unspecified cirrhosis of the liver. 
Variable Category Number (%) 
Total  81 (100.0) 
Gender 
Male 65 (80.2) 
Female 16 (19.8) 
Employment status 
Employed 19 (23.5) 
Unemployed 54 (66.7) 
Childcare/house person 0 (0.0) 
Student/pupil 0 (0.0) 
Retired/sickness/invalidity 4 (4.9) 
Not known 3 (3.7) 
Other 1 (1.2) 
Living Arrangements 
Alone 37 (45.7) 
With others 35 (43.2) 
No fixed abode 3 (3.7) 
Other 2 (2.5) 
Not known 4 (4.9) 
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Figure 3.1: Drug-related deaths reported by Coroners meeting np-SAD criteria, by age and 
gender, Wales, 2011 
 
 
 
4.  Substances implicated in death  
 
4.1 All substances 
 
Psychoactive drugs were directly implicated in 
79/81 (97.5%) cases. The principal substances 
implicated were: heroin/morphine (43.0%); 
methadone (39.2%); hypnotics/sedatives 
(30.4%); other opiates/ opioid analgesics 
(26.6%); alcohol-in-combination (21.5%); and 
anti-depressants (17.7) (Table 3.2). 
 
Figure 3.2 takes into account data where one 
of the following drugs was known to be 
implicated: alcohol-in-combination; amphet-
amines; anti-depressants; anti-epileptics; anti-
psychotics; cocaine; heroin/morphine; 
hypnotics/sedatives; methadone; and other 
opiates/opioid analgesics. 
 
4.2 Single substances 
 
Single substance deaths accounted for 31.6% 
(25/79) of all fatalities where psychoactive 
substances were implicated. Heroin/morphine 
and methadone accounted for 60.0% (15/25) 
of these deaths when implicated alone (Table 
3.2).    
 
Table 3.2: Psychoactive substances implicated in deaths reported by Coroners meeting 
np-SAD criteria, Wales, 2011  
 
Drug category Number (%) of cases where no 
other substance was implicated 
(N = 79) 
Number (%) of cases 
where drug was implicated 
(N = 79) 
   
Alcohol-in-combination - 17 (21.5) 
Amphetamines 2 (2.5) 4 (5.1) 
Anti-depressants 3 (3.8) 14 (17.7) 
Anti-epileptics 1 (1.3) 1 (1.3) 
Anti-Parkinson’s 0 (0.0) 0 (0.0) 
Anti-psychotics 0 (0.0) 6 (7.6) 
Cannabis 0 (0.0) 0 (0.0) 
Cocaine 1 (1.3) 2 (2.5) 
Ecstasy-type drugs 1 (1.3) 1 (1.3) 
GHB/GBL 0 (0.0) 0 (0.0) 
Heroin/morphine 8 (10.1) 34 (43.0) 
Hypnotics/sedatives 1 (1.3) 24 (30.4) 
Methadone 7 (8.9) 31 (39.2) 
Other opiates/opioid 
analgesics 
1 (1.3) 21 (26.6) 
Note: Column totals may sum to more than 100% since more than one substance may be implicated in a death. 
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Figure 3.2: Drug-related deaths reported by Coroners meeting np-SAD criteria, by 
selected psychoactive drug implicated, Wales, 2011 
 
17
4
14
1
6
2
34
24
31
21
0
5
10
15
20
25
30
35
40
N
u
m
b
e
r
Implicated drug
 
 
5.  Age and drug implicated in death  
 
Of the 79 drug related deaths where a 
psychoactive drug was implicated, 
heroin/morphine and methadone accounted 
for the same number of deaths in the 25-34 
age-group, followed by hypnotics/sedatives. 
Heroin/morphine accounted for one more 
death than methadone and two more than 
hypnotics/sedatives in the 35-44 age-group. 
Table 3.3 shows where any particular drug 
was implicated across the whole range of age-
groups. In the 35-44 age-group alcohol-in-
combination was reported more than in any 
other. Looking at 45 through to 64 years as a 
whole, the most commonly implicated 
substances were heroin/morphine; 
methadone; and other opiates/opioid 
analgesics. Only anti-depressants were 
implicated in the 65+ age-group.  
 
Table 3.3: Age and drug implicated in deaths reported by Coroners meeting np-SAD 
criteria, Wales, 2011 
 
Age-
group 
(years) 
Drug category (alone or in combination) most frequently 
implicated in each age-group 
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15-24 3 2 1 3 0 0 0 0 0 1 0 0 0 0 0 
25-34 12 12 10 6 2 2 1 3 3 5 0 0 0 0 0 
35-44 13 12 11 7 0 2 0 5 2 9 0 0 0 0 0 
45-54 4 5 3 4 0 0 0 3 1 2 1 0 0 0 0 
55-64 2 0 0 1 0 0 0 1 0 0 0 0 0 0 0 
65+ 0 0 0 0 0 0 0 2 0 0 0 0 0 0 0 
TOTAL 34 31 25 21 2 4 1 14 6 17 1 0 0 0 0 
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6.  Gender and drug implicated in death 
 
The pattern of drugs implicated in mortality 
was somewhat different in male and female 
cases. Among males, the most frequently 
mentioned drugs were: methadone (44.6%); 
heroin/morphine (43%); hypnotics/sedatives 
(32.3%); other opiates/opioid analgesics 
(26.1%); and alcohol-in-combination (24.6%). 
The differences between male and female 
deaths for implicated drugs were: 
heroin/morphine (43% vs. 37.5%); methadone 
(45.3% vs. 12.5%); hypnotics/sedatives 
(32.3% vs. 25%); other opiates/opioid 
analgesics (26.1% vs. 25%); and alcohol-in-
combination (25% vs. 6.3%). Among males 
there were three fatalities involving anti-
psychotics, two for both cocaine and 
amphetamines and one for ecstasy-type 
drugs.   
 
In female cases, the drugs mentioned were: 
anti-depressants (43.7%); heroin/morphine 
(37.5%); hypnotics/sedatives, and other 
opiates/opioid analgesics (25%); anti-
psychotics (18.7%); methadone (12.5%); and 
alcohol-in-combination (6.3%). Compared to 
male cases, female cases had higher 
proportions of fatality associated with anti-
depressants (43.7% vs. 10.7%); and anti-
psychotics (18.7% vs. 4.6%). Furthermore, 
there was one fatality involving anti-epileptics 
among females. 
 
7. Regional data 
 
This section contains information based on 
various geographical entities. The number of 
cases reported in 2010 and 2011 by Coroners’ 
jurisdiction; the number per 100,000 
population aged 16 years and over; and the 
percentage of all inquests accounted for by 
drug-related deaths are shown in Table 3.4. 
 
Data for Drug and Alcohol Action Team 
(DAAT) areas are given in Tables 3.5 and 3.6. 
These provide the number of deaths by 
population (rate per 100,000 population aged 
16 years and over), and show the age-group; 
gender; ethnicity; and principal psychoactive 
drugs implicated in death.  
 
From the data available, the highest rates 
were found in: Swansea; North West Wales; 
and Neath & Port Talbot Coroners’ areas, 
(Table 3.4). Heroin/morphine and 
hypnotics/sedatives were implicated the most 
in deaths occurring in Bro Taf and Iechyd 
Morgannwg (Table 3.6). 
 
np-SAD   
73                International Centre for Drug Policy 
Table 3.4: Deaths reported, rates per 100,000 (aged 16 and over), and proportion of all 
inquests, Wales, 2010 and 2011   
 
Coroner’s 
Jurisdiction 
Additional 
2010 
deaths 
reported in 
2011/12
(1)
 
Cumulative 
total  
number of 
deaths 2010 
Annual 
death rate 
per 
100,000 
population 
2010 
(2)
 
Annual 
% of all 
inquests 
held in 
2010 
(3)
 
Number 
of 
deaths 
2011 
Annual 
death rate 
per 
100,000 
population 
2011 
(2)
 
Annual 
% of all 
inquests 
held in 
2011 
Bridgend & 
Glamorgan 
Valleys 
1 23 6.72 7.14 16 4.56 3.83 
Cardiff & the 
Vale of 
Glamorgan 
0 20 5.26 4.98 14 3.64 4.24 
Carmarthenshire 0 3 2.02 4.05 7 4.64 14.2 
Central North 
Wales 
- - - - - - - 
Ceredigion 1 1 1.54 0.16 2 3.12 8.00 
Gwent 0 12 2.65 8.51 3 0.64 2.17 
Neath & Port 
Talbot 
1 3 1.78 3.65 6 5.26 7.31 
North East 
Wales 
- 2 0.87 0.98 - - - 
North West 
Wales 
3 11 7.13 8.08 12 7.56 8.82 
Pembrokeshire 0 5 1.05 1.35 5 4.97 6.94 
Powys 0 4 - - - - - 
Swansea 0 26 13.62 13.27 16 8.11 9.58 
Note: (0) refers to either no drug-related deaths or death rates of less than 0.01, whilst (–) indicates that no reports 
were submitted for the specific period from that jurisdiction or area. In subsequent reports these rates may increase 
as more inquests on deaths in 2011 are held and/or notified to the np-SAD. These rates should therefore be 
regarded as minimum rates.  
(1) Notified after the publication of the np-SAD Annual Report, 2011.  
(2) The rate per 100,000 population is based on published mid-year population estimates for local government 
administrative areas for the years in question. 
(3) Includes updated information submitted in 2011/12. 
np-SAD 
 
International Centre for Drug Policy 74 
Table 3.5: Deaths by Drug and Alcohol Action Team area (16 years and over) – number 
and rate per 100,000 population, Wales, 2011  
 
Drug and Alcohol Action Team 
Area 
National and annual 
death rate per 100,000 
population – usual area 
of residence 
National and annual 
death rate per 100,000 
population – place of 
death 
 
No Rate No Rate 
Bro Taf 18 2.89 14 2.25 
Dyfed Powys 12 2.82 12 2.82 
Gwent 2 0.43 0 0.00 
Iechyd Morgannwg  34 7.98 34 7.98 
North Wales* 12 2.13 12 2.13 
Note: There was 1 case that was usually resident outside Wales, and nine deaths that could not be allocated to a 
specific DAAT.  
 
Table 3.6: Deaths by Drug and Alcohol Action Team area – demographics and drugs 
implicated, Wales, 2011  
 
Drug and 
Alcohol Action 
Team Area 
N
o 
Gender Age-group Ethnicity 
Main Drug Strategy drug 
implicated 
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Bro Taf 18 17 1 0 5 9 4 0 0 12 0 0 1 5 7 10 7 0 0 0 
Dyfed Powys* 12 7 5 0 5 4 2 1 0 8 0 0 0 4 4 4 6 0 1 0 
Gwent 2 2 0 0 2 0 0 0 0 0 0 0 0 2 1 0 1 0 0 0 
Iechyd 
Morgannwg  
34 28 6 4 14 14 2 0 0 23 0 0 0 11 15 13 8 1 3 1 
North Wales” 12 8 4 2 1 4 1 2 2 2 0 0 0 10 5 3 1 0 0 0 
Note: There was 1 case that was usually resident outside Wales and thus could not be allocated to a specific DAAT. 
Some DAATs are covered by Coroners’ jurisdictions that did not submit information (or only partial information) to the 
np-SAD; they are marked thus - *. 
 
 
8. Commentary 
 
There was a higher ratio of male to female 
(17:1) drug-related deaths in Dyfed Powys 
compared to other areas in Wales in 2011. 
Both Iechyd Morgannwg and Dyfed Powys 
had deaths across four age-groups, with the 
majority of deaths in Wales being among 
those aged 25 to 44 years old. Deaths of 
those aged 15-24 occurred in Iechyd 
Morgannwg and North Wales. 
 
 
 
 
The profile of psychoactive substances 
implicated in deaths was broadly similar to 
other regions. Whilst there was a lesser role 
played by anti-depressants in Wales, the 
role of hypnotics/sedatives was higher than 
in England but lower than that seen in 
Northern Ireland and Scotland. Methadone 
was also implicated in a higher proportion of 
cases in Wales than in England.  
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Chapter 4: Drug-related deaths in Northern Ireland 
 
 
This chapter describes the pattern of drug-
related deaths in Northern Ireland reported by 
Coroners and from registrations data supplied 
by The Northern Ireland Statistics and Research 
Agency (NISRA) recorded by the General 
Register Office for Northern Ireland.  
 
1. Demography 
 
Notifications of 70 drug-related deaths occurring 
in 2011 were received from NISRA and 
Coroners which meet the np-SAD case criteria. 
The number of such deaths was 71 in 2009 and 
72 in 2010 including one 2009 death reported in 
2011/12.The number of deaths reported in 
2009, 2010 and 2011 has been consistent.  In 
2011 there was a rate of 4.88 drug-related 
deaths per 100,000 population aged 16 years 
and over, compared with  4.62 in 2009 and 4.94 
in 2010.  
In 2011, 62.9% of cases were male (Table 4.1), 
and 37.1% were female. Of these 62.9% were 
unemployed and 50% lived with others. 
Ethnicity was known in 61 cases with all 
decedents being White, and in the remaining 
nine cases ethnicity was not known. Addict 
status was known in 29/70 cases, 17 (58.6%) of 
which had a history of dependence or drug use. 
 
The median age at death was 42.0 years 
(interquartile range = 24.5) (Figure 4.1).  
Over half of the decedents (58.5%) were under 
the age of 45 years. 
  
 
Table 4.1: Demographic variables for drug-related deaths reported by NISRA and 
Coroners meeting np-SAD criteria, Northern Ireland, 2011  
 
 
 
2.  Location of death 
 
Most fatalities (80%) occurred at a defined 
residential address (i.e. the deceased’s home 
address or another private residential 
address); with 17.1% deaths occurring in 
hospital and 2.9% elsewhere. 
 
 
 
3. Cause(s) of death 
 
Based on the information available from 
Coroners, 41.4% of cases died from accidental 
poisoning, 14.2% from intentional self-
poisoning, and in 35.7% of cases the intent 
was undetermined. Of the remaining 6 deaths, 
3 were traumatic and 3 were due to other 
causes. 
 
Variable Category Number (%) 
Total  70 (100.0) 
Gender 
Male 44 (62.9) 
Female 26 (37.1) 
Employment status 
Employed 14 (20.0) 
Unemployed 44 (62.9) 
Childcare/house person 1 (1.4) 
Student/pupil 1 (1.4) 
Retired/sickness/invalidity 6 (8.6) 
Not known 4 (5.7) 
Living arrangements 
Alone 31 (44.3) 
With others 35 (50.0) 
Other 1 (1.4) 
Not known 3 (4.3) 
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Figure 4.1: Drug-related deaths reported by NISRA and Coroners meeting np-SAD criteria, 
by age and gender, Northern Ireland, 2011 
 
 
 
4.  Substances implicated in death  
 
4.1 All substances 
 
Psychoactive drugs were directly implicated in 
67/70 (95.7%) cases. The principal 
substances implicated were: other 
opiates/opioid analgesics (55.2%); 
hypnotics/sedatives (52.2%); anti-depressants 
(40.3%); alcohol-in-combination (35.8%); anti-
psychotics (19.4%); and heroin/morphine 
(9.0%) (Table 4.2).  
 
4.2 Single substances 
 
Single substance deaths accounted for 23.8% 
(16/67) of deaths where psychoactive 
substances were implicated. These 
substances were: other opiates/opioid 
analgesics; anti-depressants; heroin/morphine; 
hypnotics/sedatives; anti-psychotics; and 
cocaine (Table 4.2). 
 
Table 4.2: Psychoactive substances implicated in deaths reported by NISRA and 
Coroners meeting np-SAD criteria, Northern Ireland, 2011 
 
Drug category 
Number (%) of cases where no 
other substance was implicated 
(N = 67) 
Number  (%) of cases where 
drug was implicated 
(N = 67) 
   
Alcohol-in-combination - 24 (35.8) 
Amphetamines 0 (0.0) 1 (1.5) 
Anti-depressants 3 (4.5) 27 (40.3) 
Anti-epileptics 0 (0.0) 2 (3.0) 
Anti-Parkinson’s 0 (0.0) 0 (0.0) 
Anti-psychotics 1 (1.5) 13 (19.4) 
Cannabis 0 (0.0) 1 (1.5) 
Cocaine 1 (1.5) 2 (3.0) 
Ecstasy-type drugs 0 (0.0) 0 (0.0) 
GHB/GBL 0 (0.0) 0 (0.0) 
Heroin/morphine 1 (1.5) 6 (9.0) 
Hypnotics/sedatives 1 (1.5) 35 (52.2) 
Methadone 0 (0.0) 1 (1.5) 
Other opiates/opioid 
analgesics 
9 (13.4) 37 (55.2) 
Note: Column totals may not sum to 67 since more than one substance may be implicated in a death. 
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Figure 4.2 takes into account data where one 
of the following drugs was known to be 
implicated: alcohol-in-combination; amphet-
amines; anti-depressants; anti-epileptics; anti-
psychotics; cannabis; cocaine; heroin/ 
morphine; hypnotics/sedatives; methadone; 
and other opiates/opioid analgesics. 
 
5.  Gender and drug implicated in death 
 
The pattern of other drug-specific mortality 
was somewhat different in male and female 
cases. Of the 44 male deaths, the most 
frequently mentioned drugs were: other 
opiates/opioid analgesics (54.5%); 
hypnotics/sedatives (40.9%); anti-depressants 
(36.3%); alcohol-in-combination (31.8%); anti-
psychotics (18%); heroin/morphine (13.6%); 
cocaine (4.4%); with methadone, cannabis and 
amphetamines all at 2.2%. There were no 
male or female deaths involving ecstasy-type 
drugs, anti-parkinsons, barbiturates or 
GHB/GBL. 
 
Of the 26 female deaths, the drugs mentioned 
most commonly were: hypnotics/sedatives 
(65.3%); other opiates/opioid analgesics 
(50%); anti-depressants (42%); alcohol-in-
combination (38.4%); and anti-psychotics 
(19.2%). There were no female deaths 
involving: cocaine; heroin/morphine; 
methadone; cannabis; or amphetamines. 
Compared to male cases, female cases had a 
higher proportion of fatality associated with 
hypnotics/sedatives (63.5% vs. 40.9%), and 
anti-depressants (42.3% vs. 36.3%). The 
proportions of deaths for both males and 
females from anti-psychotics were similar 
(19.2% vs. 18%)  
 
 
 
 
Figure 4.2: Drug-related deaths reported by NISRA and Coroners meeting np-SAD criteria, 
by psychoactive drug implicated, Northern Ireland, 2011 
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6.  Age and drug implicated in death  
 
Overall, other opiates/opioid analgesics 
(55.2%) were the leading substances 
implicated; they also accounted for the 
majority of cases in the 25-54 age-group. 
Anti-depressants were implicated most 
across the age range 25-64 years. Table 4.3 
shows where any particular drug was 
implicated across the whole range of age-
groups.  
 
 
Table 4.3: Age and psychoactive drug implicated in deaths reported to NISRA meeting np-
SAD criteria, Northern Ireland, 2011 
 
Age-
Group 
Drug category (alone or in combination) most frequently 
implicated in each age-group 
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15-24 
5 5 2 3 0 0 1 0 0 1 0 0 0 0 
25-34 9 6 6 6 2 3 0 0 1 0 0 0 0 0 
35-44 9 7 6 5 6 3 0 2 0 0 0 0 0 0 
45-54 9 9 6 6 2 0 1 0 0 0 0 0 0 0 
55-64 5 6 6 2 3 0 0 0 0 0 0 0 0 0 
65+ 0 2 1 2 0 0 0 0 0 0 0 0 0 0 
TOTAL 37 35 27 24 13 6 2 2 1 1 0 0 0 0 
 
7. Commentary 
 
The number of deaths notified to the 
Programme from sources in Northern Ireland 
showed a small decrease in 2011. The 
demographic profile of those dying in 2011 
showed a decrease in the number of male 
deaths and an increase in the number of 
female deaths.  
 
The profile of the psychoactive substances 
implicated in these cases is broadly similar to 
previous years. The role of specific types of  
 
 
 
drugs in drug-related mortality continues to 
show differences to those occurring in 
England and to a lesser extent in Wales. 
There are proportionately fewer deaths 
involving heroin/morphine and methadone. 
However, there is a greater role played by 
other opiates/opioid analgesics, 
hypnotics/sedatives and anti-depressants. 
The relatively higher involvement of 
hypnotics/sedatives is similar to the pattern 
in Scotland, and to a lesser extent in Wales.   
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Chapter 5: Drug-related deaths in Scotland  
 
 
This chapter describes the pattern of drug-
related deaths in Scotland. The Scottish Crime 
and Drug Enforcement Agency (SCDEA) on 
behalf of the Association of Chief Police 
Officers in Scotland (ACPOS) collates data on 
drug-related deaths obtained from Scottish 
police forces. These data are used to populate 
a police/SCDEA national database which is 
maintained by the SCDEA. As such the data 
supplied to the SCDEA remain the property of 
the submitting force that is also responsible for 
its accuracy and submission to the database.  
 
Drug-related death cases are those that meet 
the definition used by the Association of Chief 
Police Officers (Scotland) – “where there is 
prima facie evidence of a fatal overdose of 
controlled drugs. Such evidence would be 
recent drug misuse, for example controlled 
drugs and/or a hypodermic syringe found in 
close proximity to the body and/or the person 
is known to the police as a drug misuser 
although not necessarily a notified addict.” 
Thus, most suicides in Scotland are excluded. 
Figures for “drug misuse” deaths registered in 
2011 have been published by the National 
Records of Scotland (NRS, 2012). 
 
1. Demography 
 
Notifications of 336 drug-related deaths 
occurring in 2011 were received by the 
SCDEA, covering the following police force 
areas: Central Scotland (3.3%); Dumfries & 
Galloway (2.4%); Fife (4.8%); Grampian 
(14.3%); Lothian & Borders (29.1%); Northern 
(6.5%); Strathclyde (30.4%); and Tayside 
(9.2%). This represents a fall of 7.9% 
compared to 2010 (365 cases). 
 
The majority (79%) of cases were male (Table 
5.1). The median age at death was 35.6 years 
(interquartile range = 12.4) (Figure 4.1). Most 
cases (86%) were under 45 years. Where 
ethnicity was known, all were White. 
 
 
 
 
 
 
2.  Location of death 
 
In line with data protection, the SCDEA 
database structure does not record 
information on living arrangements and place 
of death. Where such information was 
available (from external sources – 65 cases), 
86% died at a defined residential address, and 
11% in hospital. 
 
3. Cause(s) of death 
 
Most of the fatalities (94.9%) were considered 
to be accidental (i.e. clearly non-deliberate) 
poisoning; this reflects the definition being 
used by Scottish police. Intentional poisonings 
accounted for 2.7% and deaths caused by 
mental disorders due to psychoactive 
substances (1.5%) accounted for most of the 
remaining cases. 
 
4.  Substances implicated in death 
 
4.1 All substances 
 
Psychoactive drugs were not directly 
implicated in only 0.9% of cases (n = 3). Of the 
remaining 333 cases, the principal substances 
implicated were: methadone (49%); 
heroin/morphine (41%); hypnotics/sedatives 
(35%); other opiates/ opioid analgesics (23%); 
alcohol-in-combination with other substances 
(21%); and cocaine (8%) (Table 5.2). 
 
Figure 4.2 takes into account data where one 
of the following drugs was known to be 
implicated: alcohol-in-combination; 
amphetamines, anti-depressants; cocaine; 
ecstasy-type drugs; heroin/morphine; 
methadone; hypnotics/ sedatives; or other 
opiates/opioid analgesics. 
 
4.2 Single substances 
 
The following substances, as the sole 
implicated drug, accounted for 117 (35%) 
deaths: heroin/morphine (14%); methadone 
(14%); other opiates/opioid analgesics (3%); 
ecstasy-type (2%); amphetamines (<1%); 
cocaine (<1%) and hypnotics/sedatives (<1%)  
(Table 5.2). 
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Table 5.1: Demographic variables for drug-related deaths as reported by Scottish police 
forces to the SCDEA, 2011 
 
 
 
 
 
 
Table 5.2: Psychoactive substances implicated in drug-related deaths as reported by 
Scottish police forces to the SCDEA, 2011  
 
Drug category 
Number (%) of cases where 
no other substance was 
implicated 
Number (%) of cases 
where drug was 
implicated* 
Total 333 (100.0) 333 (100.0) 
Alcohol-in-combination - 69 (20.7) 
Amphetamines 2 (0.6) 14 (4.2) 
Anti-depressants 1 (0.3) 22 (6.6) 
Anti-epileptics 1 (0.3) 4 (1.2) 
Anti-Parkinson’s 0 (0.0) 0 (0.0) 
Anti-psychotics 1 (0.3) 2 (0.6) 
Cannabis 0 (0.0) 0 (0.0) 
Cocaine 2 (0.6) 27 (8.1) 
Ecstasy-type drugs 5 (1.5) 6 (1.8) 
GHB/GBL 0 (0.0) 0 (0.0) 
Heroin/morphine 47 (14.1) 138 (41.4) 
Hypnotics/sedatives 3 (0.9) 118 (35.4) 
Methadone 45 (13.5) 163 (48.9) 
Other opiates/opioid analgesics 10 (3.0) 75 (22.5) 
Note: Column totals may sum to more than 100% since more than one substance may be implicated in a death. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Variable Category Number (%) 
Total  336 (100.0) 
Gender 
Male 264 (78.6) 
Female 72 (21.4) 
Age-group (years) 
Under 15 0 (0.0) 
15-24 34 (10.1) 
25-34 126 (37.5) 
35-44 129 (38.4) 
45-54 31 (9.2) 
55-64 12 (3.6) 
65 & over 4 (1.2) 
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Figure 5.1: Drug-related deaths as reported by Scottish police forces to the SCDEA, by 
age and gender, 2011 
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Figure 5.2: Drug-related deaths as reported by Scottish police forces to the SCDEA, by 
selected psychoactive substance implicated, 2011 
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5.  Age and drug implicated in death  
 
Methadone was the most frequently 
mentioned drug contributing to fatality for all 
(jointly for 25-34 year-olds) of the individual 
age-groups from 15-24 to 45-54 years (Table 
5.3), occurring in between 46% and 54% of 
cases in these groups. 
 
 
Table 5.3: Age and psychoactive substance implicated in drug-related deaths as reported 
by Scottish police forces to the SCDEA, 2011  
 
Age-group (years) Number (%) 
Drug category (alone or in combination) 
most frequently implicated in each age-
group 
 
All ages 333 (100.0) Methadone (48.8) 
14 & under 0 (0.0) - 
15–24  33 (9.9) Heroin/morphine and Methadone (45.5%) 
25-34  126 (37.8) Methadone (46.0%) 
35-44  129 (38.7) Methadone (54.3%) 
45-54  29 (8.7) Methadone (51.7%) 
55-64  12 (3.6) Other opiates/opioid analgesics (50.0%) 
65 and over 4 (1.2) Other opiates/opioid analgesics (50.0%) 
 
 
 
6.  Gender and drug implicated in death 
 
In males (n = 261) and females (n = 72), the 
pattern of drug-specific fatality was somewhat 
different.  
 
Among males, the most frequently mentioned 
drugs were: heroin/morphine (45%); 
methadone (45%); hypnotics/sedatives (38%); 
other opiates/ opioid analgesics (23%); alcohol-
in-combination (23%); and cocaine (8%). 
Furthermore, there appears to be a higher 
proportion of cases of drug-specific fatality 
among males compared to females in respect 
of heroin (45% vs. 28%); hypnotics/sedatives 
(38% vs. 25%); alcohol-in-combination (23% 
vs. 14%); and other opiates/opioid analgesics 
(23% vs. 19%). 
 
Among female cases, the most frequently 
mentioned drugs were: methadone (63%); 
heroin/morphine (28%); hypnotics/sedatives 
(25%); other opiates/opioid analgesics (19%); 
anti-depressants (17%); alcohol-in-combination 
(14%); and cocaine (10%). Compared to male 
cases, it appears that female cases had a 
higher proportion of fatality associated with 
methadone (63% vs. 45%); anti-depressants 
(17% vs. 4%); and cocaine (10% vs. 8%). 
 
7. Regional data  
 
The number of drug-related deaths reported by 
police to the SCDEA and meeting the np-SAD 
case criteria fell from 312 in 2004 to 254 in 
2005 and then rose to 374 in 2006. The figure 
for 2007 was 357, but rose to a new peak of 
478 in 2008, remaining stable in 2009.  This 
figure fell in 2010 to 365, and to 336 in 2011 - a 
decrease of 7.9% (Table 5.4). The rates in the 
Grampian, Lothian & Borders, Northern and 
Tayside police force areas are on a par with 
some of the higher rates reported in England 
and Wales. 
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Table 5.4: Deaths meeting np-SAD criteria as reported by Scottish police forces to the 
SCDEA, per 100,000 population by police force area, 2009-11  
 
 
 
8. Commentary 
 
Whilst data received by np-SAD from 
Coroners suggests that the number of drug-
related deaths decreased in England but 
remained stable in Wales and fell slightly in 
Northern Ireland during 2011, information from 
the Scottish police indicates a fall in SCDEA 
cases. However, figures released by the 
National Archives of Scotland (NRS) show an 
increase in deaths registered in 2011, using a 
number of different definitions (NRS, 2012). 
The fall in notifications to the SCDEA may be 
due, in part, to reduced compliance. 
 
Where recorded by the SCDEA, the 
demographic profile of those who died from 
drug-related causes is similar to those in other 
parts of the UK e.g. a higher proportion of 
males to females, aged typically 25-44 years, 
and White. There was a concentration of 
cases between 2010 and 2011 in respect of 
the 25-44 years age-groups (66% vs. 76%). 
 
The overwhelming majority of deaths were 
accidental drug overdoses. The level in 
Scotland was much higher than in other 
regions reflecting the different case definition 
used by Scottish police forces. Opiates such 
as heroin and methadone are implicated in the 
majority of cases, and play a larger role than in 
other regions. These drugs in combination with 
other substances and hypnotics/sedatives 
(which are mostly diazepam and temazepam) 
also feature prominently in Scottish deaths. 
 
The most important changes emerging from 
these data are that for the first time 
methadone has overtaken heroin/morphine as 
the principal drug involved in deaths. This 
echoes the pattern described in deaths 
registered in Scotland during 2011 (NRS, 
2012). This decline was due to a fall in the 
proportion of heroin/morphine deaths from 59 
to 42%, and an increase for methadone from 
38 to 49%, as well as in the actual number of 
methadone-related cases. The proportion of 
cases in which hypnotics/sedatives (25% vs. 
35%) and other opiates/opioid analgesics 
(10% vs. 23%) also increased between 2010 
and 2011, but there was a fall in the proportion 
of alcohol-in-combination cases. 
Police force 
area 
Number 
of 
deaths 
2009 
Annual 
death rate 
per 100,000 
population 
2009 
(1)
 
Number 
of 
deaths 
2010 
Annual 
death rate 
per 100,000 
population 
2010 
(1)
 
Number 
of 
deaths 
2011 
Annual 
death rate 
per 100,000 
population 
2011 
(1)
 
       
Central 
Scotland 
Police 
10 4.22 11 4.60 11 4.55 
Dumfries & 
Galloway 
Constabulary 
9 7.27 2 1.62 8 6.46 
Fife 
Constabulary 
28 9.39 31 10.33 16 5.29 
Grampian 
Police 
43 9.58 38 8.36 48 10.47 
Lothian & 
Borders 
Police 
89 11.47 79 10.03 98 12.26 
Northern 
Constabulary 
15 6.33 7 2.92 22 9.16 
Strathclyde 
Police 
237 13.02 165 9.02 102 5.55 
Tayside 
Police 
48 14.54 32 9.58 31 9.19 
Scotland 479 11.19 365 8.47 336 7.74 
(1) The rate per 100,000 population is based on published mid-year population estimates for local 
government administrative areas for the years in question. 
np-SAD 
 
International Centre for Drug Policy 84 
These changes may be due, in part, to the 
heroin ‘drought’ of 2010-11 (Simonson and 
Daly, 2011; EMCDDA, 2011; Lidell, 2012), 
which particularly affected Strathclyde where 
there was a noticeable decline in the number 
of deaths notified to the police. The overall 
purity of heroin available on the streets also 
generally fell during this period, to record low 
levels (SCDEA, 2012:11). 
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Chapter 6: Drug-related deaths in the Islands (Guernsey,   
Jersey, and the Isle of Man)  
 
This chapter reports on deaths in 2011 and 
examines the pattern of drug-related deaths in 
the Islands between 2007 and 2011. Coroners 
and their equivalents in Guernsey, Jersey and 
the Isle of Man routinely submit returns on drug-
related deaths to the np-SAD that meet the 
Programme’s case criteria.  
 
As there are comparatively few cases in a single 
year, even when combining data for the Islands 
together, data for 2007-11 have been 
aggregated together so that the findings are 
more statistically robust.  
 
1. Demography 
 
The Programme has been notified of two deaths 
on Jersey, two on the Isle of Man, and three on 
Guernsey during 2011. A total of 49 drug-related 
deaths occurred between 2007 and 2011: 11 in 
2007; 9 in 2008; 14 in 2009; 8 in 2010; and 7 in 
2011. This shows a relatively stable situation in 
drug-related deaths in the three Islands between 
 
2007 and 2011, with some year to year 
fluctuations. The number of deaths in this 5-
year period was 6 in Guernsey; 25 in Jersey; 
and 18 in the Isle of Man. In 2011 the number 
of deaths per 100,000 population aged 16 
years and over was 3.80 for Guernsey; 2.44 
for Jersey; and 4.31 for the Isle of Man, 4.45 
(Tables 6.1 and 6.2). 
 
During the 5-year period 69% of deaths were 
male, and 31% female (Table 6.3). The 
median age at death was 37 years 
(interquartile range = 15.6). 81% of the cases 
were under 45 years (Figure 6.1). The 
overwhelming majority (98%) of decedents 
were White. 46% were employed with 32% 
unemployed. Living arrangements - 44% were 
living alone and 42% with others. Addict status 
was known in 41/49 cases, 46% of which had 
a history of dependence or drug use. Key 
demographics and the principal drugs 
implicated in death during 2011 are given for 
the individual Islands in Table 6.4. 
 
Table 6.1: Changes in annual death rate per 100,000 population for np-SAD cases (16 years 
old and over), and annual percentage of all inquests held, by Island, 2009 and 
2011  
 
Island 
Annual 
death rate 
per 100,000 
population 
2009
(1)
 
Annual % 
of all 
inquests 
held in 
2009
 (2)
 
Annual 
death rate 
per 100,000 
population 
2010 
(1)
 
Annual % 
of all 
inquests 
held in 
2010 
(2)
 
Annual 
death rate 
per 100,000 
population 
2011 
(1)
 
Annual % 
of all 
inquests 
held in 
2011 
(2)
 
       
Guernsey 0.00 0.00 1.91 6.67 3.80 8.70 
Jersey 8.72 14.00 4.45 9.09 2.44 5.71 
Isle of 
Man 
7.38 12.82 2.91 8.70 4.31 10.71 
Note: (0) refers to either no drug-related deaths or death rates of less than 0.01, whilst (–) indicates that no reports were 
submitted for the specific period from that jurisdiction or area. In subsequent reports these rates may increase as more 
inquests on deaths in 2011 are held and/or notified to the np-SAD. These rates should therefore be regarded as 
minimum rates.  
(1) Notified after the publication of the np-SAD Annual Report, 2011.  
(2) The rate per 100,000 population is based on published mid-year population estimates for local government 
administrative areas for the years in question. 
(3) Includes updated information submitted in 2011/12. 
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Table 6.2: Number and rate per 100,000 population (16 years and over) for np-SAD cases, 
by place of residence and death, by Island, 2011  
 
Island 
National and annual 
death rate per 100,000 
population – usual area 
of residence 
National and annual 
death rate per 100,000 
population – place of 
death 
 No Rate No Rate 
Guernsey 2 3.80 2 3.80 
Jersey 2 2.44 2 2.44 
Isle of Man 3 4.31 3 4.31 
 
 
Table 6.3: Demographic variables for drug-related deaths meeting np-SAD criteria, the 
Islands, 2007-2011  
 
 
 
 
Table 6.4: Key demographics and principal drugs implicated in death for np-SAD cases, 
by Island, 2011  
 
Island 
N
o 
Gender Age-group Ethnicity 
Principal drug 
implicated 
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Guernsey 2 0 2 0 0 1 1 0 0 2 0 0 0 0 0 0 2 0 0 0 
Jersey 2 1 1 0 0 1 0 1 0 2 0 0 0 0 0 0 0 0 0 0 
Isle of Man 3 1 2 1 2 0 0 0 0 3 0 0 0 0 1 0 0 0 0 0 
Note: Some cases were usually resident outside the Islands.  
 
 
 
 
Variable Category Number (%) 
Total  49 (100.0) 
Gender 
Male 34 (69.4) 
Female 15 (30.6) 
Employment status 
Employed 24 (46.9) 
Unemployed 16  (32.7) 
Childcare/house person 2 (4.1) 
Student/pupil 1 (2.0) 
Retired/sickness/invalidity 6 (12.2) 
Not known 1 (2.0) 
Living arrangements  
   
Alone 22 (44.8) 
With others 21 (42.8) 
No fixed abode 1 (2.0) 
Other 3 (6.1) 
Not known  2 (4.1) 
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2.  Location of death 
 
Most fatalities (79.6%) occurred at a defined 
residential address (i.e. the deceased’s home 
address or other private residential address). 
12.2% of the deaths occurred in hospital with 
8.2% elsewhere. 
 
3. Cause(s) of death 
 
Based on the information available from 
Coroners, 57% of cases died from accidental 
poisoning, 28% from intentional self-poisoning, 
and in 6% of cases the intent with regard to 
poisoning was undetermined. Other causes 
accounted for the remaining 8% of cases. 
 
Figure 6.1: Drug-related deaths meeting np-SAD criteria, by age and gender, the Islands, 
2007-2011 
 
4.  Substances implicated in death  
 
4.1 All substances 
 
Psychoactive drugs were directly implicated in 
all 49 cases. The principal substances 
implicated were: other opiates/opioid 
analgesics (17); heroin/morphine (19); alcohol-
in-combination (14); hypnotics/sedatives (11) 
anti-depressants (11); methadone (6); and 
anti-psychotics (2) (Figure 6.2).  
 
Figure 6.2 shows the number of cases where 
the following drugs were known to be 
implicated: alcohol-in-combination; anti-
depressants; anti-psychotics; cannabis; 
ecstasy-type drugs; heroin/morphine; 
hypnotics/sedatives; methadone; and other 
opiates/opioid analgesics. 
 
4.2 Single substances 
 
The following substances, as the sole 
implicated drug, accounted for 20/49 (40.8%) 
deaths: anti-depressants; heroin/morphine; 
hypnotic/sedatives; methadone; and other 
opiates/opioid analgesics (Table 6.5).
 
Table 6.5: Psychoactive substances implicated in deaths meeting np-SAD criteria, the 
Islands, 2007-2011  
 
Drug category 
Number of cases where no 
other substance was implicated 
(N = 49) 
Number of cases where 
drug was implicated 
(N = 49) 
   
Alcohol-in-combination - 14 
Anti-depressants 3 11 
Anti-psychotics 0 2 
Cannabis 0 1 
Ecstasy-type drugs 0 1 
Heroin/morphine 11 19 
Hypnotics/sedatives 1 11 
Methadone 1 6 
Other opiates/opioid 
analgesics 
4 17 
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5.  Age and drug implicated in death  
 
In all age-groups, heroin/morphine (19) was 
the leading substances implicated, followed by 
other opiates/opioid analgesics (17). For 
individual age-groups, heroin/morphine was 
the leading implicated drug among younger 
age-groups (44 years and below). In the age- 
 
 
 
group of 45 years and above, the most 
frequently mentioned substances contributing 
to fatality were other opiates/opioid analgesics; 
hypnotics/sedatives; and anti-depressants 
(Table 6.6). 
 
 
 
Figure 6.2: Drug-related deaths np-SAD criteria, by psychoactive drug implicated, the 
Islands, 2007-2011 
 
 
 
 
 
 
6.  Gender and drug implicated in death 
 
The pattern of other drug-specific fatality was 
somewhat different in male and female cases. 
Among males, the most frequently mentioned 
drugs were: heroin/morphine (17); other 
opiates/opioid analgesics (11); 
hypnotics/sedatives (8); alcohol-in-
combination (9); anti-depressants (3); 
methadone (6); cannabis (1); and anti-
psychotics and ecstasy-type were mentioned 
in one fatality.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Among female cases, the drugs mentioned 
most commonly were: anti-depressants (8); 
other opiates/opioid analgesics (6); alcohol-in-
combination (5); heroin/morphine (2); 
hypnotics/ sedatives (3); and anti-psychotics 
(1). There were no fatalities due to 
methadone, cannabis and ecstasy-types 
among females. Female deaths when 
compared to males had a higher proportion 
associated with anti-depressants (53% vs. 
8.8%); other opiates/opioid analgesics (40% 
vs. 32.4%); and anti-psychotics (7% vs. 2.9%). 
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Table 6.6: Age and psychoactive drug implicated in deaths reported by Guernsey, Isle 
of Man and Jersey Coroners meeting np-SAD criteria, 2007-2011  
 
Age-group (years) 
Number where 
substance 
implicated 
Drug category (alone or in combination) 
most frequently implicated in each age-
group 
   
All ages 49 
Other opiates/opioid analgesics (17) 
Heroin/morphine (19) 
Hypnotics/sedatives (11) 
Alcohol in combination (14) 
Anti-depressants (11) 
Methadone (6) 
Anti-psychotics (2) 
Cannabis (1) 
Ecstasy-type drugs (1) 
15-24 6 
Heroin/morphine (4) 
Other opiates/opioid analgesics (1) 
Anti-depressants (2) 
Hypnotics/sedatives (1) 
Alcohol-in-combination (1) 
25-34  14 
Heroin/morphine (9) 
Other opiates/opioid analgesics (4) 
Alcohol-in-combination (4) 
Hypnotics/sedatives (2) 
Methadone (2) 
Cannabis (1) 
Anti-depressants (1) 
35-44  20 
Heroin/morphine (5) 
Alcohol in combination (6) 
Other opiates/opioid analgesics (6) 
Hypnotics/sedatives (6) 
Methadone (3) 
Anti-depressants (4) 
Anti-psychotics (1) 
Ecstasy-type (1) 
45-54  4 
Other opiates/opioid analgesics (3) 
Alcohol-in-combination (2) 
Anti-depressants (2) 
Anti-psychotics (1) 
Heroin/morphine (1) 
Hypnotics/sedatives (1) 
55-64  3 
Anti-depressants (2) 
Other opiates/opioid analgesics (2) 
Alcohol-in-combination (1) 
65 & over 2 
Hypnotics/sedatives (1) 
Other opiates/opioid analgesics (1) 
 
 
7. Commentary 
 
The number of deaths notified to the 
Programme from the Islands showed an 
increase for the Isle of Man and Guernsey, 
with a decrease for Jersey in 2011. The 
general demographic profile of cases in the 
Islands is in line with the pattern in the UK as 
a whole, although far fewer appear to have  
 
 
 
 
had a known history of drug dependence or 
use. 
 
When data for the three Islands are 
combined together, the profile of the 
psychoactive substances implicated in these 
cases is broadly similar across the period 
2007-11. The role of specific types of drugs 
in drug-related mortality continues to show 
differences to those occurring in England and 
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to a lesser extent in Wales. There are 
proportionately fewer deaths involving 
methadone and stimulants. However, there is 
a greater role played by other opiate/opioid 
analgesics; heroin/morphine; and anti-
depressants. 
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Chapter 7: Drug-related deaths in the United Kingdom   
  
 
1. Numbers of deaths reported 
 
The total number of deaths that occurred 
during 2011 in the UK reported to the National 
Programme on Substance Abuse Deaths (np-
SAD) was 1,757. This number compares to 
1,883 cases reported by the same sources 
during the equivalent period in 2010. This 
change represents a decrease of 6.7% for the 
UK in the number of notifications to the 
Programme, but not necessarily in drug-
related mortality during this period.  
 
Of the 1,757 drug-related deaths reported for 
2011, England had 1,263; Scotland 336; 
Wales 81; Northern Ireland 70; and the Islands 
7. In 2010 out of the 1,883 England had 1,358; 
Scotland 365; Wales 81; Northern Ireland 72; 
and the Islands 7. 
 
As in the previous Annual Reports, those 
inquests which have not been completed will 
be added to next year’s figure. 
 
The number of cases reported from England 
represents a decrease of 7.0% over the 
number reported during the equivalent period 
last year. In Wales and the Islands numbers 
remained stable, and Northern Ireland 
exhibited a fall of 2.8%. Drug-related cases in 
Scotland recorded by the Scottish Crime and 
Drug Enforcement Agency (SCDEA) fell by 
7.9%. 
 
There was a decrease in the number of drug-
related deaths reported to np-SAD generally 
across the UK and Islands, particularly in 
England and Scotland, although this varied 
from region to region. This overall fall echoes 
the drop in the overall number of UK death 
registrations in 2011 using all three definitions 
of drug-related deaths reported to the  
 
 
 
European Monitoring Centre for Drugs & Drug 
Addiction (Davies et al., 2012). This decrease 
may be attributable, in part, to the declines in 
the number and proportion of deaths where 
heroin/morphine was implicated – as 
demonstrated in the present report, and 
elsewhere (ONS, 2012; NRS, 2012).  
 
2. Demography 
 
The majority (72%) of cases were male (Table 
7.1 and Figure 7.1). This proportion varied 
from 63% in Northern Ireland to 80% in Wales. 
Where ethnicity was known, the majority were 
White (97%). The proportion of individuals 
living with others ranged from 45% in England 
to 65% in Scotland. About two-fifths (42%) of 
decedents were known to be unemployed, 
ranging from 29% in the Islands to 69% in 
Wales. Where known, 65% of cases had a 
history of drug use, dependence or addiction. 
 
The median age at death was 40.1 years 
(interquartile range = 15.6 years) for all 
sources combined; the medians ranged from 
35.6 years in Scotland to 42.4 years in 
Northern Ireland. There were also differences 
in the median ages broken down by gender: 
38.7 years (interquartile range = 14.6 years) 
for males compared to 44.6 years (interquartile 
range = 18.8 years) for females. Figures 7.2 
and 7.3 give breakdowns by age-group, and 
by gender and age-group respectively. 
 
The above differences reflect distinctions in 
the nature and purpose of the data sources; 
the types of cases covered; and the volumes 
of cases dealt with by them. These variations 
also illustrate the limitations on making 
comparisons between them.  
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Table 7.1: Demographic variables for drug-related deaths, UK, 2011 
 
 
Figure 7.1: Drug-related deaths by gender, UK, 2011 
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Variable Category Number (%) 
Total  1,757 (100.0) 
Gender 
Male 1,265 (72.0) 
Female 492 (28.0) 
Age-group (years) 
Under 15  0 (0.0) 
15-24 136 (7.7) 
25-34 447 (25.4) 
35-44 585 (33.3) 
45-54 366 (20.8) 
55-64 144 (8.2) 
Over 64 79 (4.5) 
Living arrangements 
With others 623 (35.5) 
No fixed abode 29 (1.7) 
Alone 633 (36.0) 
Other 61 (3.5) 
Not known 411 (23.4 
Employment status 
Unemployed 739 (42.1) 
Employed 392 (22.3) 
Childcare/house person 31 (1.8) 
Student/pupil 24 (1.4) 
Retired/invalidity/sickness 127 (7.2) 
Other 12 (0.7) 
Not known 432 (24.6) 
History of drug use/addiction 
Yes 694 (39.5) 
No 367 (20.9) 
Not known 696 (39.6) 
Location of death 
Defined residential address 1,078 (61.4) 
Hospital 163 (9.3) 
Other 148 (8.4) 
Not known 368 (20.9) 
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Figure 7.2: Drug-related deaths by age, UK, 2011 
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Figure 7.3: Drug-related deaths by age and gender, UK, 2011 
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3.  Location of death 
 
Where place of death was reported, about 
77% died at a defined residential address (i.e. 
the deceased’s home address or other private 
residential address), 12% died in hospital and 
11% died elsewhere (e.g. in a public place). 
The proportion dying at a defined residential 
address ranged from 71% in the Islands to 
96% in Wales. The corresponding proportions 
for deaths in hospital ranged from 1% in Wales 
to 29% in the Islands. Such information was 
available in only 63 Scottish cases; of these, 
86% died at home and 11% in hospital. In line 
with data protection, the SCDEA database 
structure does not record information on living 
arrangements and place of death. 
4. Cause(s) of death 
 
The majority of fatalities (69.9%) were 
considered to be accidental (i.e. clearly non-
deliberate) poisoning, 12.9% from intentional 
self-poisoning, and 8.9% for poisonings of 
undetermined intent. The remaining cases 
(8.4%) were related to other causes of death. 
There are differences between different parts 
of the UK and Islands in the proportions of 
deaths accounted for by these main groupings 
of underlying cause(s) of death (Table 7.2). 
These reflect, in part, differences between the 
SCDEA and np-SAD case definitions. A 
detailed breakdown for all cases covered by 
this report is given in Table 7.3. 
   
 
 
Table 7.2: Main underlying causes of death, by country and territory, 2011  
 
 Country or territory 
England Wales Scotland 
Northern 
Ireland 
Guernsey Jersey 
Isle 
of 
Man 
UK & 
Islands 
         
 Number of 
deaths 
1263 81 336 70 2 2 3 1757 
         
U
n
d
e
rl
y
in
g
 
c
a
u
s
e
 o
f 
d
e
a
th
 
(%
) 
Accidental 
poisoning 
64.4 77.8 94.9 41.4 50.0 0.0 66.7 69.9 
Intentional 
poisoning 
15.4 14.8 2.7 14.3 0.0 50.0 0.0 12.9 
Poisoning of 
undetermined 
intent 
9.9 6.2 0.0 35.7 50.0 0.0 0.0 8.9 
Other causes 10.3 1.2 2.4 8.6 0.0 50.0 33.3 8.4 
         
 Rate of drug-
related 
deaths/100,000 
population 
aged 16+ 
2.94 3.23 7.74 4.89 3.79 2.45 4.32 3.42 
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Table 7.3: Drug-related deaths by underlying cause(s) of death, UK and Islands, 2011  
 
ICD-10 No. of cases 
(n = 1,757) 
% Description 
 
X40 
 
X41 
 
X42 
 
X43 
 
X44 
 
X45 
X47 
 
29 
 
150 
 
979 
 
2 
 
45 
 
15 
7 
 
1.7 
 
8.5 
 
55.7 
 
0.1 
 
2.6 
 
0.8 
0.4 
Accidental poisoning  
Non-opioid analgesics, antipyretics and anti-
rheumatics  
Anti-epileptic, sedative-hypnotic, Anti-parkinsonism 
and psychotropic drugs, not elsewhere classified 
Narcotics and psychodysleptics (hallucinogens), not 
elsewhere classified  
Other drugs acting on the autonomic nervous 
system 
Other and unspecified drugs, medicaments and 
biological substances 
Alcohol 
Gases 
 
X60 
 
X61 
 
X62 
 
X63 
 
X64 
 
 
22 
 
98 
 
96 
 
5 
 
6 
 
 
1.3 
 
5.6 
 
5.5 
 
0.3 
 
0.3 
 
Intentional self-poisoning  
Non-opioid analgesics, antipyretics and anti-
rheumatics 
Anti-epileptic, sedative-hypnotic, Anti-parkinsonism 
and psychotropic drugs, not elsewhere classified 
Narcotics and psychodysleptics (hallucinogens), not 
elsewhere classified 
Other drugs acting on the autonomic nervous 
system 
Other and unspecified drugs, medicaments and 
biological substances 
 
Y10 
Y11 
Y12 
Y14 
 
26 
48 
75 
7 
 
1.5 
2.7 
4.3 
0.4 
Poisoning of undetermined intent  
Non-opioid analgesics  
Anti-Parkinsonism drugs 
Other drugs acting on autonomic nervous system 
Other/unspecified drugs 
 
 
F10.2 
F11.0 
F11.2 
F15.0 
F15.1 
F15.2 
F16.0 
F18.0 
F19.0 
Z72.2 
 
 
3 
1 
1 
2 
1 
1 
1 
1 
2 
13 
 
 
0.2 
0.1 
0.1 
0.1 
0.1 
0.1 
0.1 
0.1 
0.1 
0.7 
Mental & behavioural disorders due to psychoactive 
substance use 
Chronic alcoholism 
Intoxication – opiates 
Dependence – opioids 
Intoxication – stimulants 
Abuse - stimulants 
Dependence – stimulants 
Intoxication - hallucinogens 
Intoxication – volatile substances 
Intoxication – unspecified substances 
Drug abuse, personal history 
 
G40.9 
G96.9 
 
1 
1 
 
0.1 
0.1 
Brain 
Epileptic seizures 
Other depression of the Central Nervous System 
 
 
I10 
I20-I25 
I25.1 
I26.9 
I33 
I46.9 
I60 
I61.9 
I70 
I72.4 
 
 
1 
3 
6 
1 
1 
1 
1 
2 
1 
1 
 
 
0.1 
0.2 
0.3 
0.1 
0.1 
0.1 
0.1 
0.1 
0.1 
0.1 
Cardiovascular system – diseases, defects or 
conditions affecting 
Essential (primary) hypertension 
Ischaemic heart diseases 
Atherosclerotic heart disease 
Pulmonary embolism 
Acute endocarditis 
Cardiac arrest, unspecified 
Subarachnoid haemorrhage 
Intracerebral haemorrhage 
Aneurysm of artery of lower extremity 
Arterial embolism/thrombosis 
 
J18.0 
J69.0 
 
5 
1 
 
0.3 
0.1 
Diseases of the respiratory system 
Bronchopneumonia 
Aspiration pneumonia 
 
K70 
K74.6 
 
3 
1 
 
0.2 
0.1 
Diseases of the liver 
Alcoholic liver disease 
Other & unspecified liver cirrhosis 
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ICD-10 No. of cases 
(n = 1,757)  
% Description 
 
V43.5 
V47.5 
V49.9 
V89.2 
 
2 
1 
2 
2 
 
0.1 
0.1 
0.1 
0.1 
Road traffic incidents 
Car driver injured in collision with car, etc 
Driver injured in collision with fixed/stationary object 
Vehicle occupant injured in RTA, unspecified 
Person injured in unspecified motor vehicle 
accident - traffic 
 
W76 
X70 
Y20 
 
1 
19 
5 
 
0.1 
1.1 
0.3 
Hanging 
Other accidental hanging and strangulation  
Intentional hanging 
Hanging, undetermined intent 
 
R09.0 
T71 
W78 
W83 
 
2 
2 
4 
3 
 
0.1 
0.1 
0.2 
0.2 
Asphyxia 
Asphyxia general 
Asphyxiation 
Aspiration of gastric contents 
Suffocation by plastic bag 
 
T75.1 
W69 
W70 
X71 
Y21 
 
1 
2 
3 
3 
1 
 
0.1 
0.1 
0.2 
0.2 
0.1 
Drowning & submersion 
Immersion in water 
Whilst in natural water 
Following fall into natural water 
Intentional self-harm by drowning 
Unspecified intent 
 
A40.0 
A41.9 
A86 
B18.2 
D65 
E10 
F33 
E87.2 
L02.2 
N17 
S02.9 
S06.8 
S09.9 
S22.4 
S51 
T07 
T14.5 
W17 
X09 
 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
3 
2 
1 
6 
1 
2 
2 
 
0.1 
0.1 
0.1 
0.1 
0.1 
0.1 
0,1 
0.1 
0.1 
0.1 
0.1 
0.1 
0.2 
0.1 
0.1 
0.3 
0.1 
0.1 
0.1 
Other 
Septicaemia due to streptococcus, group A 
Septicaemia unspecified 
Unspecified viral encephalitis 
Chronic viral hepatitis C 
Disseminated intravascular coagulation 
Diabetic ketoacidosis 
Recurrent depressive disorder 
Metabolic acidosis, exc. diabetic acidosis 
Groin abscess 
Acute renal failure 
Fracture of skull & facial bones, part unspecified 
Haemorrhagic skull (intracranial injuries) 
Head injuries, unspecified 
Multiple fractures of ribs 
Open wound of forearm 
Multiple injuries, unspecified 
Injury of blood vessel(s) of unspecified body region 
Fall from one level to another 
Inhalation of smoke and fumes 
R99 9 0.5 Unascertained 
 
Where possible, causes of death have been grouped together in terms of the mechanisms of death.  At present, although all 
causes of death on the death certificate (together with other information if available) are taken into consideration in classifying 
underlying cause of death, the principal cause of death is used here by np-SAD to allocate the ICD-10 code. In order to achieve 
a greater level of consistency, a hierarchical system was introduced for classifying the underlying cause of death using ICD-10 
criteria for deaths involving multiple substances. Deaths that involve a combination of narcotics and other psychoactive drugs are 
coded as narcotic deaths. Where possible a code which specifies intentionality is used. 
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5.  Substances implicated in death  
 
Psychoactive substances were not directly 
implicated in about 5.6% of cases (n = 99). Of 
the remaining 1,658 cases, the principal 
substances implicated were: heroin/morphine 
(32%); methadone (31%); hypnotics/sedatives 
(28%); other opiates/opioid analgesics (28%); 
alcohol-in-combination with other substances 
(27%); anti-depressants (21%); and cocaine 
(9%).  
 
Table 7.4 shows that whilst there are 
commonalities across the various parts of the 
UK and Islands in terms of the main 
psychoactive substances given above being 
implicated in death, there are noticeable 
regional differences. For example, hypnotics/ 
sedatives play a proportionately greater role in 
Northern Ireland, Scotland and Wales than in 
England. Heroin/morphine and methadone 
play lesser roles in Northern Ireland when 
compared to the rest of the UK, whereas other 
opiates/opioid analgesics play a greater role. 
The lesser role played by methadone can be 
explained, in part, by the fact that methadone 
is not prescribed as widely in Northern Ireland 
as in other areas. Anti-depressants also play a 
greater role in Northern Irish deaths. By 
contrast they hardly feature in SCDEA cases; 
however, this reflects the fact that the 
definition used by the SCDEA does not cover 
the general population or suicides but 
accidental overdoses involving controlled 
drugs. 
Table 7.4: Psychoactive substances (%) implicated in drug-related deaths, by country and 
territory, 2011  
 
 Country or territory 
England Wales Scotland 
Northern 
Ireland 
Guernsey Jersey 
Isle 
of 
Man 
UK & 
Islands 
Total 1,172 79 333 67 2 2 3 1,658 
Drug category (%)         
Alcohol-in-
combination 
27.7 21.5 20.7 35.8 50.0 50.0 66.7 26.5 
Amphetamines 3.7 3.8 4.2 1.50 0.0 0.0 0.0 3.7 
Anti-depressants 24.5 19.0 6.9 40.3 100.0 50.0 0.0 21.4 
Anti-epileptics 2.9 1.3 1.2 3.0 0.0 0.0 0.0 2.5 
Anti-Parkinson’s 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.3 
Anti-psychotics 5.6 7.6 0.6 17.9 0.0 0.0 0.0 5.2 
Cannabis 2.0 0.0 0.0 1.5 0.0 0.0 0.0 1.4 
Cocaine 10.4 2.5 8.1 3.0 0.0 0.0 0.0 9.2 
Ecstasy-type drugs 1.7 1.3 1.8 0.0 0.0 0.0 33.3 1.7 
GHB/GBL 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.6 
Heroin/morphine 30.3 39.2 41.4 9.0 0.0 0.0 33.3 32.1 
Hypnotics/sedatives 24.4 31.6 35.3 50.7 100.0 0.0 0.0 28.0 
Methadone 27.9 38.0 48.9 1.5 0.0 0.0 0.0 31.4 
Other 
opiates/opioid 
analgesics 
28.0 30.4 22.5 55.2 50.0 50.0 0.0 28.1 
Note: Column totals may sum to more than 100% since more than one substance may be implicated in a death. 
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6.  Commentary  
 
Whilst data received by np-SAD from 
Coroners suggest that the number of drug-
related deaths fell in England, they remained 
stable in Wales and Northern Ireland during 
2011. Information from the SCDEA police 
indicates a fall in Scottish police cases. 
However, figures released by the National 
Records of Scotland show an increase in 
deaths between 2010 and 2011 (NRS, 2012). 
 
Overall, demographic profiles of those who 
died from drug-related causes are similar 
across the various countries within the UK e.g. 
a higher proportion of males to females, aged 
typically 25-44 years, White, and the majority 
of cases living with others, there are 
differences within this general pattern. 
 
Most deaths were accidental drug overdoses, 
occurring at a private residential address 
(typically at home or the home of a friend). 
Opiates such as heroin, methadone and opioid 
analgesics are implicated in the majority of 
cases. Other substances playing major roles in 
deaths include alcohol-in-combination with 
substances; hypnotics/sedatives; anti-
depressants; and cocaine. However, there are 
also regional variations in these patterns. 
 
Whilst there appears to have been a decrease 
in the proportion of cases involving heroin; 
alcohol-in-combination; and anti-depressants, 
the proportions involving methadone; other 
opiates/opioid analgesics; and hypnotics/ 
sedatives all increased. The stabilisation noted 
in the previous report regarding the role of 
stimulants (cocaine; amphetamines; and 
ecstasy-type drugs) in death appears to have 
ended, with slight increases in such deaths. 
The patterns observed in different parts of the 
UK, and possible reasons for the continuing 
changes in recreational drug use, are 
examined in the following chapter. 
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Chapter 8: Commentary and emerging themes  
 
 
Introduction 
 
This chapter provides up-to-date information 
on emerging trends and issues to those who 
investigate drug-related deaths (DRDs) and 
those who are trying to prevent such 
fatalities. The main trends and issues 
highlighted here emerge from the submitted 
forms, communications from Coroners, and 
other relevant data such as published papers 
and intelligence from forensic toxicological 
agencies. 
 
 
General patterns 
 
The total number of deaths that occurred 
during 2011 in the UK reported to the 
National Programme on Substance Abuse 
Deaths (np-SAD) was 1,757. This number 
compares to 1,883 cases reported by the 
same sources during the equivalent period in 
2010. This change represents a decrease in 
the number of notifications to the 
Programme, but not necessarily in drug-
related mortality during this period. Similarly, 
the decreased number of cases reported by 
Coroners in England and by the Scottish 
Crime and Drug Enforcement Agency 
(SCDEA) for Scotland, does not necessarily 
mean a decrease in deaths related to drug 
use.  
 
The demographic profile of fatalities reported 
to the np-SAD remains consistent with 
previous reports. There was an increase in 
the proportion of UK deaths where the 
underlying cause of death was accidental 
poisoning (up from 64% to 70%) and for 
deaths of intentional self-poisoning (from 11 
to 13%) with corresponding decreases in the 
proportions recorded as poisoning of 
undetermined intent and other causes.  
 
Opiates/opioids (i.e. heroin/morphine; 
methadone; other opiates/opioid analgesics), 
alone or in combination with other drugs 
continue to account for the majority of all 
cases. Heroin/morphine alone or in 
combination with other drugs, accounted for 
the highest proportion (32%) of ‘drug misuse’ 
fatalities in 2011, a decrease over the 2010 
level of 41% (53% in 2009). There was a 
slight fall in the proportion of cases involving 
alcohol-in-combination (30% to 27%). There 
were modest increases in the proportion of 
deaths due to methadone (27% to 31%), 
other opiates/opioid analgesics (22% to 
28%), and anti-depressants (18% to 21%). 
For stimulants, there was a slight increase in 
the proportion of cases involving cocaine 
(from 8.7% to 9.2%); amphetamines (from 
2.9% to 3.7%); and ecstasy-type drugs (from 
0.6% to 1.7%). These patterns are also 
generally reflected at country level. Over 
recent years there has been a trend towards 
multiple substances, including alcohol, being 
implicated in deaths. In 2011, there was a 
stabilisation in the proportion of monovalent 
deaths, at around 34%. 
 
Prescribed heroin/morphine and methadone 
are most commonly involved in deaths where 
these substances are directly implicated in 
death. Other opiates/opioid analgesics; 
hypnotics/sedatives; and anti-depressants 
prescribed to individuals are less likely to be 
involved in their deaths.  
 
The median age at death of individuals 
notified to the np-SAD with a known history 
of drug use or dependence was 40.1 years 
(interquartile range = 15.6 years) in 2011. 
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Emerging issues 
 
Opioid-related deaths 
 
Over recent years there has been growing 
concern in North America, Australia, and the 
European Union about increasing 
recreational use and abuse of prescription 
drugs and fatalities resulting from such use, 
especially those involving synthetic opioid 
pain-killers (Fischer et al., 2013; Darke et al., 
2011;  Häkkinen et al., 2012; Rintoul et al., 
2011). Interest in these developments has 
been expressed in the UK (NTA, 2011; 
ACMD, 2013). Specific substances of 
interest are oxycodone and fentanyl 
(Mounteney et al., 2012). The former has 
featured in fatalities in the USA and Australia 
and the latter in deaths in the Baltic states. 
At the same time, there has been interest in 
the evolution of deaths involving 
buprenorphine and tramadol. The patterns in 
UK deaths involving these substances over 
the period 2000-11 are examined below 
against the background of the noticeable 
changes involving heroin/morphine and 
methadone noted above. 
 
Figure 8.1 shows that deaths involving 
buprenorphine; fentanyl; and oxycodone 
have steadily increased over the last 12 
years, particularly since 2007 but are still at 
relatively low levels. As noted in previous 
np-SAD reports, there was a steady 
increase in deaths involving tramadol 
following the tightening up of prescribing of 
the pain-killer co-proxamol. There was an 
increase in such deaths between 2008 and 
2009 followed by stabilisation in 2010; 
however, there was a further jump in 2011 
– deaths nearly tripling between 2005 and 
2011 (from 53 to 148). During the period 
2000-11, heroin/morphine deaths rose from 
768 to peak at 1219 in 2009 before falling 
by more than 50% to 551 in 2011. By 
contrast methadone-related deaths more 
than doubled, from 204 to 542. 
   
Figure 8.1: Trends in UK deaths involving 
opiate/opioid analgesics, np-
SAD data, 2000-2011  
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Heroin/morphine 768 827 855 659 883 892 984 1047 1010 1219 719 551
Methadone 204 211 237 215 249 258 352 439 472 528 474 542
Oxycodone 0 2 0 6 3 7 5 16 18 19 25 32
Fentanyl 0 1 2 4 2 4 5 6 4 13 10 21
Buprenorphine 0 0 1 2 0 3 2 5 5 9 12 13
Tramadol 10 33 19 37 45 53 76 83 79 112 111 148
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Novel Psychoactive Substances 
 
The UK Advisory Council on the Misuse of 
Drugs (ACMD) uses the following definition: 
 
“psychoactive drugs which are not prohibited 
by the United Nations Single Convention on 
Narcotic Drugs or by the Misuse of Drugs Act 
1971, and which people in the UK are 
seeking for  intoxicant use’ (ACMD, 
2011:10). 
 
This report considers substances brought 
under control by legislation after being 
examined by the ACMD, being considered 
for control/regulation, or still legal. However, 
changes in legal status may affect availability 
– and thus use.  
 
As reported in the previous np-SAD report 
(Ghodse et al., 2012), recent years saw 
decreases in the number of deaths involving 
‘traditional’ stimulants such as cocaine, 
amphetamines, and ecstasy-type 
substances. Reasons for these decreases, 
also seen in death registration statistics from 
the General Mortality Registers, may include 
a decline in cocaine purity and/or a shift to 
using alternative stimulants, including ‘legal 
highs’. For example, the mean purity of 
powder cocaine seized by the police in 
England & Wales fell from 33% in 2007 to 
24% in 2010; the purity of 'crack' cocaine is 
reported to have fallen during the same 
period from 52% to 31% (Davies et al., 
2012). Last year the use of powder cocaine 
amongst 16–59 year-olds in England & 
Wales fell from 3% in 2008/9 to 2% in 
2010/11 (Home Office, 2012). It has been 
proposed that the fall in ecstasy and 
cocaine-related deaths in the United 
Kingdom since 2008 may be as a result of 
users switching to ‘legal highs’ with the 
suggestion that this may have had an 
unintended harm reduction effect (Bird, 
2010).  
 
Whilst the use of amphetamine, ecstasy-type 
drugs and cocaine appears to have 
continued to fall between 2009 and 2011 
(Home Office, 2012), the street purity of 
these substances, including the MDMA 
content of ecstasy tablets rose in 2011 
(Davies et al., 2012:123). The proportion of 
stimulant deaths reported to the np-SAD that 
occurred in 2011 increased marginally 
compared to 2010. This is in line with the 
rises in the average street purity of the 
stimulants mentioned above. UK deaths 
registered in 2011 involving ecstasy-type 
substances and amphetamine showed 
increases whereas cocaine related fatalities 
fell (Davies et al., 2012:183). 
 
As part of its surveillance function, in recent 
years the np-SAD Annual Report has 
reported on new substances which are 
appearing on the drug scene and which have 
either been noted in post mortem 
toxicological reports and/or implicated in 
deaths reported to the Programme. 
 
 
Against this background, np-SAD has 
observed an increase in the number and 
range of Novel Psychoactive Substances 
(NPS) in the post mortem toxicology results 
and/or cause of death of cases notified to the 
Programme (see Figure 8.2). Chemical 
groups represented by these NPS include: 
aminoindanes (MDAI); amphetamine-type 
substances (Fluoroamphetamine, PMA, 
PMMA); benzofurans (APB); tryptamines 
(AMT, 5-MeO-DALT); natural products 
(Ibogaine, khat (Catha edulis), Salvia 
divinorum); and, most prominently, the 
methcathinones. 
 
Methcathinones 
 
The last two Annual Reports from the 
Programme specifically mentioned 
Mephedrone (Methylmethcathinone), MDPV 
(Methylenedioxypyrovalerone) and NRG-1 
(Naphyrone). As can be seen from Table 8.1, 
the number of cases where Mephedrone and 
MDPV were mentioned increased 
significantly in 2010, falling away in 2011. 
Other methcathinones also emerged onto 
the scene; in many instances, several such 
chemicals were involved in individual cases.  
 
During 2011 and 2012, forensic toxicologists 
continued to report increased seizures of 
‘legal highs’ derived from methcathinone, 
particularly mephedrone commonly known 
as “bubbles” and “meow-meow”. Many of 
these cases have now gone to inquest or 
through similar formal investigations by 
Procurators Fiscal in Scotland, and are being 
reported to np-SAD. This class of chemical is 
still very much present in the UK recreational 
drug scene, and its use may be developing 
into one of a problematic nature in respect of 
injecting and dependence. It is important, 
therefore, to be aware of this fact in terms of 
information and service provision, and 
prevention initiatives. 
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Table 8.1: Deaths involving Novel Psychoactive Substances, np-SAD data, 2009-11 
 
Substance  Post mortem toxicology Cause of Death 
Year  2009 2010 2011 2009 2010 2011 
Aminoindanes        
 MDAI  0 0 2 0 0 2 
ATS        
 2,5-Dimethoxy-4-
 chloroamphetamine 
0 0 1 0 0 1 
 Fluoroamphetamine  1 0 0 0 0 0 
 PMA  0 1 3 0 0 4 
 PMMA  0 0 2 0 0 2 
Benzofurans        
 APB  0 0 1 0 0 1 
Benzodiazepines        
 Phenazepam  0 0 14 0 0 7 
Ketamine derivatives        
 Methoxetamine  0 0 1 0 0 1 
Natural products        
 Cathinone (khat) 0 0 1 0 0 1 
 Datura products  1 0 0 1 0 0 
 Ibogaine 1 0 0 1 0 0 
 Noribogaine 1 0 0 0 0 0 
 Salvia  0 0 0 0 0 1 
Piperidines        
 Desoxypipradrol  0 3 0 0 3 0 
Methcathinones        
 4-MEC  0 0 5 0 0 4 
 Flephedrone  0 2 2 0 2 2 
 MDPBP  0 0 1 0 0 1 
 MDPV  0 9 3 0 6 2 
 Mephedrone  8 46 20 5 29 13 
 Methedrone  0 2 3 0 1 2 
 Methylone  0 2 0 0 2 0 
 N-desakyl-4-
 methylmethcathinone  
0 1 0 0 0 0 
 Naphyrone  0 2 0 0 2 0 
 Pentylone  0 0 1 0 0 1 
 Pyrovalerone  0 1 0 0 1 0 
Tryptamines        
 5-MeO-DALT  0 1 0 0 1 0 
 AMT  0 0 2 0 0 2 
 Tryptamine  1 0 0 1 0 0 
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Figure 8.2: Trends in UK ‘traditional’ and Novel Psychoactive Substances, np-SAD 
data, 2005-11  
 
 
Other NPS substances 
 
A number of new chemical classes were 
represented in deaths occurring in 2011 (see 
Table 8.1). New molecules of particular 
interest are the following: the aminoindane 
MDAI (5,6-Methylenedioxy-2-aminoindane) 
(Corkery et al., in press; Gallagher et al., 
2012); the amphetamine-type substances 
PMA (para-Methoxyamphetamine) and 
PMMA (para-Methoxy-N-
methylamphetamine); the benzofuran APB; 
the synthetic ketamine derivative 
methoxetamine (Corazza et al., 2012); and 
AMT (α-Methyltrypyamine). Furthermore, 
several deaths involving the benzodiazepine 
phenazepam were reported. This medication 
is not licensed for use in the UK but is used 
legally in Eastern Europe and the Russian 
republics (Corkery et al., 2012).  
 
Other chemical classes that appear to be 
emerging as substances that require 
monitoring in respect of their potential 
contribution to causing fatalities include 
synthetic cannabinoids (e.g. AM-2201) and 
indoles (e.g. 5-IT).  A select bibliography 
reflecting recent work by np-SAD can be 
found at the end of this chapter. 
 
Heroin contaminated with anthrax  
 
In the annual report for 2010 it was noted 
that since late 2008 there have been 
substantiated and authoritative reports of 
heroin (or its cutting agents) contaminated 
with anthrax, confirmed by laboratory 
investigations. During the period December 
2009 to 30 July 2010 a total of 119 cases 
were reported: 47 of which were classed as 
confirmed; 35 as probable; and 37 as 
possible cases based on the strength of the 
microbiological evidence.  Thirteen fatalities 
(and one probable) were reported in 
Scotland; 6 of these cases have been 
notified to np-SAD. There were 5 cases in 
England; four of these were fatal.  One of 
these cases has been reported to np-SAD. 
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The Scottish cases were the first 
documented outbreak associated with heroin 
use anywhere in the world. It proved to be 
the largest single common source outbreak 
of anthrax in humans in the UK in over 50 
years. The outbreak was declared over in 
Scotland on 23 December 2010 (HPS, 
2011). Factors associated with an increased 
risk of infection included longer injecting 
history, receiving opioid substitution therapy, 
and alcohol consumption. Smoking heroin 
was associated with lower risk of infection 
(Palmateer et al., 2012). 
 
Between June and December 2012 six 
further cases were reported in the UK: 4 
(including 3 fatal) cases in England 
(Blackpool, Medway and Oxford), one in 
Lanarkshire (Scotland) and one in Gwynedd 
(Wales) (HPA, 2012). It is unclear whether 
the British cases are linked to the European 
outbreak, which has affected drug users in 
Denmark, Germany and France. 
 
Conclusions 
 
Opiates, mainly heroin/morphine and 
methadone, still account for the majority of 
drug-related deaths in the UK. There is 
evidence both from np-SAD data and other 
authoritative sources that the role of 
heroin/morphine decreased in 2010 and 
2011. However, deaths involving methadone 
and other opiates/opioid analgesics rose 
slightly during this period.  
 
The marginal increase in cases involving 
stimulants (such as cocaine, amphetamines, 
and ecstasy-type drugs) following a decline 
in 2009 and stabilisation in 2010 may well 
be due to the growing use in recent years of 
so-called ‘legal highs’ such as ketamine; the 
piperazines; GHB/GBL; and more recently 
the methcathinones such as mephedrone. 
Whilst these are still available their 
popularity has declined slightly, in part as a 
consequence of them having been brought 
under the control of the Misuse of Drugs Act 
1971. However, these substances are still 
popular on the UK recreational drug scene 
and may be causing problems in terms of 
dependency. Indeed, there appears to have 
been a slight increase in deaths involving 
amphetamines and ecstasy-type 
substances. At the same time, other novel 
substances – principally other 
methcathinones and related chemicals – 
have emerged on the recreational drug 
scene in Western Europe but especially the 
British Isles.  
 
The rapidity with which these new 
substances are emerging appears to be 
increasing. It is now difficult to gauge with 
any certainty what will capture the attention 
of the experimenter or regular recreational 
drug user. The range of drug classes now on 
offer, both diverted pharmaceutical products 
such as phenazepam, and synthetic 
substances is also growing. Several new 
classes were present in the post mortem 
toxicology and cause of death in 2011 
cases. These trends appear to have 
continued into 2012.  
 
Furthermore, there is a lack of information 
provided to the potential consumer by the 
retailer as to the true nature of the 
ingredients in the substance being 
purchased. Therefore, it is important that the 
np-SAD, in collaboration with other 
surveillance systems, continues to monitor 
reports from the treatment and forensic 
toxicology fields as well as Coroners’ 
records so as to be able to alert health 
professionals about emerging issues, and to 
suggest to Coroners and pathologists what 
they might look out for. The Programme 
feeds into the formal scientific evidence-
gathering activities of the Advisory Council 
on the Misuse of Drugs (see Select 
Bibliography for examples), and the formal 
risk assessments of Novel Psychoactive 
Substances conducted by the European 
Monitoring Centre for Drugs and Drug 
Addiction.  
 
However, it is important not to overlook the 
fact that opiates/opioids still account for the 
majority of drug-related deaths in England 
and other parts of the UK. Together with 
hypnotics/sedatives (chiefly 
benzodiazepines such as diazepam and 
temazepam) the involvement of methadone 
in deaths has increased over the past year.  
 
As reported last year, the injection of heroin 
contaminated with anthrax or botulism is, at 
present, a continuing and serious risk factor 
for adverse health consequences and 
death. As heroin can be stockpiled for 
several years before being released onto 
the market it is important that vigilance is 
maintained by heroin users and those who 
treat them for any tell-tale signs of infection, 
thereby preventing premature death. 
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Appendix 1: The national programme on Substance 
Abuse Deaths (np-SAD) 
  
 
Aims and objectives 
 
The Programme’s principal aim is to reduce 
and prevent drug-related deaths in the UK due 
to the misuse of drugs, both licit and illicit, by 
collecting, analysing, and disseminating 
information on the extent and nature of death. 
The Programme offers a comprehensive 
prevention package to Drug (and Alcohol) 
Action Teams (DAATs), Primary Care Trusts 
(PCTs) and Strategic Health Authorities 
(SHAs) with a mission to tackle the problem of 
drug-related deaths.  
 
The Programme’s objectives are to: 
 Collect and collate drug-related mortality 
data 
 Develop and maintain a computerised 
surveillance system  
 Identify substances implicated in drug-
related deaths – including new drugs and 
new combinations 
 Monitor and examine patterns and trends, 
e.g. geographic, demographic, substances 
implicated in death, method of death 
 Act as an early warning system for new 
trends in mortality and drug misuse 
 Use data as an indicator to estimate the 
prevalence of substance-related problems 
and assess the hazards associated with 
substance abuse 
 Collaborate with relevant agencies in 
research on substance-related mortality 
locally, nationally and internationally  
 Inform and facilitate discussion on the 
prevention of drug-related deaths, whether 
accidental or intentional 
 Provide data for local and national drug 
abuse policy formulation and programme 
planning 
 Disseminate information on drug-related 
mortality to the scientific community, 
clinicians, policy makers and other 
interested parties 
 
Surveillance data management 
 
Data collated for this programme is stored on 
the np–SAD Coroners’ database which was 
established in 1997. Its purpose is to provide 
information for the Programme’s surveillance 
system of monitoring drug-related deaths 
reported by Coroners, procurators fiscal and 
other agencies.   
 
Data collection 
 
All coroners in the UK (see Appendix 3) are 
issued with copies of the standard data 
collection form (see Appendix 4). They are 
invited to complete the forms on all deaths that 
meet the criteria described in this report (see 
Appendix 2) and return them to the np-SAD at 
the ICDP office at St. George’s, University of 
London for coding and entry onto the 
database.  
 
Data submission is mostly directly on paper by 
coroners or their staff. There is also manual 
completion of the np-SAD data collection form 
or print-out of completed computer-generated 
forms using bespoke software. Forms are 
submitted when inquests are complete – either 
singly or in batches. Manual extraction of data 
by team members is undertaken at some 
coroners’ courts – mostly in London.  
 
A monitoring process is undertaken to 
ascertain the quality of the information 
received from coroners, as well as the extent 
to which all relevant cases are being identified 
and submitted. This assists in further 
improving the quality of the various outputs 
that the Programme seeks to provide. 
 
Data entry and coding 
 
To enable comparison with various national 
and international datasets all causes of death 
have been coded according to the 
International Classification of Diseases (ICD-
10). This is an international standard for the 
classification of diseases and health-related 
problems published by the World Health 
Organisation (1992). The online version (ICD-
10 2010) has been employed for coding all 
substances implicated in death separately 
according to its therapeutic drug category, i.e. 
hypnotics/sedatives, anti-depressants, opiates, 
etc. 
 
The ‘intentionality‘ of deaths based on the 
Coroner’s verdict and/or or other additional 
information employing ICD-10 codes is 
inadequate for informing interested parties as 
to whether certain categories of drug-related 
deaths can be prevented.  
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Whilst the ‘cause’ of death (as given in the 
preceding section) is concerned with the 
disease or injury responsible for the lethal 
sequence of events, the ‘manner’ of death 
explains how the cause of death arose, i.e. a 
natural or violent death. The categories for 
‘manner of death’ have been adopted from the 
UK practice (Explore Forensics 
http://www.exploreforensics.co.uk/the-four-
manners-of-death.html) with the additional 
categories for those where intentionality is 
unclear or manner of death is impossible to 
determine: natural, accidental, suicidal, 
homicidal, undetermined, and unclassified/not 
specified. Verdicts of ‘dependence on drugs’ 
or ‘non-dependent abuse of drugs’ are 
regarded as ‘accidental’. The ‘manner of 
death’ is derived from information such as the 
verdict or ‘finding’, history of drug misuse or 
dependence, post mortem drugs, and other 
information; and is based on the interpretation 
of the death by np-SAD and clinical 
presentation/profile of the individual case. 
   
Statistical analysis 
 
Due to the nature of the information collected 
by the programme, i.e. drug-related deaths as 
reported by the Coroners, this is an 
observational study. Hence, statistical 
methods employed are based on proportions 
and ratios. Where the data include proportions 
of incidence for particular groups of interest, 
the ratio of the proportions forms a measure of 
the relative risk in one group compared with 
that of another.  These scales of measurement 
are generally known as point estimates.  
Although point estimates can be calculated 
they do not represent the ‘true’ values. Each 
point estimate is subject to random variation. 
Confidence intervals (CI) provide an indication 
of the range in the true values for the 
population as a whole, which would be 
expected in future investigations. The methods 
used for quantitative data relied mainly on 
complex assumptions of distributional form. It 
may be the case that the assumptions are not 
always satisfied. In such cases, methods 
known as distribution-free methods can be 
applied, also known as non-parametric tests 
(e.g. Mann-Whitney). The use of decimal 
places varies in some contexts so as to 
provide greater granularity to bring out 
distinctions between apparently similar 
populations or groups. The data were 
analysed using IBM ® SPSS™ Statistics for 
Windows version 19. 
  
 
 
Data Storage 
 
The anonymised data-set for Coroners is held 
on a SPSS database for analysis.  All data 
held, whether electronic or paper, is stored 
securely and treated as confidential.  Access 
is restricted to Programme staff; only 
aggregated and anonymised data are released 
to third parties. 
 
Other activities and resources 
 
The Programme provides information to public 
consultations, Parliamentary questions, 
Ministerial briefings, as well as contributing to 
the UK’s Drugs Early Warning System. As part 
of the early warning function, emerging trends 
and potential issues are brought to the 
attention of policy-makers and Coroners in a 
special briefing. 
 
Analysis of data for specific Drug and Alcohol 
Action Teams (DAATs), Primary Care Trusts 
(PCTs) and (Special Health Authorities) SHAs 
is undertaken on request.  
 
Findings from the Programme’s annual report 
and research articles is used in national and 
international research. For example, the key 
findings from the np-SAD are included in the 
annual report from the UK Focal Point to the 
EMCDDA, and in various annual United 
Nations publications 
 
In addition to the above activities, the 
Programme  
 
 Is the official custodian of the national UK 
Addicts Index Access database and 
digitised  files covering the period 1968-
1997 Holds a copy of the official Dead 
Addicts datafile 
 Is located in an academic centre with 
input from relevant disciplines  
 Brings to a broad range of expertise from 
different professional backgrounds – 
psychiatry, psychology, social science, 
pharmacology, epidemiology, addictive 
behavioural science, database, project 
management, etc. 
 Has national and international 
experience, collaborating in research and 
training with bodies such as the World 
Health Organisation, European 
Monitoring Centre for Drugs and Drug 
Addiction (EMCDDA), and the European 
Collaborating Centres for Addiction 
Studies.   
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National Steering Group  
 
The np-SAD has a National Steering Group to 
provide additional expertise to the Programme 
through involvement and participation. Its  
 
 
 
principal role is in giving advice on the full 
range of its activities, including the national 
surveillance of Coroners and production of the 
annual report. 
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Appendix 2: Definitions of drug-related death 
 
 
Introduction 
 
There are a number of issues and problems 
associated with defining drug-related deaths 
and drug-related mortality. For a full 
discussion see Corkery (2008) and Office for 
National Statistics (2012).
 
 
np-SAD definition 
 
An np-SAD case is defined as a relevant death 
where any of the following criteria are met at a 
completed inquest, fatal accident inquiry or 
similar investigation: 
 One or more psychoactive substances* 
directly** implicated in death; 
 History of dependence or abuse of 
psychoactive drugs;  
 Presence of Controlled Drugs*** at post 
mortem; or 
 Cases of deaths directly due to drugs but 
with no inquest. 
  
Deaths where solvents and other volatile 
substances are implicated alone are also 
included. However, we do collect information 
on these cases separately; further information 
can be seen at http://www.vsareport.org. 
Alcohol is included only when implicated in 
combination with other qualifying drugs.  
 
* ‘Psychoactive’ substances are those having 
a direct effect on perception, mood, cognition, 
behaviour or motor function. Typically these 
include opiates and opioid analgesics, 
hypnotics, sedatives, anti-depressants, anti-
epileptics, anti-psychotics, hallucinogens, and 
stimulants (such as amphetamines and 
cocaine) and “legal highs”. 
 
** ‘Directly implicated’ means that drugs were 
considered by the Coroner or other person 
investigating the death to have been 
instrumental in the coming about of the 
deceased’s death (e.g. through poisoning or 
intoxication), or causing their powers of 
reasoning and/or perception to be so affected 
as to induce them to take risks which they 
would not have done had they been sober 
(e.g. thinking they could fly). 
 
*** ‘Controlled Drugs’ are those drugs 
specifically classified by the Misuse of Drugs 
Act 1971 as amended by subsequent 
legislation.  Controlled drugs include opioids, 
cocaine, amphetamines, cannabis, GHB, 
hallucinogens and most benzodiazepines.  
 
Who is a drug abuser/dependent? 
 
A drug abuser/dependent case is defined as 
one with a history of substance abuse where 
one or more of the following criteria are met: 
 Reported as a known illicit drug user by 
the coroner, based on evidence obtained 
at inquest; 
 Prescribed substitute medication for drug 
dependence; 
 Presence of an illicit drug at post mortem, 
where not prescribed; or  
 Presence of any additional information on 
the Coroner’s report suggestive of a 
history of drug abuse, and where such a 
history fulfils ICD-10 criteria: (F11-F16 
and F19, using the 4-code subdivisions of 
.0 (acute intoxication), .1 (harmful use), 
and .2 (dependence syndrome). 
 
 
“Drug misuse” definition 
 
Cause of death categories included in the 
headline indicator of ‘drug misuse’ deaths 
used to monitor progress against the 
Government’s drug strategy are defined in 
terms of ICD-10 codes and Controlled Drug 
Status.  The relevant codes from ICD-10 are 
given in brackets. 
 
The definition comprises two types of deaths: 
 
a) deaths where the underlying cause of death 
has been coded to the following categories of 
mental and behavioural disorders due to 
psychoactive substance use (excluding 
alcohol, tobacco and volatile solvents): 
(i) opioids (F11); 
(ii) cannabinoids (F12); 
(iii) sedatives or hypnotics (F13); 
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(iv) cocaine (F14); 
(v) other stimulants, including caffeine (F15); 
(vi) hallucinogens (F16); and 
(vii) multiple drug use and use of other 
psychoactive substances (F19) 
 
b) deaths coded to the following categories 
and where a drug controlled under the Misuse 
of Drugs Act 1971 was mentioned on the 
death record: 
(i) Accidental poisoning by drugs, 
medicaments and biological substances (X40–
X44); 
(ii) Intentional self-poisoning by drugs, 
medicaments and biological substances (X60–
X64); 
(iii) Poisoning by drugs, medicaments and 
biological substances, undetermined intent 
(Y10–14); 
(iv) Assault by drugs, medicaments and 
biological substances (X85); and 
(v) Mental and behavioural disorders due to 
use of volatile solvents (F18) 
 
Notes: 
 
1. Deaths coded to opiate abuse which 
resulted from the injection of contaminated 
heroin have been included in the indicator. 
This differs from the approach taken in 
Scotland, where these deaths have been 
excluded. This is because the General 
Register Office for Scotland (GROS) is able to 
identify deaths which occurred as a result of 
the use of contaminated heroin, whereas in 
England and Wales, these deaths cannot be 
readily identified. In practice, in England and 
Wales, they will only be included where the 
drug was mentioned on the death record and 
the death was coded to one of the ICD codes 
on the ONS database of drug-related 
poisonings and not to an infection code. 
2. Specific rules were adopted for dealing with 
compound analgesics which contain relatively 
small quantities of drugs listed under the 
Misuse of Drugs Act, the major ones being 
dextropropoxyphene, dihydrocodeine and 
codeine. Where these drugs are mentioned on 
a death record, they have been excluded if 
they are part of a compound analgesic (such 
as co-proxamol, co-dydramol or co-codamol) 
or cold remedy. Dextropropoxyphene has 
been excluded on all occasions, whether or 
not paracetamol or a compound analgesic was 
mentioned. This is because 
dextropropoxyphene is rarely, if ever, available 
other than as part of a paracetamol compound. 
However, codeine or dihydrocodeine 
mentioned alone were included in the 
indicator. This is because they are routinely 
available and known to be abused in this form. 
This approach is taken by both the Office for 
National Statistics and the General Register 
Office for Scotland. 
 
3. Drugs controlled under the Misuse of Drugs 
Act 1971 include class A, B and C drugs. 
 
 
 
Definition used by SCDEA 
 
Deaths reported to the SCDEA by Scottish 
police forces are those which meet the 
definition used by the Association of Chief 
Police Officers (Scotland) – “where there is 
prima facie evidence of a fatal overdose of 
controlled drugs. Such evidence would be 
recent drug misuse, for example controlled 
drugs and/or a hypodermic syringe found in 
close proximity to the body and/or the person 
is known to the police as a drug misuser 
although not necessarily a notified addict.”  
Thus, most suicides in Scotland will be 
excluded. 
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Appendix 3: Coroners’ jurisdictions/police force areas 
reporting drug-related deaths, United 
Kingdom & Islands  
 
Administrative 
county/area 
Jurisdiction Description 
 (The) Queen's Household "The Coroner of the Queen's Household has 
exclusive jurisdiction in respect of inquests and, 
semble, inquiries which do not lead to inquests, on 
persons whose bodies are lying within the limits of 
any of the Queen's palaces or within the limits of 
any other house where Her Majesty is then 
demurrant and abiding in her own royal person, 
notwithstanding the subsequent removal of Her 
Majesty from such palace or house. The limits of 
the palace or house are deemed to extend to any 
courts, gardens or other places within the curtilage 
of the palace or house but not further. Where a 
body is lying dead beyond these limits, the coroner 
of the Queen's Household has no jurisdiction." 
ENGLAND   
Avon Avon The city of Bristol and the districts of Bath & 
North East Somerset, North West Somerset & 
South Gloucestershire 
Bedfordshire Bedfordshire & Luton The whole county of Bedfordshire and the 
county of Luton 
Berkshire Berkshire The whole county of Berkshire 
Buckinghamshire Buckinghamshire The whole county of Buckinghamshire (excl. 
Milton Keynes) 
 Milton Keynes The whole county of Milton Keynes 
Cambridgeshire North & East Cambridgeshire The districts of Fenland & East Cambridgeshire 
 Peterborough The district of Peterborough 
 South & West Cambridgeshire The City of Cambridge, the districts of Huntingdon 
and South Cambridgeshire 
Cheshire Cheshire The whole county of Cheshire 
Cornwall Cornwall The whole county of Cornwall (exc. Isles of 
Scilly) 
 Isles of Scilly The Isles of Scilly 
Cumbria North and West Cumbria The districts of Allerdale, Carlisle and Copeland.  
 South and East Cumbria The districts of Barrow-in-Furness, Eden, and 
South Lakeland.  
Derbyshire Derby & South Derbyshire The county of Derby and the districts of Erewash 
& South Derbyshire. The district of Amber Valley 
(except the parts in the Coroner’s Jurisdictions 
of North Derbyshire). In the district of West 
Derbyshire, the parishes of Alkmonton, 
Ashbourne, Atlow, Biggin, Boylestone, 
Bradbourne, Bradley, Brailsford, Clifton & 
Compton, Cubley, Doveridge, Edlaston & 
Wyaston, Fenny Bentley, Hognaston, Hollington, 
Hulland, Hulland Ward, Hungry Bentley, Kirk 
Ireton, Kniveton, Lea Hall, Longford, Mapleton, 
Marston Montgomery, Mercaston, Norbury & 
Roston, Offcote & Underwood, Osmaston, 
Rodsley, Shirley, Snelston, Somersal Herbert, 
Sudbury, Thorpe, Tissington, Yeaveley and 
Yeldersley 
 North Derbyshire The District of Bolsover and North East 
Derbyshire. The Boroughs of Chesterfield and 
High Peak. In the Borough of Amber Valley the 
parishes of Denthick, Lea and Holloway, South 
Wingfield and Alfreton. The District of Derbyshire 
Dales except the parishes in the Derby and 
South Derbyshire Coroner’s District. 
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Administrative 
county/area 
Jurisdiction Description 
Devon Exeter & Greater Devon The districts of East Devon, Exeter, Mid Devon, 
North Devon, Torridge, West Devon. That part of 
the district of Teignbridge comprising the 
parishes of Alphington, Ashton, Bovey Tracey, 
Bridford, Christow, Chudleigh, 
Doddiscombsleigh, Dunchideock, Dunsford, 
Exminster, Hennock, Holcombe Burnell, Ide, 
Kenn, Lustleigh, Manaton, Moretonhampstead, 
North Bovey, Shillingford St George, Tedburn St 
Mary, Trusham & Whitestone.  
 Plymouth & South West Devon The district of Plymouth. The district of South 
Hams except the parishes in the Torbay and 
South Devon Coroner's district. 
 
 
 
Torbay & South Devon The district of Torbay. The district of Teignbridge 
except the parishes in the Coroner’s Jurisdiction of 
Exeter and Greater Devon. That part of the district 
of South Hams comprising the parishes of 
Ashprington, Berry Pomeroy, Blackawton, 
Cornworthy, Dartington, Dartmouth, Dean Prior, 
Dittisham, Halwell, Harberton, Holne, Kingswear, 
Littlehampton, Marldon, Rattery, Slapton, 
Staverton, Stoke Fleming, Stoke Gabriel, Strete, 
Totnes and West Buckfastleigh 
Dorset Bournemouth, Poole & 
Eastern Dorset 
The counties of Bournemouth & Poole, 
Christchurch, Purbeck and Wimbourne 
 Western Dorset The districts of West Dorset, North Dorset and 
Weymouth & Portland 
Durham Darlington & South Durham The county of Darlington and the districts of 
Sedgefield and Teesdale {Wear Valley also 
included] 
 North Durham The districts of Chester-Le-Street, Derwentside, 
Durham and Easington 
East Sussex Brighton & Hove The county of Brighton & Hove 
 East Sussex The whole county of East Sussex 
Essex Essex & Thurrock (Essex No 
1) 
The districts of Basildon, Braintree, Brentwood, 
Chelmsford, Colchester, Epping Forest, Harlow, 
Maldon, Tendring, Thurrock and Uttlesford 
 Southend & South East Essex 
(Essex No 2) 
The districts of Southend, Rochford and Castle 
Point 
 
Gloucestershire Gloucestershire The county of Gloucestershire 
Greater Manchester Manchester The district of Manchester 
 North Manchester The districts of Bury, Rochdale & Oldham 
 South Manchester The districts of Stockport, Tameside  and 
Trafford 
 West Manchester The districts of Wigan, Bolton and Salford 
Hampshire Central Hampshire The districts of Winchester, Test Valley and 
Eastleigh 
 North East Hampshire The districts of Basingstoke, Hart & Rushmoor 
and that part of the district of East Hampshire 
not contained in the Portsmouth & South East 
Hampshire Coroner's district 
 Portsmouth & South East 
Hants 
The county of Portsmouth and the districts of 
Fareham, Gosport and Havant and, in the district 
of East Hampshire, the parishes of Buriton, 
Clanfield, Colemore and Priors Dean, East Meon, 
Froxfield, Hawkley, Horndean, Langrish, Liss, 
Petersfield, Rowlands Castle and Steep 
 Southampton & New Forest The county of Southampton and the district of 
New Forest 
Herefordshire Herefordshire The whole county of Herefordshire 
Hertfordshire Hertfordshire The whole county of Hertfordshire 
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Administrative 
county/area 
Jurisdiction Description 
Humberside East Riding & Hull The counties of the East Riding of Yorkshire and 
the city of Kingston-upon-Hull 
Isle of Wight Isle of Wight The whole county of the Isle of Wight 
Kent Central & South East Kent The district of Shepway.  The borough of 
Ashford.  The district of Dover except those 
parishes with the North East Kent Coroner's 
district.  In the district of Swale, the parishes of 
Boughton under Bleab, Doddington, Dunkirk, 
Eastling, Faversham, Graveney & Goodnestone, 
Hernhill, Luddenham, Lynsted, Newnham, 
Norton & Buckland, Oare, Ospringe, Selling, 
Sheldwich Badlesmere & Leaveland, Stalisfield, 
Stone, Teynham, Throwley  
 Mid Kent & Medway The City of Rochester upon Medway, the districts 
of Gillingham and Maidstone. The district of 
Swale, with the exception of Faversham and the 
parishes in the Coroner’s Jurisdiction of East Kent. 
In the district of Tonbridge and Malling, the 
parishes of Addington, Aylesford, Birling, Burham, 
Ditton, East Malling & Larkfield, King's Hill, 
Leybourne, Mereworth, Offham, Ryarsh, 
Snodland, Trottiscliffe, Wateringbury & East 
Peckham, Wouldham.     
 North East Kent The district of Thanet. The City of Canterbury. In 
the district of Dover, the parishes of Ash, 
Aylesham, Deal, Eastry, Eythorpe, 
Goodnestone, Great Mongeham, Nonington, 
Northbourne, Preston, Ringwould & Kingsdown, 
Ripple, Sandwich, Sholden, Staple, Stourmouth, 
Sutton by Dover, Tilmanstone, Walmer, 
Wingham, Woodnesborough, Worth.  
 North West Kent The districts of Dartford, Gravesham, Sevenoaks 
and Tunbridge Wells. The district of Tonbridge and 
Malling, except the parishes in the Mid-Kent and 
Medway Coroner's district.  
Lancashire Blackburn, Hyndburn & Ribble 
Valley 
The districts of Blackburn, Hyndburn & Ribble 
Valley 
 Blackpool & the Fylde The districts of Blackpool and Fylde 
 East Lancashire The districts of Burnley, Pendle and Rossendale 
 Preston & West Lancashire The districts of Lancaster, Wyre, Chorley, Preston, 
South Ribble and West Lancashire 
Leicestershire Leicester City & South 
Leicestershire 
The county of Leicester and the districts of 
Blaby, Harborough, Oadby, Wigston 
 Rutland & North Leicestershire The county of Rutland and the districts of 
Charnwood, Hinckley & Bosworth, Melton and 
North West Leicestershire 
Lincolnshire Boston & Spalding The districts of Boston and South Holland 
 North Lincolnshire & Grimsby The counties of North Lincolnshire and North 
East Lincolnshire 
 Spilsby & Louth The district of East Lindsey, except the parishes 
in the West Lincolnshire Coroners' district. In the 
district of West Lindsey, the parishes of Bigby, 
Brocklesbury, Cabourne, Caistor, Claxby, 
Grasby, Great Limber, Holton Le Moor, Keelby, 
Kirmond le Mire, Legsby Linwood, Market 
Rasen, Middle Rasen, Nettleton, Normanby le 
Wold, North Kelsey, North Willingham, Osgodby, 
Owersby, Riby, Rothwell, Searby cum Owmby, 
Sixhills, Somerby, South Kelsey, Stainton le 
Vale, Swallow, Swinhope, Tealby, Thoresway, 
Thorganby and Walesby. 
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Administrative 
county/area 
Jurisdiction Description 
 Stamford In the district of South Kesteven, the parishes of 
Aslackby & Laughton, Barholm & Stowe, Baston, 
Billingborough, Bourne, Braceborough & 
Wilsthorpe, Careby Aunby & Holywell, Carlby, 
Castle Bytham, Corby Glen, Counthorpe & 
Creeton, Deeping St James, Dowsby, Dunsby, 
Edenham, Folkingham, Greatford, Haconby, 
Horbling, Irnham, Kirkby Underwood, Langtoft, 
Little Bytham, Market Deeping, Morton, Pointon & 
Sempringham, Rippingale, Stamford, Swayfield, 
Swinstead, Tallington, Thurlby, Toft with Lound & 
Manthorpe, Uffington, West Deeping and Witham 
on the Hill 
 West Lincolnshire The district of Lincoln. The district of North 
Kesteven. The district of South Kestevan, except 
the parishes in the Coroner’s Jurisdiction of 
Stamford. The district of West Lindsey, except 
the parishes in the Coroner’s jurisdiction of 
Spilsby & Louth. In the district of East Lindsey, 
the parishes of East & West Barkwith, Hatton, 
Langton by Wragby, Panton, West Torrington, 
Wragby.    
London City of London City of London 
 Eastern London The London boroughs of Barking, Havering, 
Newham, Redbridge & Waltham Forest 
 Inner North London The London boroughs  of Camden, Hackney, 
Islington & Tower Hamlets 
 Inner South London The London boroughs of Greenwich, Lambeth, 
Lewisham & Southwark 
 Inner West London The London boroughs of Wandsworth & Merton, 
the Royal Borough of Kensington & Chelsea, 
and the City of Westminster 
 Northern London The London boroughs of Barnet, Brent, Enfield, 
Haringey & Harrow 
 Southern London The London boroughs of Bexley, Bromley, 
Croydon and Sutton 
 Western London The London boroughs of Ealing, Hammersmith, 
Hillingdon, Hounslow and Richmond-upon-
Thames, and the Royal Borough of Kingston-
upon-Thames 
Merseyside Knowsley, St Helens & Sefton The districts of Knowsley, St Helens and Sefton 
 Liverpool The district of Liverpool 
 Wirral The district of Wirral 
Norfolk Norfolk The whole county of Norfolk  
Northamptonshire Northamptonshire The whole county of Northamptonshire 
Northumberland North Northumberland The districts of Alnwick and Berwick-upon-Tweed 
and so much of the districts of Castle Morpeth and 
Wansbeck as lies north of the line for the time 
being of the centre of the River Wansbeck 
 South Northumberland The districts of Blyth Valley & Tynedale, and so 
much of the districts of Castle Morpeth & 
Wansbeck as lie south of the line for the time 
being of the centre of the River Wansbeck 
North Yorkshire North Yorkshire Eastern The districts of Hambleton, Ryedale and 
Scarborough 
 North Yorkshire Western The districts of Richmondshire, Craven, 
Harrogate and Selby 
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Administrative 
county/area 
Jurisdiction Description 
 York The county of York. In the district of Harrogate, 
the parishes of Nether and Upper Poppleton. In 
the district of Ryedale, the parishes of Clifton 
(without), Earswick, Haxby, Heworth (without), 
Holtby, Huntington, Murton, New Earswick, 
Osbaldwick, Rawcliffe, Skelton, Stockton-on-the- 
Forest, Strensall, Towthorpe, Wigginton.  In the 
district of Selby, the parishes of Dunnington, 
Elvington, Fulford, Heslington, Kexby, Naburn & 
Deighton, Wheldrake.    
Nottinghamshire Nottinghamshire The whole county of Nottinghamshire and the 
City of Nottingham 
Oxfordshire Oxfordshire The whole of the county of Oxfordshire 
Shropshire Mid & North Shropshire The districts of Oswestry, North Shropshire, 
Shrewsbury & Atcham 
 South Shropshire The districts of South Shropshire and Bridgnorth 
 The Wrekin The whole county of the Wrekin 
Somerset Eastern Somerset The districts of Mendip and South Somerset 
 Western Somerset The districts of Sedgemoor, Taunton Deane and 
West Somerset 
South Yorkshire South Yorkshire East The district of Doncaster and Rotherham 
 South Yorkshire West The districts of Barnsley and Sheffield 
Staffordshire South Staffordshire The districts of Cannock Chase, East 
Staffordshire, Lichfield, South Staffordshire, 
Stafford and Tamworth.  
 Stoke-on-Trent & North 
Staffordshire 
The county of Stoke-on-Trent, and the districts 
of Newcastle-under-Lyme and Staffordshire 
Moorlands. 
Suffolk Suffolk The county of Suffolk. 
Surrey Surrey The whole county of Surrey 
Teesside Hartlepool The county of Hartlepool 
 Teesside The counties of Middlesbrough, Redcar & 
Cleveland and Stockton-on-Tees. 
Tyne & Wear Gateshead & South Tyneside The districts of Gateshead and South Tyneside 
 Newcastle-upon-Tyne The City of Newcastle-upon-Tyne 
 North Tyneside The district of North Tyneside 
 Sunderland The district of Sunderland 
Warwickshire Warwickshire The whole county of Warwickshire 
West Midlands Birmingham  The districts of Birmingham & Solihull 
 Black Country The districts of Dudley, Sandwell, and Walsall 
 Coventry The district of Coventry 
 Wolverhampton The district of Wolverhampton 
West Sussex West Sussex The whole county of West Sussex 
West Yorkshire West Yorkshire Eastern The metropolitan district of Leeds and Wakefield 
 West Yorkshire Western The metropolitan districts of Bradford, 
Calderdale and Kirklees 
Wiltshire Wiltshire & Swindon The counties of Wiltshire and Swindon 
Worcestershire Worcestershire The whole county of Worcestershire 
WALES   
 Bridgend & Glamorgan Valleys The county boroughs of Bridgend, Merthyr Tydfil & 
Rhondda, Cynon & Taff 
 Cardiff & the Vale of 
Glamorgan 
The county of Cardiff and the county borough of 
the Vale of Glamorgan 
 Carmarthenshire The districts of Carmarthen, Llanelli and Dinefwr 
 Central North Wales The county of Denbighshire, the county borough 
of Aberconwy & Colwyn. 
 Ceredigion The district of Ceredigion  
 Gwent The county of Monmouthshire, the county borough 
of Blaenau Gwent, Caerphilly, Newport and 
Torfaen 
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Administrative 
county/area 
Jurisdiction Description 
 Neath & Port Talbot The districts of Neath & Port Talbot. In the 
borough of Lliw Valley, the communties of 
Cilybebyll, Clydach, Cwmllnfell, Gwam-Cae-
Gurwen, Mawr, Pontardawe & Ystalyfera 
 North East Wales The boroughs of Flintshire and Wrexham.  In the 
district of Glyndwr, the communities of Ceiriog 
Ucha, Chirk, Glyntraian, Llangedwyn, Llangollen, 
Llangollen Rural, Llanrhaeadr-ym-Mochnant, 
Llansantffraid Glyn Ceiriog, Llansilin & 
Llantysilio.  
 North West Wales The counties of Anglesey, Caernarfonshire, 
Merionethshire 
 Pembrokeshire The district of Preseli and South Pembrokeshire 
(including Caldey Island and St Margaret's Island) 
 Powys The whole county of Powys 
 Swansea The district of Swansea.  In the borough of Lliw 
Valley, the communities of Gorseinon, 
Gowerton, Grovesend, Llangyfelach, Llwchwr, 
Penllergaer, Pontarsulais, Pont-Lliw.  
NORTHERN 
IRELAND 
  
NORTHERN 
IRELAND 
 Whole of Northern Ireland 
THE ISLANDS   
 Guernsey Alderney, Brecqhou, Guernsey, Herm, Jethou, 
Lihou, Little Sark, Sark  
 Jersey Jersey 
 Isle of Man Isle of Man 
SCOTLAND   
Argyll & Clyde Dumbarton Fiscal area (but figures included in Strathclyde 
Police figures) 
Central Scotland 
Police 
 Clackmannanshire, Falkirk, and Stirling Council 
areas 
Dumfries & 
Galloway 
Constabulary 
 Dumfries & Galloway Council area 
Fife Constabulary  Fife Council area 
Grampian Police  City of Aberdeen, Aberdeenshire, and Moray 
Council areas 
Lothian & Borders 
Police 
 East Lothian, City of Edinburgh, Midlothian, 
West Lothian, and the Borders Council areas 
Northern 
Constabulary 
 Highland, Orkney Islands, Shetlands Islands, 
and Western Isles Council areas, and parts of 
Argyllshire (Ardnamuchan and Glencoe) and 
Morayshire (Grantown-on-Spey and Cromdale) 
Strathclyde Police  Argyll and Bute, East Dumbartonshire,  
Dumbarton and Clydebank, South Lanarkshire, 
North Lanarkshire, East Ayrshire, North 
Ayrshire, East Renfrewshire, City of Glasgow, 
Inverclyde, South Ayrshire, and 
Renfrewshire Council areas 
Tayside Police  Angus, City of Dundee, and 
Perthshire and Kinross Council areas 
 
 
Since the start of 2004, the following amalgamations of Coroners' jurisdictions in England have occurred: East Berkshire, 
Reading and West Berkshire to form one for the whole county of Berkshire (1 April 2004); East and West Cornwall to 
form one for the whole county of Cornwall, but excluding the Isles of Scilly (1 February 2004); in Cumbria, Furness and 
Southern Cumbria to form South Cumbria & Furness (1 April 2004); Hertford and West & North Hertfordshire to form one 
for the whole county of Hertfordshire (1 October 2004); in Lincolnshire, Louth and Spilsby to form Spilsby & Louth (1 
December 2003); in the West Midlands, Dudley, Sandwell, and Walsall to form Black Country (1 August 2004); in 
Derbyshire, High Peak and Scarsdale to form North Derbyshire (1 February 2006); in Gloucestershire, Gloucester and 
Cheltenham to form Gloucestershire (1 April 2006); in Suffolk, Greater Suffolk and Lowestoft to form Suffolk (1 August 
2006). Further amalgamations took place in 2007. Great Yarmouth merged with Greater Norfolk to form Norfolk on 1 
April 2010. 
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The retirement of several Coroners has resulted in some Coroners taking on responsibility for additional jurisdictions.  
The Isles of Scilly (regarded as part of Cornwall) are currently being looked after by the Coroner for Plymouth & South 
West Devon.  Data for Herefordshire are also submitted now together with those for Worcestershire. The two 
jurisdictions in Durham are now being looked after by the same Coroner, but have not been formally amalgamated. The 
Coroner for Suffolk is also Coroner for Southend & South East Essex.  
 
In Northern Ireland there has been a single Coroner’s area covering the whole of the Province since 1 April 2006. It is 
centred on the Greater Belfast office and served by three full-time Coroners, overseen by a High Court judge.   
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Appendix 4: np-SAD data collection form  
The National Programme on Substance Abuse Deaths (np-SAD) 
NOTIFICATION OF DRUG-RELATED DEATHS 
 
Section I Demographic information 
Deceased forename(s): _____________________________   Gender:   Male     Female 
 
Family name: ____________________Other names known by: _______________________ 
 
Date of birth: ______/______/______ Place of birth: ________________________________ 
 
Usual address:______________________________________________________________ 
 
_____________________________________________Postcode:  __________________________ 
 
Ethnicity (tick one only) 
 White   Pakistani   Black African   Other, specify_________  
 Chinese  Bangladeshi   Black Caribbean  Not known 
 Indian   Black other, specify ______________   
 
Occupational status (tick one only) 
 Employed (manual)   Unemployed    Retired  
  Employed (non-manual)  Childcare/houseperson  Student/pupil 
 Self employed   Invalidity/sickness   Other, specify_________  
 Not known 
 
Living arrangements (tick one only) 
 Alone    Self and children   No fixed abode  
 With partner    With parent(s)  Other, specify_______________ 
 With partner & children  With friend(s)  Not known 
 
 
Section II Details of death 
 
Date of death: _______/_______/_________   
 
Place of death: (tick one only) 
 Home   Residential premises (.e. hotel)   In custody  
 Place of work   Street or highway    Place of recreation/sport 
 Treatment centre  Educational establishment   Hospital 
 Other place, specify________________________________________________________ 
 
Cause(s) of death (as given on the death certificate) 
 
1(a)_______________________________________________________________________ 
(b) _______________________________________________________________________  
  (c) ________________________________________________________________________ 
2 _________________________________________________________________________ 
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The National Programme on Substance Abuse Deaths (np-SAD) 
 
 
Toxicology 
Please list drugs and alcohol present at post mortem   (in order of importance, if known) 
 
 Drug/alcohol Level   Drug/alcohol Level 
  B T U   B T U 
1     4     
2     5     
3     6     
B = Blood; T = Tissues; U = Urine 
 
Section III  Coroner’s verdict   
 
 
 
 
Section IV  Background information 
Recent history of drug use and other relevant information: e.g. evidence of injecting drug 
use; evidence of ‘crack’ use; recently released from prison or discharged from treatment 
programme; psychiatric history; known to alcohol/drug services; length of use; poly-substance 
user; known health problems associated with substance misuse; last 24 hours of life (if 
known), time police summoned, any drugs paraphernalia, etc.: 
 
 
 
 
 
 
 
 
Was the deceased on prescribed psychoactive medication?  Yes  No  Not known 
If yes, please list drugs:  
1 _______________________________      2 ___________________________ 
3 _______________________________        4 ___________________________ 
5 _______________________________  6 ___________________________                          
 
Was the deceased a drug addict or known drug abuser?   Yes  No  Not known 
 
 
Section V Coroner’s details 
 
Coroner’s name: __________________________Date inquest completed: ____/_____/_____ 
Jurisdiction: __________________________________ Office: _______________________ 
Signature: ___________________________________ Date: _______/________/________ 
 
Please send completed form to:  
 
National Programme on Substance Abuse Deaths (np-SAD) 
    International Centre for Drug Policy 
    St George’s, University of London 
   FREEPOST LON 10141,  
London SW17 0BR 
 
For general enquiries: Tel 020 8725 5522 or Fax 020 8725 3538 
This form is available electronically 
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